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CHAPTER I  
INTRODUCTION TO ALDEHYDE OXIDASE 
 
Aldehyde Oxidase Structure 
Aldehyde oxidase (AO) is a cytosolic enzyme and member of the molybdo-
flavoenzyme family, functioning as a homodimer with two identical subunits of 
approximately 150 kDa.  Each subunit is composed of a 20 kDa N-terminal domain 
that binds two iron-sulfur clusters, a 40 kDa central domain containing a flavin-
adenine dinucleotide (FAD), and an 85 kDa C-terminal domain housing a 
molybdenum-containing tetracyclic pteridine complex (MoCo) adjacent to the 
substrate binding pocket, all of which are required for catalytic activity (Figure I.1) 
(Terao et al., 2016). Two unstructured hinge regions link domains I and II and 
domains II and III (Coelho et al., 2015).  Crystal structures of mouse AOX3 and 
human AOX1 (AO isoenzymes) have been solved, revealing high overall similarity 
(65% sequence identity), but important differences, within the MoCo active site and 
tunnel leading to the substrate binding site (Coelho et al., 2012; Coelho et al., 2015). 
The deep substrate tunnel present in both structures is wide at the protein surface 
and narrows approaching the active site and contains flexible gates that influence 
substrate entry and product release. 
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Figure I.1. An illustration of the aldehyde oxidase homodimer.  Adapted from Terao et al. 
(Terao et al., 2016). 
 
Aldehyde Oxidase Substrate Specificity and Reactions 
 As the nomenclature implies, aldehydes are among the functional groups 
metabolized by AO, which are oxidized to carboxylic acids (Pryde et al., 2010). The 
most commonly identified biotransformation catalyzed by AO, however, is oxidation 
of nitrogen-containing aromatic heterocycles such as pyridines and pyrimidines, 
which are the AO-susceptible moieties most frequently encountered in drugs or 
drug-like molecules (Pryde et al., 2010; Garattini and Terao, 2012). In addition, AO 
is capable of oxidizing iminium ions, as well as reducing amine-oxides (N-oxide) or 
sulfoxides (S-oxide), nitro groups and aromatic heterocycles (Pryde et al., 2010). A 
recent study has also demonstrated AO-mediated amide? hydrolysis (Sodhi et al., 
2015). Example biotransformations catalyzed by AO are depicted in Figure I.2. 
 3 
 
Figure I.2.  Example reactions catalyzed by aldehyde oxidase. 
 
Aldehyde Oxidase Catalytic Mechanism 
 The catalytic mechanism of AO used to oxidize aromatic azaheterocyles has 
been proposed and is depicted in Figure I.3 (Alfaro and Jones, 2008). The oxidation 
of an electrophilic carbon (typically located adjacent to a nitrogen) is believed to 
proceed via a concerted nucleophilic attack and hydride transfer to the sulfur of the 
MoCo, resulting in reduction of the molybdenum from Mo(VI) to Mo(IV). The 
reaction intermediate is hydrolyzed, releasing the oxidized product, and the 
reducing equivalents are shuttled from the MoCo to FAD via the iron-sulfur clusters.  
FADH2 is then reoxidized by molecular oxygen, generating H2O2.  
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Figure I.3. Proposed mechanism (A) and catalytic cycle (B) of aldehyde oxidase-mediated 
oxidation of an aromatic azaheterocycle.  
 
Known Clinical Aldehyde Oxidase Substrates 
 The number of drugs currently on the market known to be metabolized by 
AO is relatively few (Pryde et al., 2010), but the list is comprised of drugs with a 
variety of therapeutic targets. Both oxidative and reductive mechanisms are 
represented among these drugs, with most undergoing oxidation of an aromatic 
azaheterocycle (Pryde et al., 2010). The nonbenzodiazepine sedative hypnotic 
zaleplon, for example, is extensively cleared via AO-mediated oxidation of the 
pyrimidine ring (Lake et al., 2002a), while the second generation antipsychotic 
ziprasidone is metabolized by AO via reduction of the thiazole ring (Beedham et al., 
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2003).  In some cases, AO catalyzes secondary metabolism of an intermediate P450 
metabolite, where an aldehyde (e.g., citalopram) or imunium ion (e.g., nicotine) has 
been generated, as well as intermediates produced by other drug metabolizing 
enzymes (Pryde et al., 2010). Famciclovir, for example, is a prodrug requiring 
activation by AO to penciclovir, proceeding through an ester hydrolysis 
intermediate, 6-deoxy-penciclovir (Clarke et al., 1995; Rashidi et al., 1997). Figure 
I.4 displays examples of marketed drugs with a primary or secondary AO-mediated 
metabolite (Pryde et al., 2010). A 2010 report by Pryde et al. determined that 
approximately 10% of drugs on the market contained structural components 
expected to be potentially susceptible to AO metabolism, while an examination of 
drugs in research and development revealed that 45% had the potential to be AO 
substrates based on their structural components (i.e., nitrogen-containing aromatic 
rings) (Pryde et al., 2010). The rise in AO-susceptible compounds encountered in 
drug discovery programs has been attributed to aromatic azaheterocycle inclusion 
in chemical scaffolds to achieve requisite target interactions (e.g. kinases) and/or as 
a medicinal chemistry strategy to mitigate P450 metabolism (Pryde et al., 2010). 
The most recent AO substrate to reach the market is the phosphoinositide-3-kinase 
inhibitor, idelalisib (Figure I.4), which is cleared by both AO and P450 pathways and   
was approved for the treatment of chronic lymphocytic leukemia (Ramanathan et 
al., 2016). 
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Figure I.4. Example marketed drugs (A) or intermediate metabolites of marketed drugs (B) 
metabolized by aldehyde oxidase.  Arrows indicate the site of oxidation or reduction 
(ziprasidone, zonisamide, and sulindac). 
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Known Clinical Aldehyde Oxidase Inhibitors 
A report by Obach, et al. identified 36 drugs exhibiting greater than 80% inhibition 
of AO-mediated phthalazine oxidation at 50 M in human liver cytosol (Obach et al., 
2004). The majority of these were compounds that target the central nervous 
system (e.g. antipsychotics) or were estrogen-related drugs.  Table I.1 depicts 
examples of commonly used AO inhibitors, which illustrate a diversity of structural 
features. The selective estrogen receptor modulator raloxifene is the most potent 
known inhibitor of human AO (IC50 = 2.9 nM) (Obach, 2004; Obach et al., 2004).  
Menadione is also known to potently inhibit AO ( IC50 = 200 nM) and is commonly 
used to assess AO-mediated metabolism (Zientek and Youdim, 2015). Hydralazine is 
reported to be the most selective AO inhibitor; however, there are reports 
suggesting that hydralazine may also inhibit cytochrome P450 2D6 (Johnson et al., 
1985; Strelevitz et al., 2012; Zientek and Youdim, 2015).  Of the AO inhibitors with 
known modes of inhibition, most exhibit a mixed-mode type of inhibition with both 
uncompetitive and competitive behavior, including menadione (Barr and Jones, 
2011). However, studies with raloxifene suggest that the mode of AO inhibition may 
be substrate-dependent, as Barr et al. demonstrated raloxifene to be a purely 
competitive inhibitor of DACA oxidation, while Obach et al. observed only 
uncompetitive inhibition with respect to phthalazine oxidation (Obach, 2004; Barr 
and Jones, 2011).  Hydralazine has been demonstrated to act as both a competitive 
and time-dependent inhibitor of AO (Critchley et al., 1994; Strelevitz et al., 2012). To 
date, the only clinical drug interaction that has been reported between a drug 
metabolized by AO and a recognized AO inhibitor is a moderate interaction between 
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the AO substrate zaleplon and cimetidine; however, cimetidine inhibits not only AO, 
but also the secondary clearance pathway for zaleplon, P450 3A4 (Renwick et al., 
2002).  
 
 
Table I.1. Example AO inhibitors. IC50 values represent inhibitory potencies toward human 
liver aldehyde oxidase.  Potency of raloxifene and menadione obtained from Obach et al 
(Obach et al., 2004).  Hydralazine potency obtained from Zientek et al (Zientek and Youdim, 
2015). 
 
Aldehyde Oxidase Expression 
Single human aldehyde oxidase isoform 
 Only a single functional AO isoform is expressed in human and is encoded by 
the gene AOX1 (Garattini and Terao, 2012). Human AOX1 expression is widely 
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distributed, with high levels of mRNA found in the liver, adrenal gland, prostate and 
adipose tissue (Terao et al., 2016). It has been detected in many other tissues as 
well, including highly perfused organs such as the lung and kidney (Terao et al., 
2016).  Although liver has been identified as the richest source of AOX1 protein 
(Moriwaki et al., 2001), the enzyme’s broad tissue distribution presents the 
potential for AO-susceptible drugs to undergo extra-hepatic metabolism in vivo. 
Hutzler et al., for example, demonstrated metabolism of the AO substrate BIBX1382 
in S9 fractions of human adrenal gland, kidney, and lung, possibly explaining the 
rapid clearance observed in patients, which exceeded hepatic blood flow (Hutzler et 
al., 2014a).  
Species-specific aldehyde oxidase isoforms 
AO expression is highly variable across species, with humans and most 
primates expressing only a single AO enzyme (AOX1), while others express as many 
as 4 isoforms (AOX1, AOX2, AOX3, and AOX4) (Garattini and Terao, 2012; Terao et 
al., 2016). Table I.2 reveals the variability in expression of AO isoforms in species 
commonly used for drug metabolism and pharmacokinetics (DMPK) and toxicology 
studies (Garattini and Terao, 2012; Terao et al., 2016). Importantly, rat and mouse 
express two liver isoforms (AOX1 and AOX3), while dog expresses no functional 
liver isoform at all. Furthermore, AOX3 is the predominant isoform expressed in 
mouse liver, bearing only 65% sequence identity with human AOX1 (Coelho et al., 
2015)(in contrast to 85% homology between human and mouse AOX1). Tissue 
distribution of AO isoforms is also species-specific (Terao et al., 2016). AOX1 and 
AOX3 mRNA, for example, has been detected in many tissues in humans and/or 
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mice (Terao et al., 2016). The mouse AOX2 isoform, however, is specifically 
expressed in the nasal mucosa (Terao et al., 2000). Furthermore, the tissues 
expressing the highest levels of AOX1 mRNA in mice do not overlap with those in 
human except for the liver, and mouse AOX1 and AOX3 expression is not as widely 
distributed as human AOX1 (Terao et al., 2016). Challenges in predicting human 
clearance of drugs metabolized by AO have been attributed to these species 
differences in AO expression, in addition to other factors, discussed later. 
 
 
Table I.2. Aldehyde oxidase isoenzymes expressed in liver and other tissues of humans and 
experimental animals. Inactive pseudogenes are also listed. Adapted from Garattini and 
Terao (Garattini and Terao, 2012).  
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Age-dependent aldehyde oxidase expression   
From a developmental perspective, AOX1 activity and protein levels have 
been found to be low in liver cytosol of human infants under 4 months of age, 
reaching adult levels by age 2 (Tayama et al., 2012). Likewise, AOX1 protein and 
activity has been demonstrated to be low in rats until 4 weeks of age (Tayama et al., 
2007) and in mice until adulthood, while AOX3 plateaus in mice by 5 days (Terao et 
al., 2016).  
Regulation of aldehyde oxidase expression 
Studies indicate that mouse (Hu et al., 2006), rat (Maeda et al., 2012), and 
human (Shintani et al., 2015) AOX1/Aox1 gene expression is regulated by the 
transcription factor Nrf2, which has been demonstrated to bind antioxidant 
responsive elements (ARE) located in the 5’-upstream region of the rat AOX1 gene, 
resulting in activation of gene expression (Maeda et al., 2012).  Nrf2 is also 
associated with regulating expression of other drug-metabolizing enzymes as well 
as drug transporters (Huang et al., 2015).  In addition, studies in rabbits (Johnson et 
al., 1984), rats (Ohkubo et al., 1983), and mice (Rivera et al., 2005) suggest AO is an 
inducible enzyme.  Induction of mouse AOX1 and AOX3 in the presence of dioxin, 
along with an absence of induction in cells lacking the aryl hydrocarbon receptor 
(AHR) or aryl hydrocarbon receptor nuclear translocator (ARNT) proteins, indicate 
that AO induction proceeds through the AHR pathway (Rivera et al., 2005). 
However, another AHR ligand, 3-methylcholanthrene, has been shown to have no 
inductive effect on mouse AO, indicating the possibility that other elements may 
influence the AO inductive mechanism (Sugihara et al., 2001).  Upregulation of 
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human AOX1 has also been observed in a human bronchial epithelial cell line 
(16HBE cells) treated with the corticosteroid dexamethasone, which was found to 
be associated with increased airway epithelial barrier integrity (Shintani et al., 
2015).   
 
Species-Specific Aldehyde Oxidase Activity 
As might be expected due to variation in the number of AO isoforms 
expressed across species, differences in hepatic AO activity have been observed, 
with human and monkey generally exhibiting higher activity than rats, and no 
activity in dog (Pryde et al., 2010). However, with the exception of dog, the relative 
activity between species is substrate-dependent and does not exclusively abide by 
this trend. For example, while rat underpredicted the oral bioavailability of AO 
substrates BIBX1382 (Dittrich et al., 2002) and FK3453 (Akabane et al., 2011), 
metabolism of VU0409106 (Morrison et al., 2012) and zoniporide (Dalvie et al., 
2010) in Sprague Dawley (SD) rat were comparable to or greater than human.  
Monkey has demonstrated similar AO-mediated metabolism to human for several 
substrates (Kawashima et al., 1999; Itoh et al., 2006; Diamond et al., 2010a; 
Morrison et al., 2012; Hutzler et al., 2014a), which is not surprising considering 
monkeys, like humans, express only the AOX1 isoform (in the liver) (Garattini and 
Terao, 2012), which bears 96% sequence identity to human AOX1 (Hoshino et al., 
2007).  However, cynomolgus monkey failed to predict human clearance of the p38 
kinase inhibitor RO1 (Zhang et al., 2011), and rhesus monkey cytosol exhibited 20-
 13 
fold higher intrinsic clearance of pthalazine versus human cytosol (Choughule et al., 
2013a), again reiterating the substrate dependency of AO metabolism across 
species.  Analysis of human AOX1 and mouse AOX3 crystal structures revealed 
differences in the MoCo active site and substrate channel, helping to explain 
differences in AO activity observed between species (Coelho et al., 2015). Likewise, 
homology modeling of the four mouse AO isoforms also indicated differences in the 
substrate-binding region (Terao et al., 2016).  Accordingly, of the select substrates 
evaluated in a report by Vila et al, most exhibited a higher intrinsic clearance by 
mouse AOX1 relative to AOX3 (Vila et al., 2004).  
 
Sex Differences in Aldehyde Oxidase Activity 
 Differences in AO activity have been reported in male and female nonclinical 
species, albeit in a substrate and species-specific manner (Beedham, 1985; Klecker 
et al., 2006; Akabane et al., 2011; Dalvie et al., 2013). For example, AO-mediated 
metabolism of zoniporide measured in hepatic S9 fractions revealed higher activity 
in males for some species (e.g., SD rat), while female activity was higher in other 
species (e.g., Gottingen minipig) (Dalvie et al., 2013). Differences in zoniporide 
metabolism were even noted across different strains of rat, with females exhibiting 
elevated AO activity versus males in Wistar and Fischer rat strains in contrast to SD 
rat (Dalvie et al., 2013).  In addition to the species-dependent differences in AO 
activity between the sexes, substrate-dependent differences have also been noted.  
For example, while a 6-fold increase in the AO-mediated intrinsic clearance (CLint) of 
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zoniporide (Dalvie et al., 2013) was observed in liver S9 of male CD-1 mice relative 
to female, a 50-fold difference was observed in the AO-mediated metabolism of 
zebularine (Klecker et al., 2006) between male and female CD-1 mouse liver cytosol. 
Alternatively, in SD rat liver fractions, male exhibited a 2-fold higher intrinsic 
clearance of zoniporide versus female (Dalvie et al., 2013), while no difference was 
observed for zebularine (Klecker et al., 2006).  Furthermore, intrinsic clearance of 
FK3453 was found to be 11-fold greater in female SD rats over males (Akabane et 
al., 2011).  Human, however, has been consistently reported to exhibit no 
differences in AO activity between males and females (Al-Salmy, 2001; Klecker et al., 
2006; Dalvie et al., 2013). Studies in mice demonstrated that growth hormone and 
testosterone increased hepatic AO activity, while it was decreased by estradiol 
(Yoshihara and Tatsumi, 1997). Likewise, testosterone increased AOX1 and AOX3 
mRNA and protein in mouse liver (Kurosaki et al., 1999) (Terao et al., 2000). 
Conversely, testosterone was shown to decrease expression of AOX4 in the 
Harderian gland of mice (Terao et al., 2009). Interestingly, despite no differences 
observed between male and female AOX1 expression or activity in human liver, 
estradiol, ethinyl estradiol, and estrogen-related drugs raloxifene and tamoxifen 
were found to inhibit human AO in vitro (Obach et al., 2004).  Estradiol, however, 
was reported to inhibit AO predominantly through an uncompetitive mode of 
inhibition, and although it exhibited some degree of competitive inhibition, plasma 
concentrations in women are predicted to be well-below the estimated Kis 
(dissociation constant for the enzyme-inhibitor complex) value, precluding the 
likelihood of a significant inhibitory effect in vivo (Barr and Jones, 2011). 
 15 
Endogenous Aldehyde Oxidase Substrates and Physiological Relevance 
While several endogenous compounds have been identified as AO substrates, 
including but not limited to retinaldehyde, indol, pyridoxal, and nicotinamide, the 
physiological role of AO (aside from xenobiotic metabolism) remains poorly 
understood (Garattini et al., 2008; Sanoh et al., 2015; Terao et al., 2016). The 
differences in AO expression across species further complicate the elucidation of the 
enzyme’s role in human physiology. For example, it is possible that AOX4 and AOX2 
have species specific functions not carried out by AOX1 in humans, as AOX4 is 
predominantly expressed in the Harderian gland (absent in humans) in the eye, and 
AOX2 is exclusively expressed in the nasal cavity, possibly serving a role in olfaction 
for mammals expressing this isoform (Terao et al., 2016). Many potential 
physiological contributions of AOX1 have been proposed, including, but not limited 
to, maintenance of airway epithelial barrier integrity, adipogenesis, myocyte 
differentiation, and nitric oxide production under hypoxic conditions (Terao et al., 
2016), as well as metabolism of an endogenous DNA adduct following excision and 
repair (Otteneder et al., 2006).  However, studies are limited, and extrapolation of 
data available on endogenous AO substrates across species and even interpretation 
of physiological relevance within a single species is difficult due to a lack of data on 
relative specificity of identified endogenous substrates for the different inter- and 
intra-species AO isoforms.  
The most data available regarding an endogenous role for AO surrounds 
vitamin A metabolism.  All-trans retinoic acid (ATRA) is the active form of vitamin A, 
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which is involved in development of many tissues and organs in vertebrate 
embryos, as well as vision and growth/differentiation of skin epithelial and 
hematopoietic cells in adult organisms (Terao et al., 2016).  All-trans retinaldehyde 
(RAL) has been identified as a substrate of rabbit liver AOX (Tomita et al., 1993; 
Huang et al., 1999) as well as all four mouse AOX isoforms (Huang et al., 1999; 
Kurosaki et al., 2004; Vila et al., 2004; Terao et al., 2009; Terao et al., 2016), with the 
enzymes demonstrating conversion of RAL to ATRA. Furthermore, Aox4 knockout 
mice exhibited decreased levels of ATRA in skin and Harderian gland and 
downregulation of retinoid-dependent genes, as well as perturbations in lipid 
homeostasis and thickening of the epidermis (Terao et al., 2009).  However, kinetic 
studies revealed that mouse liver AOX1 and AOX3 are unlikely to contribute 
substantially to the formation of ATRA due to high levels of aldehyde 
dehydrogenases exhibiting much higher affinity and activity towards RAL relative to 
AOX1 and AOX3 (Garattini et al., 2008; Terao et al., 2009). As AO activity is only 
detectible in mice after birth, a role for AO-mediated involvement of vitamin A in 
developing mouse embryos is unlikely (Terao et al., 2016). 
 
Human Aldehyde Oxidase Single Nucleotide Polymorphisms 
 Multiple single nucleotide polymorphisms (SNPs) have been identified for 
the human AOX1 gene. The clinical significance of these SNPs in drug metabolism, 
however, remains unclear. One study of a cohort of 180 Italian patients reported 
three nonsynonymous SNPs associated with poor (rs56199635) and fast 
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(rs55754655 and rs3731722) metabolizers, determined using enzymes purified 
after heterologous expression in Escherichia coli (Hartmann et al., 2012).  
Accordingly, the two fast metabolizer variants have been associated with poor 
response to the immunosuppressant azathioprine, which is inactivated by AO 
(Smith et al., 2009). However, another study evaluating human hepatocytes from 75 
donors reported no statistically significant differences in the intrinsic clearance 
measured in hepatocytes from wild-type donors versus those with either the 
rs55754655 or rs3731722 variants (Hutzler et al., 2014b).  In addition, patients 
treated with the topoisomerase II inhibitor XK469 exhibited a wide range of 
clearance values, which were not explained by the SNPs identified in these patients; 
however, a significant decrease in clearance was associated with the rs10931910 
variant when a cohort of patients with solid tumors was considered in isolation 
(Ramirez et al., 2014).  A recent report by Foti et al. identified two AOX1 mutations 
resulting in the inability to synthesize a stable protein due to loss of FeSII insertion 
(C44W) and another resulting in a stable protein but complete loss of activity 
(G1269R) (Foti et al., 2016).   
 
Identification of Aldehyde Oxidase Metabolism 
 Strategies to identify AO-mediated metabolism have been established that 
involve a variety of in vitro techniques.  The structure of a compound offers an initial 
indication as to the potential for AO metabolism, particularly the presence of an 
aromatic nitrogen-containing heterocycle, as previously noted. In fact, an evaluation 
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by Pryde et al. found no correlation between AO-mediated metabolism and 
physiochemical properties such as cLogP and polar surface area, but rather 
concluded that the presence of an unsubstituted aromatic carbon adjacent to the 
nitrogen of an aromatic ring is more likely to indicate a potential for AO 
susceptibility (Pryde et al., 2010).  In addition, AO exhibits several characteristics 
that can be utilized to distinguish AO-mediated metabolism from that catalyzed by 
other enzymes, particularly P450-mediated metabolism (Table I.3).  First of all, AO 
is a cytosolic enzyme, whereas P450s are localized to the endoplasmic reticulum.  
Consequently, metabolism occurring in the cytosolic subcellular (liver) fraction, but 
not the microsomal fraction, indicates the possibility of AO-mediated metabolism 
(Dalvie and Zientek, 2015). Likewise, the S9 fraction, which contains both the 
cytosolic and microsomal fractions, can be employed in the absence and presence of 
NADPH to differentiate between AO and P450-mediated metabolism, respectively, 
since, unlike cytochrome P450s, AO does not require the co-factor NADPH for 
catalytic activity (Dalvie and Zientek, 2015). Accordingly, the recognition of NADPH-
independent metabolism indicates the potential involvement of AO, even when the 
metabolism occurs in microsomes, which at times may be contaminated with small 
amounts of cytosol (Diamond et al., 2010a; Dalvie and Zientek, 2015).  Because the 
closely related molybdo-flavoenzyme xanthine oxidase (XO) is also localized to the 
cytosol and can catalyze NADPH-independent oxidation of aromatic 
azaheterocycles, the use of AO and/or XO-specific inhibitors are required to confirm 
AO metabolism (Dalvie and Zientek, 2015).  As previously discussed, common AO 
inhibitors include menadione, raloxifene, and hydralazine, the latter of which is 
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believed to be the most AO-specific (Obach et al., 2004; Strelevitz et al., 2012; Dalvie 
and Zientek, 2015).  Allopurinol is frequently used to identify XO-mediated 
metabolism and is clinically marketed as an XO inhibitor (Kitamura et al., 2006). 
Hepatocytes are commonly employed in drug metabolism assessments, as they 
contain the full complement of hepatic drug-metabolizing enzymes and co-factors.  
Hepatocytes, therefore, may also be employed to identify the involvement of AO via 
the utilization of AO-specific inhibitors (Dalvie and Zientek, 2015). Finally, the 
catalytic mechanism of molybdenum hydroxylases can also be exploited to isolate 
AO/XO metabolism. Because P450s utilize molecular oxygen as their source for 
oxidative metabolism (Guengerich, 2001), in contrast to AO/XO which derive their 
oxygen from water (Alfaro and Jones, 2008), substrate incubation with hepatocytes 
or S9/cytosol in the presence of 18O-labeled water will result in 18O-incorporation 
into the metabolite if AO (or XO) is involved (Diamond et al., 2010a; Hutzler et al., 
2012; Morrison et al., 2012).  
 
 
Table I.3. Distinctive characteristics of cytochrome P450s versus aldehyde oxidase. 
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Failed Clinical Aldehyde Oxidase Substrates 
Several drug candidates have failed in clinical trials in recent years due to 
unexpectedly rapid clearance or toxicity related to an AO-mediated metabolite that 
went unrecognized in preclinical development (Table I.4) (Kaye et al., 1985; Dittrich 
et al., 2002; Diamond et al., 2010a; Zhang et al., 2011; Lolkema et al., 2015). In these 
cases, inappropriate use of microsomes (lacking cytosol, thus lacking AO) for in vitro 
intrinsic clearance estimates resulted in the underprediction of human hepatic 
clearance, and employment of preclinical species with decreased (e.g., rat and 
mouse) or absent (dog) AO activity towards the candidate drug relative to humans 
resulted in an overestimation of human oral exposure. Carbazeran, BIBX1382, RO1, 
and FK3453 were all terminated during clinical assessment due to poor exposure 
(Dittrich et al., 2002; Akabane et al., 2011). Two other clinical candidates, c-Met 
inhibitors SGX523 and JNJ-38877605, were recently terminated not because of 
unexpected rapid clearance, but due to renal toxicity associated with a poorly 
soluble AO metabolite (Diamond et al., 2010a).  Again, preclinical species (rat and 
dog) employed in toxicology assessments produced lower quantities of the AO 
metabolite relative to human, thus preventing occurrence of the AO metabolite-
associated renal toxicity in these animals (Diamond et al., 2010a; Lolkema et al., 
2015).  
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Table I.4. Drugs that have failed in clinical trials due to unidentified/underpredicted human 
AO-mediated metabolism. Arrows indicate the site of AO oxidation. Adapted from Hutzler et 
al. (Hutzler et al., 2013). 
 
 
Challenges in Predicting Human Pharmacokinetics of Aldehyde Oxidase 
Substrates 
 It is clear from the recent failures in clinical trials that traditional methods 
for predicting human PK are often unsuitable for AO substrates. In addition to the 
species differences in AO activity and expression, broad tissue distribution (i.e., 
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potential for extra-hepatic metabolism), and AOX1 single nucleotide 
polymorphisms, several other factors may contribute to the difficulty in predicting 
the human disposition of drugs metabolized by AO. Several reports, for example, 
have found that scaled in vitro estimates of intrinsic clearance for AO substrates 
using human hepatic S9/cytosol or fresh/cryopreserved hepatocytes under-predict 
the clearance observed in vivo (Zientek et al., 2010; Akabane et al., 2012; Hutzler et 
al., 2012). In addition, a wide range in variability has been reported for in vitro 
clearance estimates of AO substrates (Hutzler et al., 2014b). Uncertainty remains as 
to which factor(s) are responsible for these observations.  While polymorphisms 
may contribute, it has also been proposed that the processing of liver tissue for 
preparation of hepatocytes and liver fractions may destabilize the protein (e.g., 
dimer dissociation) or a deficiency of the MoCo may play a role (Fu et al., 2013). 
Furthermore, two laboratories have reported a 50-fold difference in levels of AOX1 
quantified by LC-MS from pooled human liver cytosol (21-40 pmol/mg)(Barr et al., 
2013) or cytosol of individual donors (0.74-2.3 pmol/mg) (Fu et al., 2013).  Finally, 
environmental factors and disease states may also influence AO expression and 
activity, but at present are poorly understood (Fu et al., 2013; Hutzler et al., 2014b; 
Terao et al., 2016). The recent increase in AO metabolism of compounds in drug 
discovery and development (Pryde et al., 2010) highlights the importance of 
continued attention to the study of AO function and regulation, and particularly to 
improved methods for predicting human PK and disposition of AO substrates.  
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CHAPTER II 
MATERIALS AND METHODS 
 
Materials 
VU0409106 was prepared and characterized by the Department of Medicinal 
Chemistry within the Vanderbilt Center for Neuroscience Drug Discovery.  
Potassium phosphate, ammonium formate, formic acid, magnesium chloride, 
dimethyl sulfoxide, 1-aminobenzotriazole (ABT), hydralazine hydrochloride, 
allopurinol, carbamazepine, O6-benzylguanine, and zaleplon were purchased from 
Sigma-Aldrich (St. Louis, MO). Nicotinamide adenine dinucleotide phosphate 
(NADPH) tetrasodium salt was purchased from VWR (Radnor, PA). Zoniporide 
dihydrochloride, BIBX1382 dihydrochloride, and SGX523 were purchased from 
Tocris Bioscience (R&D Systems, Minneapolis, MN). Pooled human (150-donor, 
mixed gender) or male Sprague-Dawley (SD) rat hepatic microsomes and S9 were 
obtained from BD Biosciences (San Diego, CA). Pooled male CD-1 mouse, 
cynomolgus monkey, and SD rat hepatic S9 were obtained from Corning Inc. 
(Tewksbury, MA). Pooled male rhesus monkey and Hartley guinea pig hepatic S9 
were purchased from XenoTech (Lenexa, KS), and pooled male Gottingen minipig 
hepatic S9 was purchased from BioreclamationIVT (Baltimore, MD). Pooled female 
SD rat, Gottingen minipig, Hartley guinea pig, and cynomolgus monkey hepatic S9 
were purchased from BioreclamationIVT, pooled female rhesus monkey hepatic S9 
was purchased from XenoTech, and pooled female CD-1 mouse hepatic S9 was 
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purchased from Corning Inc. Male SD rat, CD-1 mouse, Hartley guinea pig, and 
Gottingen minipig plasma was purchased from BioreclamationIVT. Bacterial 
membranes (Escherichia coli) containing human cytochrome P450 enzymes (1A2, 
2C9, 2C19, 2D6, and 3A4) co-expressed with human NADPH-cytochrome P450 
reductase were obtained from Cypex Ltd (Dundee DD2 1NH, United Kingdom). All 
solvents used for bioanalysis were purchased from Sigma-Aldrich or Fisher 
Scientific (Waltham, MA) and were of high-performance liquid chromatography 
(HPLC) grade. 
 
In Vitro Biotransformation and Clearance of VU0409106 
Biotransformation in hepatic microsomal and recombinant human P450 incubations  
The in vitro metabolism of VU0409106 was investigated in rat and human 
hepatic microsomal fractions and recombinant human P450 enzymes (rhP450; 1A2, 
2C9, 2C19, 2D6, and 3A4). A potassium phosphate-buffered reaction (100 mM, pH 
7.4) of VU0409106 (10 M), hepatic microsomes (1 mg/mL) or rhP450 (0.2 
nmol/mL), MgCl2 (3 mM) and NADPH (2 mM) was incubated at 37°C in borosilicate 
glass test tubes under ambient oxygenation for 60 minutes with or without pre-
incubation with the AO inhibitor hydralazine (25 M). The total incubation volume 
was 0.5 mL. Reactions were initiated by the addition of VU0409106, terminated 
with the addition of 2 volumes of acetonitrile, and subsequently centrifuged at 3500 
rcf for 10 min. The resulting supernatant was dried under a stream of nitrogen and 
reconstituted in 85:15 (v/v) water:acetonitrile in preparation for LC/MS analysis. 
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Metabolite formation in hepatic S9 fractions  
Experiments in hepatic S9 were designed to measure formation of the 
VU0409106 AO metabolite M1 in the presence and absence of P450 activity. 
Formation of M1 was measured in incubations of VU0409106 (1 M) with rat and 
human hepatic S9 fractions (2.5 mg/mL) containing potassium phosphate buffer 
(100 mM, pH 7.4), and MgCl2 (3 mM), with or without NADPH (1 mM). Total 
incubation volume was 200 L. Reactions were initiated with addition of 
VU0409106, and at designated times (t = 0, 7, 15, 30, 45, and 60 minutes), aliquots 
were removed and precipitated with ice-cold acetonitrile containing an internal 
standard (carbamazepine, 50 nM). The mixture was centrifuged at 3500 rcf for 5 
min and resulting supernatants diluted with water in preparation for LC/MS/MS 
analysis.  Experiments were performed in triplicate. 
Intrinsic clearance in hepatic S9 fractions  
Intrinsic clearance (CLint) of VU0409106 was determined in rat and human S9 
fractions at three different concentrations of VU0409106, using NADPH and 
hydralazine to isolated the NADPH-dependent (P450), NADPH-independent (AO), 
and total (P450 + AO) hepatic S9 CLint for each species.  For measurement of a) total, 
b) NADPH-independent, and c) NADPH-dependent S9 CLint, VU0409106 (0.1 M, 1 
M, or 10 M) was incubated in rat or human S9 fractions (2.5 mg/mL) containing 
potassium phosphate buffer (100 mM, pH 7.4), and MgCl2 (3 mM), a) in the presence 
of NADPH, b) in the absence of NADPH, or c) in the presence of NADPH after pre-
incubation with the AO-specific inhibitor hydralazine (50 M), respectively. Total 
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incubation volume was 200 L. Reactions were initiated with addition of 
VU0409106, and at designated times (t = 0, 7, 15, 20, 30, and 45 minutes), aliquots 
were removed and precipitated with ice-cold acetonitrile containing an internal 
standard (carbamazepine, 50 nM). The mixture was centrifuged at 3500 rcf for 5 
min and resulting supernatants diluted with water in preparation for LC/MS/MS 
analysis of substrate depletion, by monitoring the analyte/internal standard ratio. 
Experiments were performed in triplicate. Calculation of CLint (mL/min/kg) was 
estimated using the substrate depletion method (see Figure II.1 and Equation II.1). 
 
In Vivo Metabolism and Disposition of VU0409106 in Sprague-Dawley Rats 
Animal studies were approved by the Vanderbilt University Medical Center 
Institutional Animal Care and Use Committee. To evaluate the pharmacokinetics of 
VU0409106, 8-12 week old male SD rats (n = 2) weighing between 250 and 325 g 
were purchased from Harlan (Indianapolis, IN) with catheters surgically implanted 
in the carotid artery and jugular vein for intravenous administration of 1 mg/kg 
VU0409106.  SD rats weighing between 350 and 415 g receiving 1 mg/kg 
VU0409106 via the mesenteric ileal vein or the hepatic portal vein were surgically 
implanted with catheters in either the mesenteric ilea vein or the hepatic portal vein 
and the jugular vein. The cannulated animals were acclimated to their surroundings 
for approximately 1 week before dosing and provided food and water ad libitum.  
Similarly, in-life studies in SD rats receiving an intraperitoneal dose of 3 mg/kg (n = 
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3 for control group and n = 4 for ABT group) or 10 mg/kg (n = 2 for all groups) of 
VU0409106 were conducted at Frontage Laboratories (Exton, PA).   
Intravenous or intraperitoneal administration of VU0409106  
Inhibitors of P450 (ABT), aldehyde oxidase (hydralazine), or xanthine oxidase 
(allopurinol) were administered orally to male SD rats at 50 mg/kg at a dose volume 
of 5 mL/kg (ABT, 1% methylcellulose), 2.5 mL/kg (allopurinol, 1% methylcellulose), 
or 20 mL/kg (hydralazine, water).  Two hours following inhibitor administration, a 
dose of VU0409106 (10% ethanol/70% PEG400/20% saline) was administered at 3 
or 10 mg/kg intraperitoneally (IP), or intravenously (IV) at 1 mg/kg. Blood (200 L) 
was collected via the carotid artery at 0.0833, 0.25, 0.5, 1, 2, 4, 6, 8, 10, 12 and 24 
hours post administration of VU0409106. Samples were collected in chilled, EDTA-
fortified tubes and centrifuged for 5 min (1700 rcf, 4°C), and the resulting plasma 
was stored at - 80°C until LC/MS/MS analysis. The resulting plasma samples were 
protein precipitated with ice-cold acetonitrile containing internal standard 
(carbamazepine, 50 nM), centrifuged (3500 rcf for 5 min) and the resulting 
supernatants diluted with water in preparation for LC/MS/MS analysis. For 
individual analysis of M4 and M6, plasma aliquots (samples collected at 1, 2, 4, and 6 
hours) from rats receiving 10 mg/kg VU0409106 were pooled and precipitated with 
acetonitrile, then centrifuged at 3500 rcf for 10 min. Supernatants were dried under 
a stream of nitrogen, and resulting residues reconstituted in 85:15 (v/v) 
water:acetonitrile in preparation for LC/MS analysis. 
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Hepatic portal vein or mesenteric ileal vein administration of VU0409106  
Studies were also conducted with VU0409106 dosed via the mesenteric ileal 
vein, which drains into the hepatic portal vein.  Vehicle (1% methylcellulose), ABT 
(50 mg/kg ) or hydralazine (10 mg/kg) was administered orally at a dose volume of 
5 mL/kg, 2 hours prior to administration of 1 mg/kg VU0409106 (dose volume of 5 
mL/kg, 10% EtOH 70% PEG400 20% saline) via the mesenteric ileal vein.  The study 
was conducted in a crossover fashion, with rats (n =3) receiving vehicle pre-
treatment first, then crossed over to ABT pre-treatment, and finally hydralazine 
pretreatment, each with a one week washout period in between inhibitor groups.  
Deshmukh, et al previsouly reported ABT had no residual effects on drug disposition 
in male SD rats following a 7-day washout (Deshmukh et al., 2008). Blood and 
plasma collection was carried out as described above, with blood collected at 0, 
0.033, 0.117, 0.25, 0.5, 1, 2, 4, and 8 hours after VU0409106 administration.   
Administration was conducted via the mesenteric ileal vein as a substitution for the 
hepatic portal vein in order to avoid potential problems with maintaining portal 
vein cannulation throughout this extended study period, as hepatic portal vein 
cannulation requires an invasive surgical procedure.  Prior to conducting studies 
with inhibitors, a pilot study was conducted to ensure that dosing via the mesenteric 
ilea vein would produce similar pharmacokinetics to hepatic portal vein 
administration.  For this study, VU0409106 was formulated as described above and 
administered to a mesenteric ileal vein cannulated rat (n =1) and to hepatic portal 
vein cannulated rats ( n = 2), followed by blood collection at 0.033, 0.117, 0.25, 1, 2, 
4, 8, and 24 hours. 
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In Vitro Biotransformation and Clearance of Zaleplon, O6-Benzylguanine, 
Zoniporide, BIBX1382, and SGX523 
Biotransformation in hepatic S9 incubations  
The in vitro metabolism of zaleplon, O6-benzylguanine, zoniporide, BIBX1382, 
and SGX523 was investigated in human (mixed gender), and male CD-1 mouse, 
Sprague-Dawley rat, Hartley guinea pig, cynomolgus monkey, rhesus monkey, and 
Gottingen minipig S9 fractions.  A potassium phosphate-buffered reaction (100 mM, 
pH 7.4) of substrate (25 M), hepatic S9 (5 mg/mL), and MgCl2 (3 mM), with or 
without NADPH (2 mM) was incubated at 37°C in borosilicate glass test tubes under 
ambient oxygenation for 60 minutes. The total incubation volume was 1 mL. 
Reactions were initiated by the addition of substrate, terminated with the addition 
of 2 volumes of acetonitrile, and subsequently centrifuged at 3500 rcf for 10 min. 
The resulting supernatant was dried under a stream of nitrogen and reconstituted 
in 85:15 (v/v) water:acetonitrile in preparation for LC/MS analysis. 
Intrinsic clearance and estimated hepatic clearance from hepatic S9 incubations  
Zaleplon, O6-benzylguanine, zoniporide, BIBX1382, or SGX523 (1 M) was 
incubated at 37°C in a potassium phosphate-buffered reaction (100 mM, pH 7.4) 
containing hepatic S9 from human (mixed gender) or male and female CD-1 mouse, 
Sprague-Dawley rat, Hartley guinea pig, cynomolgus monkey, rhesus monkey, or 
Gottingen minipig (2.5 mg/mL), MgCl2 (3 mM), with or without NADPH (1 mM). 
Reactions were initiated with addition of substrate, and at designated times (t = 0, 7, 
15, 30, 45, and 60 min), aliquots were removed and precipitated with ice-cold 
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acetonitrile containing an internal standard (carbamazepine, 50 nM). The mixture 
was centrifuged at 3500 rcf for 5 min and resulting supernatants diluted with water 
in preparation for LC/MS/MS analysis of substrate depletion, by monitoring the 
analyte/internal standard ratio. Experiments were performed in triplicate. Hepatic 
intrinsic clearance (CLint) was estimated using the substrate depletion method (see 
Figure II.1 and Equation II.1). Hepatic clearance (CLHEP) was estimated using the 
well-stirred model, described by Equation II.2, and the hepatic extraction ratio (E) 
was estimated using Equation II.3.  Subsequently, CLint obtained from incubations in 
S9 of male preclinical species were used to predict human S9 CLint by multispecies 
simple allometry (Equation II.13) and single-species scaling (Equation II.14).  
Estimation of fraction metabolized by aldehyde oxidase (Fm, AO) in hepatic S9 
Zaleplon, O6-benzylguanine, zoniporide, BIBX1382, or SGX523 (1 M) was 
incubated at 37°C in a potassium phosphate-buffered reaction (100 mM, pH 7.4) 
containing hepatic S9 from human (mixed gender) or male CD-1 mouse, Sprague-
Dawley rat, Hartley guinea pig, cynomolgus monkey, rhesus monkey, or Gottingen 
minipig (2.5 mg/mL), MgCl2 (3 mM), with or without NADPH (1 mM), and with or 
without 15 minute pre-incubation with the AO inhibitor hydralazine. Reactions 
were initiated with addition of substrate, and at designated times (t = 0, 7, 15, 30, 
45, and 60 min), aliquots were removed and precipitated with ice-cold acetonitrile 
containing an internal standard (carbamazepine, 50 nM). The mixture was 
centrifuged at 3500 rcf for 5 min and resulting supernatants diluted with water in 
preparation for LC/MS/MS analysis of substrate depletion, by monitoring the 
analyte/internal standard ratio. Experiments were performed in triplicate. Hepatic 
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intrinsic clearance (CLint) was estimated using the substrate depletion method 
(Figure II.1 and Equation II.1). Subsequently, the Fm, AO of the five substrates was 
estimated for each species, using two different methods (A and B), described by 
Equations II.4 and II.5, respectively 
 
Multispecies Determination of Pharmacokinetic Parameters of Zaleplon, O6-
Benzylguanine, Zoniporide, BIBX1382, and SGX523  
Intravenous cassette administration of zaleplon, O6-benzylguanine, zoniporide, 
BIBX1382, and SGX523 
In-life studies in minipigs and guinea pigs were conducted at WIL Research 
(Ashland, OH) and studies in rats and mice were conducted at Frontage 
Laboratories (Exton, PA). Test articles were formulated (5% DMSO/5% 
ethanol/40% PEG-400/50% phosphate buffered saline) and administered as a 
cassette via an IV bolus dose at 0.2 mg/kg per compound. Male Gottingen minipigs 
(n = 2) age 3-5 months weighing approximately 7.5 kg were purchased from 
Marshall Bioresources and Hartley guinea pigs (n = 3) age 4-6 weeks weighing 400-
430 g were purchased from Charles River Laboratories. Minipigs received the test 
article formulation (2 mL/kg) via ear vein administration and blood (1 mL) was 
collected via the jugular vein. Guinea pigs were cannulated in the left jugular vein for 
administration (2 mL/kg) and the right jugular vein for blood collection (500 L).  
Blood samples were collected from minipigs and guinea pigs at 2, 7, 15, and 30 
minutes and 1, 2, 4, 8, 12, and 24 hours post-dosing. Male Sprague-Dawley rats (n= 
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3) age 7-9 weeks weighing approximately 300-400 g and CD-1 mice (n = 3 per time 
point, 30 mice in total) age 8-12 weeks weighing 19-25 g were purchased from 
Charles River Laboratories. Juguar vein cannulated rats received the test article 
formulation (2 mL/kg) via the femoral vein and blood (200 L) was collected via the 
jugular vein. Mice were administered the test article formulation (4 mL/kg) via the 
tail vein and blood was collected (100-200 L) via terminal cardiac puncture.  Blood 
samples were collected from rats and mice at 2, 5, 15, and 30 minutes and 1, 2, 4, 6, 
8, and 24 hours post-dosing. Blood was collected over EDTA and centrifuged for 
plasma isolation.  Plasma was stored at -80oC until shipment on dry ice to Vanderbilt 
for bioanalysis. 
 
Liquid Chromatography-Mass Spectrometry Methods 
 Quantitation of analytes (substrate or metabolite) present in extracts of 
plasma or hepatic S9 incubations was performed using liquid chromatography-
tandem mass spectrometry (LC/MS/MS).  Qualitative detection/identification of 
analytes (substrate or metabolite) present in extracts of plasma, hepatic 
microsomes, S9, or recombinant human P450 incubations was performed using 
liquid chromatography-ultraviolet detection-tandem mass spectrometry 
(LC/UV/MS/MS).   
Quantitation from hepatic S9 incubations  
Substrate depletion or metabolite formation (VU0409106 metabolites M1 
and M6) in S9 fraction incubations with VU0409106, zaleplon, O6-benzylguanine, 
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zoniporide, BIBX1382, or SGX523 was determined by quantitation of the 
analyte:internal standard (carbamazepine, 237→194 ) peak area ratio using 
LC/MS/MS via electrospray ionization on a Sciex API-4000 triple quadrupole 
instrument (Sciex, Foster City, CA) coupled to LC-10AD pumps (Shimadzu, 
Columbia, MD)  and a CTC PAL autosampler (Leap Technologies, Carrboro, NC) or on 
an AB Sciex API-5500 QTrap instrument (Applied Biosystems, Foster City, CA) 
coupled to LC-20AD pumps (Shimadzu, Columbia, MD) and a CTC PAL autosampler 
(Leap Technologies, Carrboro, NC). Analytes were separated by gradient elution 
(Table II.1) using a Fortis C18 column (3 × 50 mm, 3 μm; Fortis Technologies Ltd., 
Cheshire, UK) warmed to 40°C. Mobile phase A was 0.1% formic acid in water (pH 
unadjusted); mobile phase B was 0.1% formic acid in acetonitrile, and the flow rate 
was 0.5 mL/min. Mass spectral analyses were performed using multiple reaction 
monitoring (MRM), with transitions (Table II.1) and voltages specific for each 
analyte using a Turbo Ion Spray source (source temp 500°C) in positive ionization 
mode (5.0 kV spray voltage). Data were analyzed using Sciex Analyst 1.5.1 software.   
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Table II.1. HPLC gradients and ion transitions monitored (multiple reaction monitoring) 
during LC/MS/MS quantitative analysis. 
 
Quantitation from plasma 
The quantitation of VU0409106 and its metabolites (M1, M2, M4-M6) from rat 
plasma or  zaleplon, O6-benzylguanine, zoniporide, BIBX1382, and SGX523 (cassette 
dose) from plasma of mouse, rat, guinea pig, or minipig was conducted via 
electrospray ionization on an AB Sciex API-5500 QTrap (Applied Biosystems, Foster 
 35 
City, CA) instrument that was coupled with LC-20AD pumps (Shimadzu, Columbia, 
MD).  Analytes were separated by gradient elution using a Fortis C18 column (3 × 50 
mm, 3 μm; Fortis Technologies Ltd., Cheshire, UK) warmed to 40°C. Mobile phase A 
was 0.1% formic acid in water (pH unadjusted); mobile phase B was 0.1% formic 
acid in acetonitrile. HPLC flow rate was 0.5 mL/min. The source temperature was 
set at 500°C, and mass spectral analyses were performed using multiple reaction 
monitoring, with transitions (Table II.1) and voltages specific for each analyte using 
a Turbo Ion Spray source in positive ionization mode (5.0 kV spray voltage). Data 
were analyzed using Sciex Analyst 1.5.1 software.  Concentrations of analytes were 
determined using matrix-matched standard curves (8 – 10 points) with a lower limit 
of quantitation = 0.5 ng/mL for VU0409106, zaleplon, and O6-benzyguanine, 5 
ng/mL for zoniporide, 5 ng/mL for BIBX523, and 1 ng/mL for SGX523. As no 
authentic standard was available to determine VU0409106 metabolite 
concentrations, a semi-quantitative analysis was expressed as the analyte:internal 
standard (carbamazepine, 237→194) peak area ratio (Morrison et al., 2012). 
Metabolite detection in hepatic microsomal, S9, and rhP450 incubations and in rat 
plasma  
Detection of VU0409106 metabolites generated in vitro or obtained from 
pooled rat plasma samples was performed with an Agilent 1100 HPLC system 
coupled to a LCQ Deca XPPLUS ion trap mass spectrometer (Thermoelectron Corp., 
San Jose, CA) and an Agilent 1100 diode array detector. Detection of metabolites of 
zaleplon, O6-benzylguanine, zoniporide, BIBX1382, and SGX523 generated in S9 
incubations was performed with an Agilent 1290 Infinity HPLC system coupled to a 
 36 
Thermo LTQ XL ion trap mass spectrometer (Thermoelectron Corp., San Jose, CA) 
and an Agilent 1290 Infinity diode array detector.  Analytes were separated by 
gradient elution using a Supelco Discovery C18 column (5 m, 2.1  150 mm; Sigma-
Aldrich, St. Louis, MO) over a total run time of 30 minutes (Table II.3). Solvent A was 
10 mM (pH 4.1) ammonium formate, and solvent B was acetonitrile. For the 
deuterium exchange experiment (VU0409106 metabolite M6), solvent A was 10 mM 
(pH 4.1) ammonium formate prepared in deuterium hydroxide. The flow rate was 
0.400 ml/min. The HPLC eluent was first introduced into the diode array detector 
(254 nM) followed by electrospray ionization-assisted introduction into the ion trap 
mass spectrometer operated in positive ionization mode. Ionization was assisted 
with sheath and auxiliary gas (ultra-pure nitrogen), according to Table II.2.  
Electrospray temperatures and voltages and heated ion transfer capillary 
temperatures and voltages are also listed in Table II.2. Data were analyzed using 
Thermo Xcalibur 2.0 (LCQ Deca XP) or Xcaliber 2.2 (LTQ XL) software. 
 
 
Table II.2. Tune settings for ion trap mass spectrometers used in LC/UV/MS/MS analysis of 
biotransformation. 
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Table II.3. HPLC gradients for LC/UV/MS/MS analysis of biotransformation.  
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Data Analyses 
Plots and graphs were generated using GraphPad Prism version 5.04 
(GraphPad Software, San Diego, CA). Area-under-the-curve (AUC) values of 
VU0409106 metabolites M1 and M6 from S9 experiments were also generated in 
GraphPad Prism (trapezoid rule). Pharmacokinetic (PK) parameters were obtained 
using WinNonLin (noncompartmental analysis; Phoenix version 6.2; Pharsight, 
Mountain View, CA).  Allometric coefficients and exponents for multispecies 
allometry were obtained from plots of body weight versus intrinsic clearance using 
linear regression analysis in Microsoft Excel 2010 by fitting data points to the power 
function described by Equation II.13. 
In vitro clearance measurements  
In vitro hepatic intrinsic clearance (CLint) was estimated from hepatic S9 
incubations with substrate, using the substrate depletion method (in vitro half-life 
method).   The in vitro half-life is calculated from the elimination rate constant, k, 
which represents the slope determined from linear regression analysis of the 
natural log of the percent remaining substrate as a function of incubation time 
(Figure II.1). Equation II.1 is then applied to calculate hepatic CLint (mL/min/kg) 
from the in vitro half-life (Zientek et al., 2010). 
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Figure II.1. Representative plot of the natural log of the percent remaining substrate versus 
incubation time for the determination of in vitro half-life. 
 
 
𝐶𝐿𝑖𝑛𝑡 =
𝑙𝑛2
𝑡1/2 (𝑚𝑖𝑛)
×
𝑚𝐿
2.5 𝑚𝑔 𝑝𝑟𝑜𝑡𝑒𝑖𝑛𝑆9 
×
120.7 𝑚𝑔 𝑝𝑟𝑜𝑡𝑒𝑖𝑛𝑆9
𝑔 𝑙𝑖𝑣𝑒𝑟 𝑤𝑒𝑖𝑔ℎ𝑡
×
(𝐴)𝑔 𝑙𝑖𝑣𝑒𝑟 𝑤𝑒𝑖𝑔ℎ𝑡
𝑘𝑔 𝑏𝑜𝑑𝑦 𝑤𝑒𝑖𝑔ℎ𝑡
 
Equation II.1. Determination of hepatic intrinsic clearance (CLint) by the in vitro half-life 
method (substrate depletion method). The species-specific hepatic scaling factor, A, is listed 
below in Table II.4. 
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Table II.4. Species-specific hepatic scaling factors (A) applied to Equation II.1 for 
determination of hepatic intrinsic clearance (CLint). Cyno, cynomolgus monkey 
a Davies and Morris,(1993) Pharm Res. 10(7):1093-95. 
b Suenderhauf and Parrott,(2013) Pharm Res. 30(1):1-15. 
c Boxenbaum,(1980) J Pharmicokinet Biopharm. 8(2):165-76. 
d Lin et al,(1994) Drug Metab Dispos. 24(10):1111-20. 
 
Subsequently, CLint was used to estimate hepatic clearance (CLHEP) according to the 
well-stirred model, uncorrected for protein binding, described by Equation II.2 
(Wilkinson and Shand, 1975; Pang and Rowland, 1977; Obach, 1999).  The well-
stirred model assumes the liver to be a single, well-stirred, homogenous 
compartment, where the rate of drug elimination is a function of the rate of drug 
presentation to the liver (governed by hepatic blood flow) and the intrinsic 
clearance of the drug (governed by drug metabolizing enzyme capacity). 
 
𝐶𝐿𝐻𝐸𝑃 (𝑚𝐿 𝑚𝑖𝑛/𝑘𝑔⁄ ) =
𝑄𝐻 ×  𝐶𝐿𝑖𝑛𝑡
𝑄𝐻 +  𝐶𝐿𝑖𝑛𝑡
 
Equation II.2. Determination of CLHEP, where QH is the species-specific hepatic blood flow, 
listed below in Table II.5. 
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Table II.5. Species-specific hepatic blood flow (QH) applied to Equation II.2 for estimation of 
hepatic clearance. Cyno, cynomolgus monkey 
a Davies and Morris,(1993) Pharm Res. 10(7):1093-95. 
b Suenderhauf and Parrott,(2013) Pharm Res. 30(1):1-15. 
c Boxenbaum,(1980) J Pharmicokinet Biopharm. 8(2):165-76. 
 
The hepatic extraction (E), which is a measure of the efficiency of the liver to 
remove drug, can be estimated from the CLHEP and QH, and was calculated according 
to Equation II.3 (Rane et al., 1977). E represents the fraction of drug removed during 
one pass through the liver. 
𝐸 =  
𝐶𝐿𝐻𝐸𝑃
𝑄𝐻
 
Equation II.3. Determination of hepatic extraction (E).  
 
In vitro estimation of fraction metabolized by aldehyde oxidase (Fm, AO)  
The Fm,AO of zaleplon, O6-benzylguanine, zoniporide, BIBX1382, and SGX523 was 
estimated in hepatic S9 of human (mixed gender) and male minipig, rhesus monkey, 
cynomolgus monkey, guinea pig, rat, and mouse.  Hydralazine has been proposed as 
a selective AO inhibitor suitable for use in determination of Fm,AO in hepatocytes 
(Strelevitz et al., 2012). Utilizing this method in hepatic S9 fractions, incubations 
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were fortified with NADPH in the presence or absence of hydralazine, and Equation 
II.4 (method A) was applied to estimate the Fm,AO.   
 
𝐹𝑚,𝐴𝑂 (𝐴) =  
𝐶𝐿𝑖𝑛𝑡 −  𝐶𝐿𝑖𝑛𝑡 (+𝐻𝑦𝑑)
𝐶𝐿𝑖𝑛𝑡
 
Equation II.4. Estimation of Fm, AO in hepatic S9 by method A, where CLint is the intrinsic 
clearance in S9 fortified with NADPH, and CLint (+Hyd) is the intrinsic clearance in S9 
containing both NADPH and the AO inhibitor hydralazine. 
 
 
Alternatively, the Fm,AO can also be estimated with Equation II.5 (method B), utilizing 
S9 in the absence of NADPH.  This method takes advantage of the NADPH-dependent 
nature of P450 and the NADPH-independent nature of AO to distinguish AO-
mediated clearance from P450 (or other NADPH-dependent enzymes present in S9, 
such as FMO).  Because xanthine oxidase (XO) is also present in S9 and is NADPH-
independent, hydralazine serves to distinguish any potential XO activity (or other 
NADPH-independent enzyme such as esterases) from AO activity. 
 
𝐹𝑚,𝐴𝑂 (𝐵) =  
𝐶𝐿𝑖𝑛𝑡 (𝑛𝑜 𝑁𝐴𝐷𝑃𝐻) − 𝐶𝐿𝑖𝑛𝑡 (𝑛𝑜 𝑁𝐴𝐷𝑃𝐻+𝐻𝑦𝑑)
𝐶𝑙𝑖𝑛𝑡
 
Equation II.5. Estimation of Fm, AO in hepatic S9 by method B, where CLint is the intrinsic 
clearance in S9 fortified with NADPH, CLint (no NADPH) is the intrinsic clearance in S9 without 
NADPH, and CLint (no NADPH+Hyd) is the intrinsic clearance in S9 containing the AO inhibitor 
hydralazine without NADPH. 
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In some cases, low turnover prevented an estimation of CLint in S9 incubations 
containing NADPH and hydralazine (CLint (+Hyd) = 0) or in S9 incubations absent 
NADPH (CLint (no NADPH) = 0), which results in an Fm,AO estimation equal to 1 by 
method A or 0 by method B, respectively. Due to this limitation, both methods A and 
B were used to approximate Fm,AO in the event that at least one method would 
permit a calculation of Fm,AO. In addition, agreement between the two methods 
provides more confidence in the estimate. In some cases, low turnover prevented a 
calculation of Fm,AO by both methods A and B.  
Pharmacokinetic parameters 
 Pharmacokinetic parameters described below (AUC, CLp, t1/2, Vss, MRT, and 
Cmax) reported for VU0409106 and its metabolites, and for zaleplon, O6-
benzylguanine, zoniporide, BIBX1382, and SGX523 were obtained by 
noncompartmental analysis (NCA) of their plasma concentration versus time 
profiles using WinNonLin (Phoenix version 6.2; Pharsight, Mountain View, CA) 
pharmacokinetic analysis software. 
Area under the plasma concentration-time curve (AUC) 
 The AUC is the area under the plasma concentration-time curve and is a 
measure of the total drug exposure, expressed in units of amount x time/volume. 
AUC was estimated by the linear trapezoidal rule (Equation II.6) or the logarithmic 
trapezoidal rule (Equation II.7). 
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𝐴𝑈𝐶𝑡1
𝑡2 =  
𝐶1 + 𝐶2
2
 (𝑡2 − 𝑡1) 
Equation II.6. Estimation of AUC by the linear trapezoidal rule 
 
𝐴𝑈𝐶𝑡1
𝑡2 =  
𝐶2 − 𝐶1
𝑙𝑛 (
𝐶2
𝐶1
)
 (𝑡2 − 𝑡1) 
Equation II.7. Estimation of AUC by the logarithmic trapezoidal rule 
 
Plasma clearance (CLp) 
 Plasma clearance (CLp) is the volume of plasma containing drug that is 
eliminated per unit time, and is expressed in units of volume/time. CLp was 
estimated from the AUC and the dose administered, according to Equation II.8. 
 
𝐶𝐿𝑝 =  
𝐷𝑜𝑠𝑒
𝐴𝑈𝐶
 
Equation II.8. Estimation of CLp by noncompartmental analysis (NCA) 
 
 
Half-life (t1/2) 
 Half-life (t1/2) is the time it takes for the plasma drug concentration to 
decrease by 50%.  For the purpose of these studies, t1/2, represents the terminal 
half-life, unless otherwise indicated, and is described by Equation II.9. 
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𝑡1
2⁄
=
𝑙𝑛2
𝑘𝑒𝑙
 
Equation II.9. Estimation of the terminal half-life (t1/2), where kel is the first order 
elimination rate constant of the terminal exponential phase, estimated by linear regression 
of time versus log concentration. 
 
Mean residence time (MRT) 
 Mean residence time (MRT) represents the average amount of time a drug 
molecule spends in the body, and is expressed in units of time.  MRT was estimated 
by dividing the area under the first moment curve (AUMC, Equation II.10) by the 
AUC, as described by Equation II.11.  
𝐴𝑈𝑀𝐶 = 𝐴𝑈𝑀𝐶𝑙𝑎𝑠𝑡 +
𝑡𝑙𝑎𝑠𝑡 × 𝐶𝑙𝑎𝑠𝑡
𝑘𝑒𝑙
+
𝐶𝑙𝑎𝑠𝑡
𝑘𝑒𝑙
2  
Equation II.10. Estimation of AUMC by NCA.  AUMClast  is equal to the area under the 
moment curve from the time of dosing to the last measurable concentration, tlast is the time 
of the last measurable concentration, Clast is the last measurable concentration, and kel is the 
first order elimination rate constant of the terminal exponential phase. 
 
 
𝑀𝑅𝑇 =  
𝐴𝑈𝑀𝐶
𝐴𝑈𝐶
 
Equation II.11. Estimation of MRT by NCA 
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Volume of distribution at steady state (Vss) 
 The volume of distribution at steady state (Vss) describes the extent of drug 
distribution into the blood and tissues and is expressed in units of volume.  Vss was 
estimated from the AUC and CLp, according to Equation II.12. 
 
𝑉𝑠𝑠 = 𝑀𝑅𝑇 × 𝐶𝐿𝑝 
Equation II.12. Estimation of Vss by NCA. 
 
Maximum plasma concentration (Cmax) 
 The maximum plasma concentration (Cmax) is the peak plasma concentration 
observed in a given plasma concentration-time curve. 
Multispecies allometry (MA) 
From a biological perspective, the term allometry, which literally means “a 
different measure,” refers to the study of changes in biological characteristics as a 
function of size (Mahmood, 2007). Allometry describes a parameter that is not 
directly proportional to size (i.e., isometry), but rather changes with size according 
to a power-law function (e.g., Equation II.13, where the parameter, clearance, 
changes with body weight) (Mahmood, 2007). Allometry was originally used to 
demonstrate an empirical relationship between body surface area of a species and 
its body weight, and has since been widely used to quantitatively relate a range of 
biological parameters to body weight, including pharmacokinetic parameters 
(Adolph, 1949; Dedrick, 1973; Boxenbaum, 1982). Liver size and liver blood flow, 
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which govern hepatic drug clearance, are related to body weight according to an 
allometric relationship. (Boxenbaum, 1982).  Accordingly, an allometric relationship 
has been demonstrated between drug clearance and body weight, and consequently, 
allometry has been adopted as a common method to predict human clearance from 
the clearance of preclinical species (Boxenbaum, 1982; Mahmood and Balian, 1996; 
Nagilla and Ward, 2004; Hosea et al., 2009).  In the present investigation, simple 
allometry was used for the prediction of human clearance values, where preclinical 
clearance values were plotted against the species’ body weight (Figure II.2) and 
subsequently fit to the simple allometric equation (power function), described by 
Equation II.13.  Simple allometry was used to predict human plasma clearance (CLp, 
total body clearance) from CLp values of three or four preclinical species (minipig, 
cynomolgus, guinea pig, rat, mouse), which was obtained by IV administration of a 
cassette dosing formulation containing zaleplon, O6-benzylguanine, zoniporide, 
BIBX1382, and SGX523, or from CLp values in the literature, where indicated (e.g., 
cynomolgus monkey data). Simple allometry was also used to predict human in vitro 
S9 intrinsic clearance (CLint) from in vitro CLint values obtained from hepatic S9 
incubations of three or four preclinical species (minipig, rhesus, cynomolgus, guinea 
pig, rat, mouse). When plotting in vitro CLint values, a standard body weight was 
used for each species (Table II.6), whereas actual (mean) body weight was used 
when plotting CLp, unless otherwise indicated.  
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Figure II.2. Representative plot of CL vs Body Weight to obtain the allometric coefficient 
and exponent (a and b, respectively) used to calculate a predicted human CL with the simple 
allometric equation (Equation II.13).  Solid shapes represent experimental data obtained 
from preclinical species. The open symbol represents the predicted human CL value. For 
scaling of in vitro data, CL represents CLint obtained from hepatic S9 incubations.  For scaling 
of in vivo data, CL represents plasma clearance (CLp) obtained from in vivo administration of 
drug. 
 
                                                      𝐶𝐿 (𝑚𝐿 𝑚𝑖𝑛)⁄ = 𝑎 × 𝑊𝑏    
Equation II.13. Simple allometric equation for the prediction of human clearance by 
multispecies allometry (MA), where W is body weight, and a and b are the allometric 
coefficient and exponent, respectively, obtained from a plot of CL versus W of 3 or 4 species 
(Figure II.2). The allometric exponent, b, describes the rate of change between CL and W. 
 
 
Table II.6. Standard body weights used for multispecies allometry and single-species 
scaling of in vitro S9 intrinsic clearance data (CLint). Cyno, cynomolgus 
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Single-Species Scaling (SSS) 
Following the same principle of multispecies allometry, Equation II.14 was 
applied in single-species scaling (SSS) analyses, where human clearance is directly 
extrapolated from the clearance of a single species (Hosea et al., 2009). A fixed 
exponent of 0.75 has been proposed for prediction of CL by SSS, based on the 
understanding that many physiological factors including basal metabolic rate and 
passive renal clearance may be scaled using this exponent (Boxenbaum, 1982; 
Hosea et al., 2009). 
 
                                        𝐶𝐿ℎ𝑢𝑚𝑎𝑛 (𝑚𝐿 𝑚𝑖𝑛)⁄ = 𝐶𝐿 𝑎𝑛𝑖𝑚𝑎𝑙  ×
𝑊ℎ𝑢𝑚𝑎𝑛
𝑊𝑎𝑛𝑖𝑚𝑎𝑙
0.75
 
Equation II.14. Prediction of human clearance by single-species scaling (SSS), where 
CLhuman is the predicted human clearance value (CLint or CLp), CLanimal is the observed 
clearance value obtained from the preclinical species in vivo (CLp) or in vitro in hepatic S9 
(CLint),  Wanimal is the body weight of the preclinical species, and Whuman is the human body 
weight.   
  
 
Success criteria for prediction of human clearance by MA or SSS 
The success of each individual human clearance prediction (in vitro or in 
vivo) was assessed by calculation of the fold-error, described by Equation II.15. Due 
to the variability in human pharmacokinetics, it is standard for a fold-error of ≤ 3 to 
be considered successful in the prediction of human clearance and was therefore 
used as a benchmark of success in these studies.   
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𝑓𝑜𝑙𝑑 𝑒𝑟𝑟𝑜𝑟 =  
𝐶𝐿 𝑝𝑟𝑒𝑑
𝐶𝑙𝑜𝑏𝑠
 
Equation II.15. Determination of fold-error in the prediction of CLint ,CLHEP, or CLp, where 
CLobs equals either the CLint or CLHEP measured in human hepatic S9 or the human CLp 
obtained from the literature, and CLpred equals the predicted human hepatic S9 CLint or CLHEP 
obtained from either MA or SSS of hepatic S9 CLint from preclinical species, or the predicted 
human CLp obtained from either MA or SSS of CLp from preclinical species.   
 
 
The success of each prediction method was assessed by calculation of the absolute 
average fold-error (AAFE) and the average fold error (AFE), described by Equations 
II.16 and II.17, respectively (Obach et al., 1997; Tang et al., 2007), for the fold-errors 
in the human clearance predictions obtained for the five compounds, zaleplon, O6-
benzylguanine, zoniporide, BIBX1382, and SGX523. AFE is equal to the geometric 
mean of the fold-error and represents a measurement of the overall bias in both 
directions (above or below the reference value of 1), whereas the AAFE gives both 
overpredictions and underpredictions equal value. Therefore the overall bias of the 
prediction method towards under- or overprediction is represented by the AFE, and 
the AAFE is an unbiased representation of the fold-error.  An AAFE of ≤ 3 was 
considered successful.  The percentage of compounds within 2-fold error (fold error 
= 0.5-2.0) and 3-fold error (fold error = 0.33-3.0) was also considered when 
assessing each method. 
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𝐴𝐴𝐹𝐸 = 10
∑|𝑙𝑜𝑔(𝑓𝑜𝑙𝑑 𝑒𝑟𝑟𝑜𝑟)|
𝑁  
Equation II.16. Determination of absolute average fold-error (AAFE), where N equals the 
total number of compounds, and fold error (Equation II.15) is the ratio of the CLpred to the 
CLobs. 
 
𝐴𝐹𝐸 = 10
∑ 𝑙𝑜𝑔(𝑓𝑜𝑙𝑑 𝑒𝑟𝑟𝑜𝑟)
𝑁  
Equation II.17. Determination of average fold-error (AFE), where N equals the total 
number of compounds, and fold error (Equation II.15) is the ratio of the CLpred to the CLobs. 
 
 
Statistical Analyses 
All statistical analyses were conducted with GraphPad Prism version 5.04 
(GraphPad Software, San Diego, CA), including calculations of standard deviations 
(SD) and standard errors of the mean (SEM). Likewise all plasma concentration-
time curves and other data plots were generated in GraphPad Prism, unless 
otherwise noted. 
Pharmacokinetic analysis of VU0409106 and metabolites.  
GraphPad Prism was employed in the statistical analyses of in vivo 
pharmacokinetic parameters of VU0409106 and metabolites, using a two-tailed 
unpaired t-test (paired t-test for the crossover study) with a significance level of p < 
0.05.  
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Calculation of intrinsic clearance from incubations with hepatic S9  
CLint was only calculated and reported if the mean ln[C] versus time slope 
was significantly different from zero (determined using GraphPad Prism version 
5.04 by an F test with a significance level of p < 0.05). If the slope was exclusively 
dependent on the terminal time point in order to be considered different from zero, 
CLint was not calculated.  
SSS Correlation with Fm or E.  
The fold-error for in vitro SSS predictions (CLint or CLHEP) was plotted against 
either Fm, AO or E, with correlation coefficients (r2) determined using GraphPad 
Prism (Figures IV.6-7). For plots involving Fm,AO, estimates calculated by method B 
were used, with the exception of zaleplon for mouse and minipig, in which case 
estimates calculated by method A were instead used since method B assumed an 
Fm,AO = 0 (no measurable turnover in the absence of NADPH).  Zaleplon and O6-
benzylguanine data for rat, O6-benzylguanine data for mouse and minipig, and 
BIBX1382 data for mouse were excluded altogether because CLint was only 
measurable in the presence of NADPH without hydralazine, resulting in an Fm,AO 
estimation of 1 by method A and 0 by method B. Fm,AO estimations > 1, were 
assumed to be equal to 1 for the purposes of this analysis.  In addition, the same 
correlation analyses were performed using in vivo data derived from a report by 
Deguchi et al of SSS to predict human CLp of uridine diphosphate-
glucuronosltransferase (UGT) substrates (Figure IV.8) (Deguchi et al., 2011). For 
twelve UGT substrates, Deguchi et al. reported CLp in each species (mouse, rat, 
monkey, and dog), human predictions of CLp obtained from SSS, and Fm,UGT in each 
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species estimated from in vivo production of glucuronide metabolites excreted into 
the bile and urine.  For our correlation analyses using UGT substrate data from 
Deguchi et al., fold-errors of the SSS predictions were calculated as described above 
in Equation II.15 from the observed human CLp values and SSS CLp predictions 
reported by Deguchi et al.  Fm,UGT was not reported by Deguchi et al for imipramine 
in mouse, nor was it reported for levofloxacin and telmisartan in human, resulting in 
exclusion of levofloxacin and telmisartan from the Fm,UGT analysis. In place of a 
correlation analysis involving E, a similar analysis was conducted using CLp as a 
percentage of QH obtained from Deguchi et al’s report. Equation II.3 was adapted to 
calculate CLp as a percentage of QH using CLp values reported by Deguchi et al. and 
species-specific hepatic blood flow, resulting in Equation II.18: 
 
𝐶𝐿𝑝 𝑎𝑠 𝑎 𝑝𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝑜𝑓 𝑄𝐻 =  
𝐶𝐿𝑝
𝑄𝐻
 
 
Equation II.18. Determination of plasma clearance (CLp) as a percentage of liver blood 
flow(QH), where QH is the species-specific hepatic blood flow listed in Table II.5.  
 
When CLp is exclusively mediated by hepatic elimination, this value (CLp as a 
percentage of QH) will be equal to E.  If extra-hepatic elimination is present, this 
value will be greater than E.  Therefore, levofloxacin and furosemide, which are 
predominantly excreted unchanged in the urine, were excluded from this analysis.  
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CHAPTER III 
 
EVALUATING THE DISPOSITION OF A MIXED ALDEHYDE 
OXIDASE/CYTOCHROME P450 SUBSTRATE IN RATS WITH ATTENUATED P450 
ACTIVITY  
 
INTRODUCTION 
Our initial interest in AO stemmed from the prior discovery in our laboratory 
that VU0409106, a novel negative allosteric modulator of the metabotropic 
glutamate receptor subtype 5 (mGlu5 NAM) synthesized at the Vanderbilt Center for 
Neuroscience Drug Discovery (VCNDD) (Felts et al., 2013), was metabolized in an 
NADPH-independent manner in rat and human hepatic S9 and cytosolic fractions 
(Morrison et al., 2012). Further exploration revealed that VU0409106 was oxidized 
by aldehyde oxidase on the pyrimidine ring to the primary metabolite M1 (Morrison 
et al., 2012). Our continued interest in VU0409106 has been driven largely by the 
observation that P450 pathways also contribute to its biotransformation, resulting 
in formation of metabolites M4, M5 and M6 (Figure III.1). This observation provided 
us with a unique opportunity to investigate the consequences of inhibiting either the 
P450 clearance pathway or the AO clearance pathway on the disposition of 
VU0409106 and the associated P450 and AO metabolites. 
The 2012 US Food and Drug Administration (FDA) draft guidance on defining 
the drug interaction potential of new chemical entities (NCEs) in drug discovery and 
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development 
(http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformati
on/Guidances/ucm292362.pdf) focuses primarily on human in vitro and nonclinical 
in vivo approaches to model clinical drug-drug interactions (DDIs) involving 
cytochrome P450s and drug efflux proteins (Prueksaritanont et al., 2006; Di et al., 
2013; Prueksaritanont et al., 2013). However, sparse attention has been paid to the 
potential for drug interactions involving compounds metabolized by enzymes falling 
outside these two classes of drug disposition proteins, including AO. Significant 
strides have been made towards understanding the structure-activity relationships 
(SAR) of AO binding and metabolism (Beedham et al., 1995; Dalvie et al., 2012; 
Coelho et al., 2015), species differences (Beedham et al., 1987; Garattini and Terao, 
2012; Dalvie et al., 2013), human AO variability (Hartmann et al., 2012; Hutzler et 
al., 2014b), and inhibition of AO in vitro (Obach et al., 2004; Barr and Jones, 2011), 
while studies defining the importance of this enzyme in an in vivo drug interaction 
scenario are lacking, perhaps owing to a deficiency of well-established specific AO 
inhibitors considered suitable for in vivo pharmacokinetic studies. 
To date, limited pharmacokinetic drug interactions involving the few marketed 
[known] AO substrates have been recognized, despite identification of several 
clinical drugs demonstrating AO inhibitory activity in vitro (Obach et al., 2004). 
Rather, the few reported clinical interactions for AO-cleared drugs involve inhibition 
or induction of a secondary non-AO metabolism pathway (Ramanathan et al., 2016). 
For example, FDA labeling for the nonbenzodiazepine sedative hypnotic zaleplon 
recommends a dose adjustment when co-administered with cimetidine, which 
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inhibits not only AO (primary route of zaleplon metabolism in humans), but also 
P450 3A4 (secondary route of zaleplon metabolism) 
(http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/020859s011lbl.pdf). 
Additionally, changes in exposure to the phosphatidylinositol 3-kinase- inhibitor 
idelalisib were noted with co-administration of the P450 3A inhibitor ketoconazole, 
or the inducer rifampin (Ramanathan et al., 2016). A noteworthy report by Li et al. 
recently indicated an important role for AO in a drug interaction between BILR 355 
and the P450 3A inhibitor ritonavir, where co-administration resulted in a 
metabolic “switch” from P450 3A metabolism of BILR 355 to gut bacterial and 
subsequent AO metabolism (Li et al., 2012a; Li et al., 2012b). Furthermore, Li’s 
studies monitoring formation of this AO metabolite in human S9 in the presence and 
absence of NADPH were consistent with a metabolic shunt towards AO when the 
P450 pathway was inactive. This report brought attention to the possibility of a 
drug interaction leading to a metabolic switch and the potential for AO to contribute 
to such an event. 
Drawing on observations from Li’s report demonstrating a drug interaction that 
elicits a metabolic switch in a unique scenario requiring an intermediate gut 
bacterial metabolism step, we hypothesized that hepatic P450 inhibition may result 
in an elevated exposure to the AO metabolite of a drug cleared via both AO and P450 
enzymes. Because AO and P450 commonly generate different metabolites due to 
opposing substrate specificities (AO prefers to oxidize electron-deficient carbons 
whereas P450 prefers electron-rich sites), this creates a potential scenario for 
increased exposure to one metabolite when the other metabolic pathway is 
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inhibited. The observation that VU0409106 was metabolized exclusively by AO to 
M1 and to M4-M6 by P450 enzymes presented an opportunity to investigate the 
disposition of a mixed AO:P450 substrate and the corresponding AO and P450 
metabolites in a drug interaction scenario of P450 inhibition. Given the similarities 
in rodent metabolism and clearance of VU0409106 to that observed in human S9 
and hepatocytes (Morrison et al., 2012) we designed this drug interaction scenario 
in vivo in Sprague-Dawley (SD) rats, a conventional species historically employed in 
nonclinical pharmacokinetic investigations (Di et al., 2013), via co-administration of 
VU0409106 and the pan-P450 inactivator 1-aminobenzotriazole (ABT). 
Observations from these in vitro and in vivo investigations indicate evidence of 
metabolic shunting towards AO metabolism in the disposition of VU0409106 in rat 
when P450 activity is attenuated, resulting in elevated exposure to the AO 
metabolite M1.  In addition, we investigated the impact of inhibiting AO metabolism 
with the co-administration of the AO inhibitor hydralazine to rats receiving 
VU0409106. Results from these studies indicate a similar pattern of increased 
exposure to the P450 metabolite(s); however, as hydralazine possesses 
characteristics that limit its utility in pharmacokinetic drug interaction studies, 
identification of a more suitable in vivo AO inhibitor will be necessary to gain a 
better understanding of this potential interaction.    
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RESULTS 
A Mixed AO:P450 Metabolism Phenotype of VU0409106 in vitro. 
Metabolism of VU0409106 in rat and human hepatic microsomes and recombinant 
human P450s.  
Our laboratory previously reported that the primary biotransformation 
pathway of VU0409106 was catalyzed by AO to the principal metabolite M1, plus 
other P450-mediated metabolites (e.g., M4 and M5) detected in nonclinical species 
and human hepatic S9 fractions (Figure III.1), as well as in vivo in Sprague-Dawley 
(SD) rats receiving intraperitoneal administrations of VU0409106 (Morrison et al., 
2012).  
 
Figure III.1. Metabolism of VU0409106 in vitro and in vivo in Sprague-Dawley rats and in 
vitro in human. 
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Furthermore, an in vitro:in vivo correlation of the predicted hepatic and plasma 
clearance of VU0409106 in rats and nonhuman primates was demonstrated, a 
finding which established the relevancy of a principle AO mechanism of clearance in 
vivo, with a secondary contribution from P450 in the disposition of VU0409106. 
Presently, we employed liquid chromatographic-mass spectrometry analysis 
(LC/UV/MS) and hepatic microsomes to define the role of P450 in the metabolism of 
VU0409106 in rat and human, and to monitor P450 metabolites in the investigation 
of a metabolic shunt involving AO. Data from hepatic microsomal incubations of 
VU0409106 indicated the NADPH-dependent formation of the hydroxylated 
metabolites M5 and M6 (Table III.1); the retention time and respective MS/MS 
fragmentation data of M5 was consistent with our laboratory’s previous report 
detailing the biotransformation of VU0409106 (Morrison et al., 2012). Structural 
identification of M6, which was not characterized in Morrison’s previous report, is 
depicted in Figures III.3-6. While the thiazole-hydroxylated metabolite, M4, was 
observed in vivo in rat plasma, as well as in rat and human hepatocytes (attenuated 
with ABT pretreatment) (Morrison et al., 2012), it was below our detection limits in 
rat or human hepatic microsomes in the present study. With the rat-to-human 
translation of the P450 mediated clearance of VU0409106 in vitro, we sought to 
demonstrate the specific P450 enzymes involved in the formation of metabolites 
observed in human microsomes, specifically, those enzymes commonly associated 
with drug metabolism and clinical drug interactions. Table III.1 depicts the results of 
incubations of VU0409106 with recombinant expressed human P450 enzymes 
(rhP450) 1A2, 2D6, 2C9, 2C19 and 3A4. While the proposed hydroxylated 
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metabolite M6 was formed in reactions of all five P450 enzymes examined, the 
hydroxylated-pyrimidine metabolite M5 was observed in all but reactions 
containing P450 1A2. The AO-mediated metabolite, M1, was not detected in 
incubations with recombinant expressed P450 enzymes, consistent with prior 
studies indicating AO exclusively mediates formation of M1 (Morrison et al., 2012).  
 
 
 
Table III.1. LC/MS detection of metabolites in vivo (SD rat) or in vitro in SD rat and human 
microsomes or recombinant human P450 enzymes (rhP450).  
aCytosolic AO contamination of microsomes produced low levels of M1. See Figure III.3. 
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The appearance of M1 in rat and human microsomal incubations was NADPH-
independent and indicative of trace contamination of the microsomal fraction with 
cytosol (containing AO); this finding of background AO activity in contaminated 
hepatic microsomes is not uncommon (Diamond et al., 2010a), and was confirmed 
by suppression of M1 formation with the AO-specific inhibitor hydralazine (Figure 
III.2). 
 
 
Figure III.2. The AO inhibitor hydralazine inhibited the formation of M1 in incubations of 
VU0409106 (25 M) with rat hepatic microsomes. 
 
 
 
LC/MS/MS characterization of VU0409106 metabolite M6.  
The MS/MS of M6 is depicted in Figure III.3.  A protonated molecular ion, [M 
+ H]+ , for M6 was observed at m/z 347, a +16 Da mass shift over the parent 
VU0409106 (indicates oxidation), which produced a [M + H]+  at m/z 331 (Morrison 
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et al., 2012).  A loss of 18 Da (loss of water) represented the major fragment ion at 
m/z 329.  The minor fragment ion at m/z 217, which was also present in the MS/MS 
spectra of the parent VU0409106, suggested that the oxidation was likely located on 
the methyl-thiazole moiety.  The fragment ion at m/z 320 corresponds to a +16 Da 
mass shift over the fragment ion at m/z 304 produced by the parent VU0409106. 
 
 
 
Figure III.3 LC/MS/MS and proposed structure of metabolite, M6, detected in SD rat and 
human hepatic microsomes and recombinant human P450 incubations.  
 
 
An MS3 experiment (347329) produced a fragment ion again at m/z 217 and a 
fragment ion at m/z 302, which corresponds to loss of water (-18 Da) from the 
fragment ion at m/z 320 (Figure III.4).  These data support the assignment of the 
oxidation to the methyl-thiazole moiety.   
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Figure III.4. LC/MS3 and proposed structure of metabolite, M6, detected in SD rat and 
human hepatic microsomes and recombinant human P450 incubations (MS3: 347329 (-
H2O; 18 Da)302, 217 Da).  
 
 
Available locations for oxidation to occur on the methyl-thiazole moiety include the 
sulfur or nitrogen atoms, the carbon alpha to the sulfur, or the carbon of the methyl 
group. In order to determine if the oxidation is located on either of the two 
heteroatoms versus either of the two carbon atoms, a deuterium exchange 
experiment was performed, where the mobile phase A buffer (10 mM ammonium 
formate) used for LC/MS analysis was prepared in D2O.  The protonated molecular 
ion of VU0409106 contains two exchangeable hydrogen atoms, which upon free 
exchange with deuterium ions in the mobile phase results in a deuterated molecular 
ion, [M + D]+,  at m/z 333 (whereas the [M + H]+ = 331).  The [M + H]+ for M6 occurs 
at m/z 347; therefore, if the oxidation is located on either of the heteroatoms, the [M 
+ D]+ will be one Da lower (m/z 349) than if the oxidation is located on either of the 
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carbon atoms (m/z 350), as the metabolite would contain one less exchangeable 
hydrogen in the former case (Figure III.5).   
 
 
 
Figure III.5 A full scan LC/MS deuterium exchange experiment, where the mobile phase A 
buffer (10 mM ammonium formate) is prepared in D2O, will produce an [M+D]+ for M6 at 
m/z 350 Da if hydroxylation occurs on a carbon atom of the thiazole moiety, versus that of 
the N or S, in which case calculated [M+D]+ = 349 Da. Exchangeable hydrogens are 
highlighted in red. 
 
 
The [M + D]+ was indeed observed at m/z 350 in the full scan MS experiment (100% 
relative abundance, Figure III.6), suggesting that the oxidation occurs on a carbon 
atom. This observation opposes the potential for M6 to also be generated by flavin 
monooxygenases (FMOs), as these enzymes characteristically oxidize N or S atoms, 
not carbon atoms.  
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Figure III.6 A full scan LC/MS deuterium exchange experiment, where the mobile phase A 
buffer (10 mM ammonium formate) was prepared in D2O, produced an [M+D]+ for M6 at 
m/z 350 Da, indicative of a hydroxylation of a carbon atom. 
 
 
Intrinsic Clearance of VU0409106 and Relative Formation of M1 in Rat and 
Human S9 Fractions Implicate a Metabolic Shunting Mechanism Mediated by 
Aldehyde Oxidase 
M1 formation in hepatic S9.  
When VU0409106 was incubated (1 M, 60 min incubation) in both rat and 
human hepatic S9 fractions (+/- NADPH), the observed magnitude of M1 formation 
in S9 incubations, absent the P450 reducing cofactor NADPH, was greater than that 
observed when incubations were fortified with NADPH (Figure III.7).  An 
approximate 50% increase in the area under the curve (AUC) of M1 was observed in 
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S9 incubations absent NADPH relative to those incubations containing NADPH from 
both human and rat experiments (Table III.2).  
 
 
Figure III.7. Formation of M1 in incubations of VU0409106 with (A) human hepatic S9 or 
(B) SD rat hepatic S9 in the presence (closed circles) or absence (open circles) of NADPH. 
Data points are expressed as the peak area ratio of analyte/internal standard and represent 
the mean of a triplicate determination ( SD). 
 
 
 
Table III.2. Exposure of M1 Formed from human or rat hepatic S9 incubations of 
VU0409106 in the presence or absence of NADPH. AUC expressed as the peak area ratio 
(analyte/IS*min) and represent means of triplicate determinations ( SD). 
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Concentration-dependence of total, NADPH-dependent, and NADPH-independent 
hepatic S9 intrinsic clearance (CLint) of VI0409106.  
We previously demonstrated that subsequent metabolism of M1 to M2 is 
catalyzed by xanthine oxidase (XO) (Figure III.1) (Morrison et al., 2012), an enzyme 
which does not require the reducing cofactor NADPH for catalytic activity, thus 
excluding P450-mediated conversion of M1 to M2 as the mechanism responsible for 
this observation. The observed increase in M1 in S9 incubations absent NADPH may 
likely be due to an increase in substrate exposure to AO in the absence of NADPH-
dependent P450 metabolism. To explore this possibility, we measured the CLint of 
VU0409106 in rat and human S9 fractions in the presence and absence of NADPH 
and in the presence of NADPH and the AO inhibitor, hydralazine, to estimate the 
CLint mediated by both AO and P450, AO only, and P450 only, respectively 
(Table III.3), and over a concentration range of VU0409106 (0.1 M, 1 M, and 10 
M).   
 
 
Table III.3. Total, NADPH-dependent, and NADPH-independent rat and human hepatic S9 
intrinsic clearance (mL/min/kg) of VU0409106 at concentrations of 0.1 M, 1 M, and 10 
M. Data represent means of triplicate determinations ( SD). 
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While NADPH-dependent CLint in both species decreased with increasing 
concentration of VU0409106, NADPH-independent CLint remained constant in rat, 
with some decrease in human S9 incubations. The decrease in NADPH-dependent 
CLint at higher concentrations was also reflected by a decrease in the total CLint 
observed when both P450 and AO are active. These data indicate the likelihood that 
the overall Km (Michealis constant) for the P450 pathways is lower than that for the 
AO pathway and are consistent with a mechanism of metabolic shunting towards AO 
under conditions of attenuated P450 metabolism and greater substrate availability 
for AO. While the NADPH-independent CLint observed in the present experiments 
was slightly elevated than previously reported (Morrison et al., 2012), this finding is 
not surprising, given the potential in vitro variability of AO recently described across 
multiple individual hepatocyte donors, for example (Hutzler et al., 2014b).  In 
addition, various laboratories have reported different AO-mediated CLint values for 
the same AO substrate (Kitamura et al., 1999; Al-Salmy, 2001; Sahi et al., 2008).  
Altogether, the present in vitro metabolism and clearance data indicate that SD 
rat represents an acceptable nonclinical model to study the in vivo disposition of 
VU0409106 and its metabolites under drug interaction duress (e.g., P450 
inhibition), particularly the occurrence of metabolic shunting from P450 towards 
AO. 
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ABT Pretreatment Results in Increased Exposure to Parent VU0409106 and 
the AO Metabolite M1 In Vivo in SD Rats. 
VU0409106  
To evaluate the impact of P450 inhibition on the disposition of VU0409106 
and its metabolites, SD rats received an IP administration of VU0409106 (3 mg/kg) 
with or without oral pretreatment with the pan-P450 inactivator ABT (50 mg/kg). 
We then generated standard plasma concentration-time profiles (Figure III.8) 
employing contemporary LC/MS/MS quantitation and reported standard PK 
parameters (e.g., Cmax, AUC0-inf, CLp, Vss, t1/2, Table III.4-5). Statistically significant 
changes were observed in the plasma clearance (CLp), AUC, and maximal 
concentration (Cmax) of VU0409106 in rats pretreated with ABT, versus vehicle 
pretreatment. In rats pretreated with ABT, a 7.8-fold increase in the plasma AUC of 
VU0409106 was observed (Figure III.8A, Table III.4). Likewise, the Cmax was 
increased 3.1-fold. The PK of VU0409106 was also obtained (Table III.4), following 
an intravenous (IV) administration of VU0409106 to rats, where an increase in the 
AUC of VU0409106 was again observed (3.5-fold), along with a corresponding 
reduction in the average CLp from 53.5 to 15.3 mL/min/kg in rats pretreated with 
ABT. 
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Figure III.8. Mean plasma concentration-time profiles of (A) VU0409106, (B) M1, (C) M4-
M6, and (D) M2 following administration of VU0409106 to control (black) or ABT 
pretreated (blue) SD rats. Each data point represents the mean ( SD; n = 2-3 (control), n = 
3-4 ABT pretreated). 
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Table III.4.  Pharmacokinetic (PK) parameters of VU0409106 following the IV (1 mg/kg) or 
IP (3 mg/kg) administration of VU0409106 to control rats or rats pretreated with ABT. AUC 
= area under the plasma concentration-time curve; C
max
 = peak plasma concentration; CL = 
plasma clearance; t
1/2 
= half-life (t
1/2 
= MRT* ln2); Vss  = volume of distribution at steady-
state.  Data for control and ABT groups represent a mean of n = 2 ( SEM). Data for control 
(n = 3) and ABT (n = 4) groups represent a mean ( SD). Statistical analysis performed using 
a two-tailed unpaired t test. *p <0.05, **p < 0.01. 
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M1 
 We also observed an increase in the exposure to the AO metabolite M1 in rats 
receiving the ABT pretreatment, with a 15-fold and 7.3-fold increases in the average 
AUC and Cmax values, respectively (Figure III.8B, Table III.5). We submit that this 
finding is consistent with the contributions of a shunting mechanism towards the 
AO pathway when P450 activity is attenuated by ABT (as was observed in hepatic 
S9 incubations of VU0409106 that were performed without NADPH). We previously 
reported that M1 is converted to M2 via XO, followed by an oxidative-defluorination 
to M3 (Figure III.1) (Morrison et al., 2012). Consequently, a substantial increase in 
M2 was also observed in rats as a result of ABT pretreatment (11-fold and 14-fold 
increase in mean Cmax and AUC, respectively) (Figure III.8D, Table III.5).  
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Table III.5. Pharmacokinetic (PK) parameters of metabolites M1, M2, and M4-M6 following an IP administration of VU0409106 (3 
mg/kg) to control rats or rats pretreated with ABT. AUC and C
max
 of all metabolites reported as peak area ratio analyte/IS*h and 
analyte/IS, respectively. Data represent a mean ( SD).  
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While the increase in M2 can be explained by an increase in its precursor 
metabolite, M1, we considered the possibility that accumulation of M2 in ABT-
pretreated rats occurred as a result of reduced P450-mediated conversion of M2→M3 
(Figure III.1), with the potential to reduce the rate of M1 conversion to M2 (e.g., 
product inhibition). In order to investigate contributions of secondary P450-
mediated metabolism of M2 to the observed plasma levels of M1, rats were orally 
administered either ABT (50 mg/kg), the XO inhibitor allopurinol (50 mg/kg), or a 
combination of the two inhibitors prior to the IP injection of compound VU0409106 
(10 mg/kg). Similar to rats receiving the 3 mg/kg dose of VU0409106, rats receiving 
the 10 mg/kg dose displayed a 14-fold increase in the AUC of M2 when pretreated 
with ABT (Figure III.9A, Table III.6). M2 was below the detection limits in rats 
pretreated with the XO inhibitor allopurinol and was detectable only at the latter 
time points collected from rats pretreated with both allopurinol and ABT (these 
data points, therefore, are not shown in Figure III.9). Pretreatment with allopurinol 
revealed a relatively small increase of 2.6-fold in the AUC of M1 compared to a 9.1-
fold increase following ABT pretreatment (Figure III.9B, Table III.6). Importantly, 
when rats were pretreated with both allopurinol and ABT, the AUC of M1 increased 
15-fold (Figure III.9B, Table III.6). These data indicate that the accumulation of M1 
from inhibition of the M2→M3 pathway is likely a minimal contributing factor 
towards the increase in M1 exposure in rats experiencing the ABT-induced DDI 
duress. 
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Figure III.9. Mean plasma concentration-time profiles of (A) M2 or (B) M1 after 
intraperitoneal administration of VU0409106 (10 mg/kg) to rats with or without an 
inhibitor. (A) Relative levels of M2 in rats pretreated with ABT (blue squares) versus 
control (black squares). (B) Relative levels of M1 in rats pretreated with ABT (blue circles), 
allopurinol (black triangles), or ABT + allopurinol (blue triangles) versus control (black 
circles). Data is expressed as the peak area ratio of analyte/internal standard and represent 
the mean ( SEM, n = 2). 
 
 
 
 
 
 
 
Table III.6. Systemic exposure of metabolites M1 and M2 following an IP administration of 
VU0409106 (10 mg/kg) to control rats or rats pretreated with ABT, allopurinol, or 
allopurinol + ABT. AUC reported as peak area ratio (analyte/IS*h), as no authentic 
metabolite standards were available. Data represent a mean of n = 2 ( SEM). Statistical 
analyses performed using a two-tailed unpaired t test. **p < 0.01.
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M4-M6  
The P450-mediated metabolites M4 and M6 were monitored to ascertain the 
impact of ABT pretreatment in vivo (Figure III.8C). Due to the complexity in the 
chromatographic resolution of M4 and M6, their isobaric mass, as well as their 
identical MS/MS transitions, LC/MS/MS peak areas of these metabolites were 
grouped accordingly, for the purpose of determining a semi-quantitative plasma 
concentration-time profile and exposure analysis as a measure of the contribution of 
P450 in the metabolism of VU0409106 in vivo. While a decrease was observed in the 
Cmax of M4-M6 (0.64-fold), a 2.1-fold increase was observed in the AUC of these 
metabolites in the ABT pretreated rats (Table III.5). This observation may be due to 
alterations in the secondary metabolism and clearance mechanisms acting on M4 
and/or M6. 
 
Pretreatment of SD Rats with Hydralazine Mildly Increased Exposure to P450 
Metabolites M4-M6 
 To evaluate the impact of AO inhibition on the disposition of VU0409106 and 
its metabolites, we also pretreated rats with the AO inhibitor hydralazine prior to an 
IP dose of 10 mg/kg VU0409106.  Table III.7 lists the PK parameters for 
VU0409106, M1, M2, and M4-M6 in control rats or rats receiving hydralazine.  Data 
for rats receiving ABT is included for comparison (Figure III.10, Table III.7).  
Interestingly, only a 1.3-fold increase in the AUC of VU0409106 was observed in rats 
pretreated with hydralazine, in comparison to the 4.8-fold increase observed in rats 
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receiving ABT pretreatment (Figure III.10A, Table III.7).  As expected, decreases in 
the Cmax and AUC of M1 (0.83-fold and 0.33-fold, respectively) and M2 (0.16-fold and 
0.43-fold, respectively) were observed (Figure III.10B and D, Table III.7). As an 
increase in exposure to the AO metabolite M1 occurred when P450 metabolism was 
inhibited by ABT, an increase was also observed in the P450 metabolites M4-M6 
(1.6-fold increase in AUC) when the AO inhibitor hydralazine was administered, 
albeit to a much lesser extent (Figure III.10C, Table III.7).  In addition, the Cmax was 
not increased, but rather decreased 0.77-fold in rats pretreated with hydralazine. 
 
Figure III.10. Mean plasma concentration-time profiles of (A) VU0409106 , (B) M1, (C) M4-
M6, and (D) M2 following administration of VU0409106 to control (black), ABT pretreated 
(blue), or hydralazine pretreated (green) SD rats. Each data point represents the mean ( 
SEM, n = 2). 
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Table III.7. Pharmacokinetic (PK) parameters of VU0409106 and metabolites M1, M2, and 
M4-M6 following an IP administration of VU0409106 (10 mg/kg) to control rats or rats 
pretreated with ABT or hydralazine. AUC and C
max
 of all metabolites reported as peak area 
ratio analyte/IS*h and analyte/IS, respectively. Data represent the mean ( SEM, n = 2).  
 
 
M4, but not M6, was decreased in pooled plasma samples of rats pretreated with ABT.  
While the M4-M6 AUC unexpectedly increased in ABT-pretreated rats, the 
significant increase in AUC and decrease in the total body CL of parent VU0409106 
indicates ABT did inhibit P450-metabolism of VU0409106 in vivo.  A possible 
explanation for this observation is that ABT also inhibited secondary metabolism of 
M4-M6. Alternatively, as M4 and M6 were quantified together, it is also possible that 
the AUC of one metabolite was increased, while that of the other was decreased, 
potentially resulting from differences in inhibitory activity towards enzymes 
responsible for formation and/or clearance of M4 and M6.  Prior studies of ABT 
inhibitory activity towards human P450 enzymes found that P450 2C9 is only 
minimally impacted by ABT (60% remaining activity following 30 min pretreatment 
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of human liver microsomes with 1 mM ABT) (Linder et al., 2009); the differential 
inhibitory activity of ABT towards rat P450 isoforms is unknown.  Consequently, we 
analyzed pooled plasma samples (1-6 hours) from rats pretreated with ABT relative 
to control rats using a 30 minute LC method to chromatographically resolve the two 
metabolites and found there to be an approximate 65% decrease in M4 compared to 
a 25% increase in M6 (Figure III.11), indicating ABT may have differentially 
impacted the disposition of the two metabolites. Conversely, when pre-treated with 
hydralazine, M4 was increased approximately 2-fold and M6 1.5-fold. 
 
 
Figure III.11. Relative abundance of (A) M4 and (B) M6 detected in extracts of pooled 
plasma collected between 1-6 hours from rats (n = 2) receiving 10 mg/kg of VU0409106 
alone or pretreated with 50 mg/kg ABT or 50 mg/kg hydralazine. 
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Similar Trends in VU0409106 and Metabolite Disposition in Response to 
Inhibitors in Crossover Experiment of Rats Receiving 1 mg/kg VU0409106 via 
Mesenteric Vein Administration 
In addition, we conducted a crossover experiment, where rats were 
administered VU0409106 via the mesenteric vein (as a surrogate for hepatic portal 
vein administration, as the mesenteric ileal vein drains into the hepatic portal vein) 
either with vehicle, ABT, or hydralazine pretreatment with a one week washout in 
between each dosing group. This experiment was designed to reduce potential 
sources of variability associated with the absorption phase in IP dosing or possible 
inter-individual variability in AO activity.  A pilot study was first conducted to 
ensure similar exposures were obtained via both hepatic portal vein (n = 2) and 
mesenteric ileal vein (n = 1) administration (Figure III.12), and a similar 
VU0409106 AUC was indeed obtained via mesenteric ileal vein administration and 
hepatic portal vein administration (Table III.8).   
 
Figure III.12. Individual plasma concentration-time profiles of VU0409106 following 
administration of VU0409106 via the hepatic portal vein (red and blue) or the mesenteric 
ileal vein (green) to SD rats. 
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Table III.8. Exposure of VU0409106 in SD rats receiving VU0409106 via the hepatic portal 
vein or the mesenteric ileal vein.  
 
 
Mean pharmacokinetics of VU0409106 and metabolites   
Following inhibitor pretreatment, similar pharmacokinetic trends were again 
observed, though the average magnitude of change was smaller (Table III.9) versus 
previous IP dosing studies.  The AUC of VU0409106 was increased 2.0-fold and 2.9-
fold when rats were pretreated with hydralazine and ABT, respectively, along with 
1.5 and 1.9-fold increases in Cmax, respectively. Relative to vehicle pretreatment, the 
Cmax and AUC of M1 was increased (1.3-fold and 2.0-fold, respectively) when rats 
were pretreated with ABT, and decreased (0.49-fold and 0.51-fold, respectively) 
when pretreated with hydralazine. The Cmax of M4-M6, conversely, was increased 
1.5-fold and decreased 0.67-fold when rats received hydralazine and ABT 
pretreatment, respectively.  While the AUC was increased 1.9-fold in the hydralazine 
group, the AUC for the ABT group was again increased 1.4-fold rather than 
decreased as would be anticipated under conditions of P450 inhibition.   
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Table III.9. Mean pharmacokinetic (PK) parameters of VU0409106 and metabolites M1, 
M2, and M4-M6 following an administration of VU0409106 (1 mg/kg) via the mesenteric 
vein to control rats or rats pretreated with ABT or hydralazine. AUC and C
max
 of all 
metabolites reported as peak area ratio analyte/IS*h and analyte/IS, respectively. Data 
represent a mean of n = 3 ( SD). Statistical analysis performed using a two-tailed paired t 
test. *p <0.05, **p < 0.01. 
 
Individual pharmacokinetics of VU0409106 and metabolites.  
Individual plasma concentration-time profiles for VU0409106 and the M1 
and M4-M6 metabolites in each rat are displayed in Figure III.13. In each case, when 
rats were pretreated with ABT, an increase in the exposure of both the parent 
VU0409106 and the M1 metabolite were observed (Figure III.13A and B, Table 
III.10).  Rat B exhibited approximately 10-fold lower exposure to the M1 metabolite 
relative to rats A and C.  In contrast, concentrations of the M4-M6 metabolites were 
relatively similar among the three animals (Figure III.13C, Table III.10).  
Interestingly, though the VU0409106 exposure in rat B was higher than rats A and C, 
it did not reach 10-fold higher exposure as might be expected considering the 10-
fold lower exposure to M1.  M2 exposure in rat B was also decreased approximately 
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10-fold relative to rats A and C, suggesting that the comparatively decreased levels 
of M1 were not a result of increased conversion to M2. 
 
 
Figure III.13. Individual plasma concentration-time profiles of (A) VU0409106, (B) M1, (C) 
M4-M6, and (D) M2 following MV administration of VU0409106 to control (black) ABT, 
(blue) or hydralazine pretreated (green) SD rats. Each of the three rats first received vehicle 
pretreatment, then after one week washout was crossed over to ABT pretreatment, and 
then finally hydralazine pretreatment after one week washout. 
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Table III.10. Individual pharmacokinetic (PK) parameters of VU0409106 and metabolites 
M1, M2, and M4-M6 following an administration of VU0409106 (1 mg/kg) via the 
mesenteric vein to rats A, B, and C when pretreated with either vehicle (control), ABT, or 
hydralazine. AUC and C
max
 of all metabolites reported as peak area ratio analyte/IS*h and 
analyte/IS, respectively. 
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DISCUSSION 
 
While successful approaches have been developed to evaluate the impact of 
enzyme inhibitors and inducers on P450-mediated drug clearance and subsequent 
changes in drug exposure for prediction of clinical drug interactions (Zhang et al., 
2009; Di et al., 2013), approaches towards predicting drug interaction potential of 
NCEs undergoing non P450 metabolism are less established, much less those 
exhibiting both P450 and AO clearance routes. Recognition of AO and P450 
contributions to the clearance of VU0409106 in vitro and in vivo provided an 
opportunity to investigate how P450 inhibition may impact the disposition and PK 
of a mixed AO:P450 substrate and its metabolites. Similarities between rat and 
human in vitro metabolism of VU0409106 permitted the use of rat as a nonclinical 
P450 inhibition model, which revealed a trend towards increased exposure to the 
AO metabolite M1 in rats with ABT-attenuated P450 activity (Figure III.14).  
 
 
 
Figure III.14. Increase in M1 formation observed in rats following ABT inhibition of P450. 
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In principle, co-administration of a perpetrator drug could result in observed 
elevations in metabolite plasma levels as a consequence of several possible 
mechanisms: a) decreased metabolite clearance due to inhibition of secondary 
metabolism, b) metabolic activation (stimulation of enzyme activity), c) enzyme 
induction, or d) metabolic shunting towards the uninhibited pathway (e.g., AO) 
when another pathway is inhibited (e.g., P450). It is unlikely that the elevated M1 
levels were due to a decrease in M1 clearance in rats pretreated with ABT, as the 
major M1 clearance pathway in vitro was previously determined to be XO-mediated 
metabolism to M2 (Morrison et al., 2012). While the activation of AO has been 
previously suggested (Nirogi et al., 2014), the present increased M1 formation 
observed in hepatic S9 fractions absent NADPH relative to NADPH-containing 
reactions support a mechanism independent of ABT-mediated cooperativity on AO. 
Furthermore, prior data from our laboratory outlining incubations of VU0409106 
with hepatocytes revealed no increase in M1 formation when ABT was present.  
Finally, while the induction of AOX1/Aox1 in mice, rats, and rabbits (Garattini and 
Terao, 2012) has been demonstrated, an induction mechanism accounting for our 
observations is highly unlikely, given the single dose study design and duration 
thereof. Our observed increase in M1, therefore, appears to have primarily resulted 
from a condition of increased substrate availability to AO when the P450 
pathway(s) of metabolism was attenuated. In additional support of this mechanism, 
the decrease in NADPH-dependent S9 CLint (P450 pathway), with a maintenance of 
NADPH-independent S9 CLint (AO pathway) with increased concentrations of 
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VU0409106, indicates a lower Km, P450 relative to the Km, AO, according to the 
relationship: 
 
𝐶𝐿𝑖𝑛𝑡,𝑡𝑜𝑡𝑎𝑙 =  (
𝑉𝑚𝑎𝑥,𝐴𝑂
𝐾𝑚,𝐴𝑂 + 𝑆
) + (
𝑉𝑚𝑎𝑥,𝑃450
𝐾𝑚,𝑃450 + 𝑆
) 
Equation III.1. Relationship between Michaelis-Menten parameters, Vmax and Km, and 
intrinsic clearance (CLint). 
 
 
where Vmax is the maximum reaction velocity of the enzyme, Km is the substrate 
concentration that yields half the maximal velocity, and S is the substrate 
concentration (Pang and Rowland, 1977). Incidentally, our findings associate an 
increase in metabolite exposure with the co-administration of VU0409106 and an 
enzyme inhibitor, whereas this type of DDI situation would typically be anticipated 
with co-administration of a victim drug and an enzyme inducer or stimulator. We 
might have expected this metabolic shunting observation to prevent an extensive 
increase in the AUC of VU0409106, with AO compensating for loss of P450 activity. 
However, as ABT is a pan-P450 inactivator, we have likely forced the shunt towards 
a single enzyme (AO), potentially limiting the capacity for compensation (versus 
inhibiting one enzyme with the possibility of shunting towards multiple enzymes).  
  Besides significant increases in exposure to the parent compound 
VU0409106, mean increases observed in the AUC and Cmax of the AO metabolite M1 
highlight the potential for a drug interaction resulting from increased exposure to a 
metabolite of a drug with both AO and P450 clearance routes when co-administered 
with a P450 inhibitor. Clinically used drugs exhibiting a major clearance pathway 
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via AO are few, and to date, no clinically relevant DDIs resulting from AO inhibition 
have been recognized, despite the identification of many clinical drugs 
demonstrating AO inhibition in vitro (Obach et al., 2004). However, our data indicate 
that inhibition of alternate clearance routes (e.g., P450) for drugs also metabolized 
by AO may result in elevation of a circulating AO-mediated metabolite, which, 
importantly, could have clinical implications when metabolites exhibit 
pharmacological or toxicological activity (Smith and Obach, 2005). For example, 
cases of dose-dependent renal toxicity associated with AO-mediated formation of a 
low-solubility metabolite have been reported for methotrexate (Smeland et al., 
1996) and the two c-Met inhibitors SGX523 and JNJ-38877605, recently 
discontinued in clinical trials (Infante et al., 2013; Lolkema et al., 2015).  
Additionally, the primary circulating metabolite of idealisib, GS-563117, is a 
mechanism-based inhibitor of P450 3A, which is not the case for the parent drug.  In 
this instance, however, both AO and P450 3A (minor) contribute to the formation of 
GS-563117 (Ramanathan et al., 2016). 
While a small percentage of currently marketed drugs are cleared via AO, a 2010 
study indicated the proportion of NCEs in research and development containing 
potentially AO-susceptible moieties is much higher (Pryde et al., 2010). Drug 
discovery scientists are more frequently encountering AO metabolism due to 
incorporation of nitrogen-containing aromatic rings for either target engagement 
(e.g. kinases) or mitigation of P450 metabolism (reduced lipophilicity). As many AO 
substrates (e.g., zaleplon and idealisib) are known to also undergo metabolism via 
enzymes other than AO (Strelevitz et al., 2012; Ramanathan et al., 2016), it is likely 
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that current and future NCEs exhibiting AO metabolism will also undergo 
metabolism via alternate enzymes.  As such, metabolic shunting may be important 
to consider during toxicology and DDI assessment of these compounds.  Likewise, 
this consideration may also be important for NCEs not displaying AO metabolism 
without concomitant administration of an enzyme inhibitor, yet containing an AO-
susceptible structural moiety (potential for metabolic switching (Li et al., 2012a; Li 
et al., 2012b)). The likelihood of substantial elevations in metabolite exposure (via 
metabolic shunting) may be increased for drugs cleared by both AO and P450 
enzymes versus drugs cleared only by multiple P450 pathways, as different P450 
enzymes commonly generate the same metabolite, in which case the metabolite 
would be expected to be generated at decreased or similar levels when one of the 
P450 pathways is inhibited. 
While the P450 inhibition aspect of these studies bears potential clinical 
significance due to the number of known P450-inhibiting drugs on the market,  our 
studies in rats pretreated with the AO inhibitor hydralazine also indicate a potential 
for shunting towards P450 metabolism when a mixed AO/P450 substrate is co-
administered with an AO inhibitor.  Several factors, however, may complicate the 
interpretation of the in vivo data obtained from rats receiving hydralazine 
pretreatment.  First of all, the therapeutic action of hydralazine is vasodilatation.  
For this reason, it is possible that hydralazine altered hepatic blood flow, in which 
case any changes in the disposition of VU0409106 and its metabolites may not be 
the result of changes in AO-mediated intrinsic clearance alone, but also changes in 
hepatic blood flow, according to the well-stirred model of hepatic drug clearance: 
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𝐶𝐿𝐻𝐸𝑃 =
𝑄𝐻 × 𝑓𝑢𝐶𝐿𝑖𝑛𝑡
𝑄𝐻 +  𝑓𝑢𝐶𝐿𝑖𝑛𝑡
 
Equation III.2.  Well stirred model of hepatic clearance. 
 
 
where CLHEP is hepatic clearance, QH is hepatic blood flow, fu is the unbound drug 
fraction, and CLint is intrinsic clearance (Wilkinson, 1987). Wolf et al. and Saretok et 
al. reported that hydralazine increased hepatic blood flow by approximately 30% in 
healthy human subjects (Wolf et al., 1994) and by 57% in normovolemic dogs 
(Saretok et al., 1984), respectively. In addition, a report by Svensson et al. found that 
administration of a 7.5 mg/kg oral hydralazine pretreatment to male SD rats 
resulted in a small, but significant, decrease in antipyrine plasma clearance, which 
was proposed to be associated with hypothermia in animals receiving hydralazine 
(Svensson et al., 1987). Furthermore, while hydralazine is considered to be a 
selective inhibitor of AO, it has been reported to potentially inhibit P450 2D6 as well 
(Strelevitz et al., 2012; Zientek and Youdim, 2015).  The rat P450 inhibition profile 
of hydralazine is not known, and we did not conduct reaction phenotyping of 
VU0409106 to determine which rat isoforms are responsible for M6 formation; 
however, we did find that M6 was generated in incubations with recombinant 
human 2D6.  Altogether, these factors limit the interpretation of the PK analysis in 
rats treated with hydralazine.  A specific AO inhibitor without these potentially 
confounding characteristics (which is presently unavailable) would be required to 
better understand the impact of AO inhibition in vivo.      
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In conclusion, our studies with VU0409106 and ABT using rat as a nonclinical PK 
model revealed increased exposure to both the parent drug and the AO metabolite. 
The present investigation highlights the potential drug interactions that may occur 
with co-administration of a P450 inhibitor and a mixed AO/P450 substrate. The 
similarities we observed in vitro between SD rat and human in the formation of AO 
and P450 metabolites, trends in the impact of P450 activity on the formation of M1, 
and in the kinetic behavior of the two enzymatic pathways indicate that our 
observations in vivo in rat may translate to human in vivo. We submit that rat may 
offer a nonclinical model to probe drug interactions (and mechanisms thereof) 
where a mixed AO:P450 substrate experiences a clinical drug interaction duress, 
while underscoring the potential existence of the compound-dependent use of 
nonclinical models to predict AO-mediated interactions. As investigators are more 
frequently encountering AO metabolism through the drug discovery and 
development continuum, understanding the drug interaction potential for drugs 
exhibiting an AO clearance component will be important in the successful 
advancement and safe clinical implementation of future drug candidates bearing 
this nonP450 phenotype. 
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 CHAPTER IV 
ALLOMETRIC SCALING OF IN VITRO HEPATIC CLEARANCE OF DRUGS 
POSSESSING AN ALDEHYDE OXIDASE CLEARANCE PATHWAY IN HUMAN 
 
INTRODUCTION 
As noted previously, interest in AO-mediated drug metabolism has increased 
in recent years as new generations of drug candidates increasingly contain AO-
susceptible aromatic azaheterocyles (Pryde et al., 2010).  Importantly, the 
termination of several promising development programs during clinical trial 
assessment due to unrecognized or underestimated AO metabolism highlights the 
necessity for innovative approaches to predict human pharmacokinetics (PK) and 
disposition where AO is the primary clearance mechanism. For example, 
discontinuation of BIBX1382 (Dittrich et al., 2002), FK3453 (Akabane et al., 2011), 
and RO1 (Zhang et al., 2011) during clinical trials resulted from unexpectedly poor 
oral bioavailability attributed to AO-mediated clearance that went unidentified in 
preclinical and in vitro studies. Primary use of microsomes (lacking cytosol, thus 
lacking AO) and preclinical species with decreased (e.g., rat) or absent (e.g., dog) AO 
activity towards these candidate drugs relative to humans was deemed responsible 
for their clinical failures. 
A challenge in predicting human drug clearance where AO-mediated 
metabolism predominates has been attributed to species differences in AO 
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expression and activity. While humans express only one functional gene, AOX1, AO 
expression in other species commonly used to model human PK range anywhere 
from 2-4 isoforms (e.g., rat) to none at all (e.g., dog, except for non-liver isoforms) 
(Garattini and Terao, 2012). Human liver S9, cytosolic fractions, and hepatocytes 
have proven useful in identifying AO metabolism, although at times these systems 
have resulted in under-prediction or variable activity, proposed to be associated 
with possible single nucleotide polymorphisms (SNPs) in the AOX1 gene, instability 
of the dimer, or deficiency of the essential molybdenum cofactor (Hartmann et al., 
2012; Hutzler et al., 2012; Fu et al., 2013; Hutzler et al., 2014b). Consequently, 
promising compounds are routinely discarded or structurally modified to eliminate 
AO metabolism, often at the expense of pharmacological potency and/or selectivity.  
The most common methods for estimating human clearance include in vitro 
and in vivo approaches (Obach et al., 1997) (Di et al., 2013).  In vitro systems are 
commonly employed when metabolism represents the primary mechanism of 
clearance, where clearance is measured in human hepatocytes or hepatic 
microsomes and is subsequently scaled up to estimate an in vivo (hepatic) clearance 
(Obach et al., 1997; Di et al., 2013).  An alternative approach is to use allometry to 
predict human in vivo clearance via extrapolation from the in vivo clearance of 
preclinical species, where clearance is related to body weight (Obach et al., 1997; Di 
et al., 2013).  While research has been conducted to evaluate human in vitro 
methods to predict AO-mediated clearance (Zientek et al., 2010; Akabane et al., 
2012; Hutzler et al., 2012; Hutzler et al., 2014b), studies investigating allometric 
scaling approaches are limited.  Allometric scaling of in vivo plasma clearance in 
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nonclinical species is commonly used to predict human total body clearance of 
drugs eliminated renally and/or via hepatic metabolism (Mahmood, 2007).  
However, differences observed in AO expression and activity of species commonly 
employed in allometric scaling (particularly dog) versus that of human have 
resulted in decreased confidence in the utility of this method (Garattini and Terao, 
2012).  Interestingly, despite variability across species in the uridine diphosphate-
glucuronosyltransferase (UGT)-mediated clearance of several drugs, success with 
single- or multi-species allometry in predicting human clearance of these drugs has 
been demonstrated (Deguchi et al., 2011). Several of these compounds are also 
metabolized by cytochrome P450s (P450), a factor that may have contributed to the 
successful scaling, given the established ability to reasonably predict human P450-
mediated clearance with allometry (Hosea et al., 2009). Furthermore, while rat 
underestimated the human plasma clearance of the AO substrate BIBX1382, a 
report by Hutzler et al. demonstrated comparable BIBX1382 plasma clearance (as a 
percentage of liver blood flow) between cynomolgus monkey and human, indicating 
single-species scaling (SSS) may be useful in predicting the clearance of drugs 
subject to AO metabolism (assuming appropriate species selection) (Hutzler et al., 
2014a). Given these findings, we sought to investigate the use of these allometric 
scaling approaches in predicting the human clearance of AO substrates. However, an 
additional complication in predicting AO-mediated human clearance is the extra-
hepatic expression of AO (Kurosaki et al., 1999; Moriwaki et al., 2001; Nishimura 
and Naito, 2006; Terao et al., 2016), which is presently understudied, particularly in 
species other than rodent and human. In particular, the contribution of extra-
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hepatic AO metabolism to the total body clearance of AO substrates is poorly 
understood. Thus, we sought to evaluate the ability to allometrically scale hepatic 
intrinsic clearance of compounds exhibiting an AO metabolic pathway, utilizing 
hepatic S9 to accomplish this aim. Specifically, the in vitro intrinsic clearance (CLint) 
of five compounds (Figure IV.1) known to be cleared either predominantly or 
partially by AO in human, was determined in hepatic S9 from multiple preclinical 
species (mouse, rat, guinea pig, cynomolgus monkey, rhesus monkey, and minipig) 
and was subsequently subjected to allometric scaling by either multi- or single-
species allometry for the prediction of human in vitro hepatic CLint. In anticipation 
that Fm, AO (fraction of metabolism mediated by AO) or estimated hepatic extraction 
(E) between human and preclinical species may influence the accuracy of the human 
CLint prediction obtained by these scaling methods, we estimated Fm,AO and E for the 
five substrates in each species and evaluated the correlation between these 
parameters and prediction accuracy by SSS.  In addition, we evaluated the 
biotransformation of each substrate in each of the seven species to understand the 
metabolic pathways potentially contributing to any species differences observed in 
the in vitro clearance of these substrates.  These in vitro studies may prove useful in 
serving as a tool to guide species selection for in vivo pharmacokinetic (PK) studies 
and subsequent allometric scalng of in vivo plasma clearance (CLp) for prediction of 
human in vivo CLp. In a recent review on nonP450-mediated metabolism, Cerny 
noted the need to improve in vitro-to-in vivo extrapolation methods for predicting in 
vivo clearance via these enzymes (Cerny, 2016).  The studies presented herein serve 
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as a step in this direction, towards a better understanding of how to predict human 
clearance of AO substrates.   
 
 
 
Figure IV.1. Structures of AO substrates subjected to in vitro allometric scaling. Arrows 
indicate site of AO oxidation. 
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RESULTS 
Intrinsic Clearance in Hepatic S9 Fractions 
Intrinsic clearance (CLint) estimates measured in hepatic S9 fractions of 
human and nonclinical species are summarized in Table IV.1.  These data represent 
estimates from incubations in the presence of NADPH, thus encompassing clearance 
mediated by NADPH-independent (e.g., AO) as well as any NADPH-dependent (e.g. 
P450) pathways. Hepatic clearance (CLHEP) in each species was also estimated using 
the well-stirred model, uncorrected for fraction unbound in plasma, and is 
summarized in Table IV.2.  Table IV.2 also lists the estimated hepatic extraction (E).  
For the purpose of this discussion, the in vitro clearance estimates described as low, 
moderate, or high are characterized as such according to the E value, where E ≤ 0.3 
is considered “low,” and E ≥ 0.7 is considered “high,” and values falling between 0.3 
and 0.7 are considered “moderate.”  CLint estimates for zaleplon were generally low, 
with E estimated to be ≤ 0.32 in each species.  O6-benzylguanine CLint estimates were 
moderate in human, monkey, and guinea pig and lower in rat, mouse and minipig, 
resulting in E estimates that ranged from approximately 0.1 (rat, mouse, minipig) to 
approximately 0.5 (human, cynomolgus, and guinea pig). Conversely, zoniporide 
was moderately cleared in human, monkey, guinea pig, and minipig S9 incubations 
(E = 0.41 - 0.59), while it was rapidly cleared in incubations with rat and mouse S9 
(E = 0.87 and 0.79, respectively).  Estimated CLint of BIBX1382 was high in human, 
monkey, and minipig (E = 0.72 - 0.83), moderate in guinea pig (E = 0.54), and low in 
rat and mouse (E = 0.30 and 0.27, respectively).  SGX523 exhibited low-moderate 
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clearance in all species, with E ranging from 0.25 – 0.50.  No single species was fully 
representative of human when considering E for each compound, but rather, 
substrate-dependence was observed.  However, E estimated in monkey was most 
similar to human overall, followed by guinea pig and minipig, with rat and mouse 
generally providing the worst representation of human E.  
Table IV.1.  Multispecies intrinsic clearance (CLint, mL/min/kg) of zaleplon, O6-
benzylguanine, zoniporide, BIBX1382, and SGX523 in incubations with hepatic S9 of human 
(mixed gender), and male mouse, rat, guinea pig, cynomolgus monkey, rhesus monkey, and 
minipig (in the presence of NADPH).  Data represent means of triplicate determinations 
from 2-3 experiments ( SD). 
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Table IV.2. Multispecies hepatic clearance (CLHEP, mL/min/kg) of zaleplon, O6-
benzylguanine, zoniporide, BIBX1382, and SGX523 in incubations with hepatic S9 (in the 
presence of NADPH) and the estimated hepatic extraction ratio (E). Data, calculated using 
CLint values from Table IV.1, represent means of triplicate determinations from 2-3 
experiments ( SD). 
 
In addition, comparison of the relative intrinsic clearance for each substrate within 
any one species (Table IV.1) reveals that the rank order  for monkey and guinea pig 
was the most similar to human, while mouse and rat rank order was the most 
dissimilar to human.  It is important to note, however, that, in some cases, the rank 
order was determined by a very small difference in CLint between substrates (e.g., 
zoniporide and O6-benzylguanine in human). The substrate rank order of CLint for 
each species is summarized in Table IV.3.    
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Table IV.3. Substrate rank order of intrinsic clearance obtained from incubations with 
multiple species’ hepatic S9 in the presence of NADPH. 
 
 
Estimation of Fm,AO in Hepatic S9 Fractions 
Tables IV.4-8 summarize Fm,AO estimated for each compound in each species 
from incubations with male hepatic S9 (mixed gender for human) using two 
different methods, A and B (see Equations II.4 and II.5, respectively).  Fm,AO obtained 
for O6-benzylguanine, zaleplon, zoniporide, and BIBX1382 in human is consistent 
with those previously reported by others (Hutzler et al., 2012; Strelevitz et al., 
2012); a human Fm,AO for SGX523 has not been previously reported to our 
knowledge.  In addition, with a few exceptions, the two methods used to estimate 
human Fm,AO generally produced similar values, providing more confidence in these 
estimates. It is important to note that the lower the rate of depletion, the less 
accurate the estimation of CLint, (and thus, Fm,AO) using the substrate depletion 
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method due to difficulty in distinguishing legitimate metabolism-mediated depletion 
from biological or bioanalytical noise (Di and Obach, 2015; Hutzler et al., 2015).  For 
example, in some cases, low turnover resulted in an Fm,AO estimation of 1 or 0, by 
method A or B, respectively (e.g., estimation of zaleplon Fm,AO in rat), and in these 
cases, Fm,AO was reported as “n/a.”  
Zaleplon Fm,AO  
CLint of zaleplon in human S9 incubations with hydralazine could not be 
measured; however, a Fm,AO estimate of 0.71 was determined using method B (Table 
IV.4), consistent with previous reports (Strelevitz et al., 2012). Cynomolgus monkey, 
rhesus monkey, and guinea pig demonstrated similar Fm,AO to human, with estimates 
ranging between 0.42-0.70, while mouse and minipig estimates were ≤ 0.22.  
Turnover of zaleplon in rat S9 was only measurable in incubations with NADPH 
absent hydralazine, preventing an Fm,AO estimate from being obtained.  
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Table IV.4. Multispecies CLint of zaleplon estimated from S9 fractions containing NADPH, 
containing NADPH and hydralazine, without NADPH, or containing hydralazine without 
NADPH, and the estimated fraction metabolized by AO (Fm,AO) calculated from the CLint data 
using methods A and B. CLint data represent means of triplicate determinations ( SD). Fm,AO was 
calculated using mean CLint values.  n/c = CLint not calculated because mean ln[C] versus time 
slope not significantly different from zero; n/a = insufficient CLint data to calculate Fm,AO; a = 
mean of duplicate determinations. 
 
O6-benzylguanine Fm,AO   
A high Fm,AO (≥ 0.70) was estimated for O6-benzylguanine in all species except 
rat, mouse, and minipig, which could not be determined due to low turnover of the 
compound (Table IV.5). As was the case for zaleplon in rat S9 incubations, a lack of 
measurable turnover of O6-benzylguanine in rat, mouse, and minipig S9 incubations 
in the presence of both NADPH and hydralazine, as well as in incubations absent 
NADPH, prevented estimation of Fm,AO.    
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Table IV.5. Multispecies CLint of O6-benzylguanine estimated from S9 fractions containing 
NADPH, containing NADPH and hydralazine, without NADPH, or containing hydralazine 
without NADPH, and the estimated fraction metabolized by AO (Fm,AO) calculated from the 
CLint data using methods A and B. CLint data represent means of triplicate determinations ( SD). 
Fm,AO was calculated using mean CLint values.  n/c = CLint not calculated because mean ln[C] 
versus time slope not significantly different from zero; n/a = insufficient CLint data to calculate 
Fm,AO; b = calculations resulting in an Fm,AO > 1 were assumed to be equal to 1. 
 
Zoniporide Fm,AO  
A high Fm,AO (> 0.70) for zoniporide was estimated in all species (Table IV.6). 
In human, rat, and guinea pig, NADPH-independent clearance of zoniporide was not 
completely inhibited by hydralazine. Literature reports indicate hydrolysis as a 
secondary metabolism pathway of zoniporide (Dalvie et al., 2010; Strelevitz et al., 
2012), which may account for this observation. This pathway will be further 
discussed in the section on biotransformation of zoniporide. Xanthine oxidase (XO) 
is not expected to contribute to the NADPH-independent clearance observed in the 
presence of hydralazine, as Dalvie et al. reported that allopurinol did not inhibit 
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formation of the M1 metabolite (major NADPH-independent metabolite) (Dalvie et 
al., 2010). 
 
Table IV.6. Multispecies CLint of zoniporide estimated from S9 fractions containing NADPH, 
containing NADPH and hydralazine, without NADPH, or containing hydralazine without 
NADPH, and the estimated fraction metabolized by AO (Fm,AO) calculated from the CLint data 
using methods A and B. CLint data represent means of triplicate determinations ( SD). Fm,AO was 
calculated using mean CLint values.  n/c = CLint not calculated because mean ln[C] versus time 
slope not significantly different from zero; n/a = insufficient CLint data to calculate Fm,AO; b = 
calculations resulting in an Fm,AO > 1 were assumed to be equal to 1. 
 
BIBX1382 Fm,AO  
Fm,AO for BIBX1382 was estimated to be approximately ≥ 0.70 by both 
methods in all species except rat and mouse (Table IV.7).   BIBX1382 reportedly 
undergoes some degree of P450 2D6-mediated metabolism (Dittrich et al., 2002), 
and it has been reported that hydralazine may exert mild human 2D6 inhibition 
(Strelevitz et al., 2012; Zientek and Youdim, 2015), in which case method A could 
potentially estimate an inflated Fm,AO; however, both methods A and B resulted in a 
very similar Fm,AO estimation in human, suggesting that either P450 2D6-mediated 
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clearance was insignificant, or hydralazine did not inhibit this pathway. This result 
is in agreement with a previous report phenotyping BIBX1382 clearance in human 
hepatocytes, where substrate depletion was predominantly mediated by AO 
(Hutzler et al., 2012).  Interestingly, CLint in rat S9 incubations fortified with NADPH 
was only slightly inhibited by hydralazine (decreased from 29 to 25 mL/min/kg), 
suggestive of predominantly NADPH-dependent clearance; however, in incubations 
absent NADPH, a CLint of 19 mL/min/kg still remained. This finding suggests the 
possibility that the cytosolic enzyme xanthine oxidase (XO) may mediate part of the 
NADPH-independent clearance in rat S9 since XO is not inhibited by hydralazine; 
however, no measurable substrate depletion was observed in incubations 
containing hydralazine without NADPH.  Minor depletion of BIBX1382 CLint was 
observed in human S9 incubations containing hydralazine without NADPH, but no 
other species exhibited measurable depletion under these conditions. Experiments 
to confirm XO involvement were not conducted. In addition, while Fm,AO was 
estimated to be 0.69 in rat by method B, similar to other species, the value obtained 
via method A (Fm,AO = 0.09) was drastically lower.  Given our previous report of 
metabolic shunting with the mixed AO/P450 substrate VU0409106 (Chapter III), it 
is possible that a metabolic shunt towards NADPH-dependent pathway(s) in the 
presence of hydralazine may have compensated for the inhibited AO pathway, 
resulting in an apparent Fm,AO = 0.09 via method A, whereas method B yields an 
estimate of 0.69 because no NADPH-dependent pathways are active to contribute to 
compensatory metabolism in the presence of hydralazine.  It is also possible that the 
discrepancy may simply be due to low turnover of BIBX1382 by rat S9 and 
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consequently an inability to accurately measure CLint by the substrate depletion 
method.  
 
Table IV.7. Multispecies CLint of BIBX1382 estimated from S9 fractions containing NADPH, 
conaining NADPH and hydralazine, without NADPH, or containing hydralazine without 
NADPH, and the estimated fraction metabolized by AO (Fm,AO) calculated from the CLint data 
using methods A and B. CLint data represent means of triplicate determinations ( SD). Fm,AO was 
calculated using mean CLint values.  n/c = CLint not calculated because mean ln[C] versus time 
slope not significantly different from zero; n/a = insufficient CLint data to calculate Fm,AO; b = 
calculations resulting in an Fm,AO > 1 were assumed to be equal to 1. 
 
 
SGX523 Fm,AO  
Considerable variability between the two methods was observed in the Fm,AO 
of SGX523 in some species (e.g., guinea pig), but overall a low-moderate Fm,AO was 
estimated in all species (range of 0.03 – 0.68, Table IV.8).  In some species (mouse, 
rhesus, and guinea pig), not all NADPH-independent activity was inhibited by 
hydralazine, suggesting possible XO-mediated clearance; however, experiments to 
confirm involvement of XO were not conducted.  
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Table IV.8. Multispecies CLint of SGX523 estimated from S9 fractions containing NADPH, 
containing NADPH and hydralazine, without NADPH, or containing hydralazine without 
NADPH, and the estimated fraction metabolized by AO (Fm,AO) calculated from the CLint data 
using methods A and B. CLint data represent means of triplicate determinations ( SD). Fm,AO was 
calculated using mean CLint values.  n/c = CLint not calculated because mean ln[C] versus time 
slope not significantly different from zero; n/a = insufficient CLint data to calculate Fm,AO. 
 
 
 In general, the Fm,AO calculated by the two different methods were in better 
agreement for compounds/species exhibiting more rapid clearance, and thus, more 
confidence can be placed in the accuracy of these estimations. Overall, monkey and 
guinea pig demonstrated Fm,AO values most similar to human. However, because low 
turnover prevented an Fm,AO calculation for some compounds in mouse, rat, and 
minipig, it is unclear how closely these species replicate human Fm,AO.  Though CLint 
may also be estimated from Michaelis-Menten kinetic parameters according to the 
relationship described by Equation IV.1, 
 
 
109 
𝐶𝑙𝑖𝑛𝑡 =
𝑉𝑚𝑎𝑥
𝐾𝑚 + 𝐶
 
Equation IV.1. Determination of intrinsic clearance (CLint) from Michaelis-Menten 
parameters, where Vmax is the maximum rate of metabolite formation, Km is the Michaelis-
Menten constant, which is equal to the substrate concentration when the metabolite 
formation rate is ½ of Vmax, and C is the substrate concentration. 
 
this method unfortunately is not feasible for the purpose of our studies.  In order to 
estimate the total CLint from the Michaelis-Menten parameters, an authentic 
standard of each metabolite that contributes to the overall clearance of each 
substrate would be required. Furthermore, different metabolites are sometimes 
produced by different species, adding further complication to this method.  
Therefore, although the substrate depletion method is limited by slow turnover 
rates, it is the most reasonable method available to obtain the total CLint mediated 
by all metabolic pathways.     
 
Prediction of Human Hepatic S9 Clearance by Multi- or Single-Species 
Allometry 
Intrinsic clearance estimates (Table IV.1) from hepatic S9 incubations of 
male mouse, rat, guinea pig, cynomolgus, rhesus, and minipig were employed in 
various combinations of 3 or 4 species for allometric scaling (multispecies simple 
allometry, MA) as well as individually for direct extrapolation from a single-species 
(single-species scaling, SSS).  Human CLint values predicted from MA and SSS were 
compared to CLint measured in incubations with human hepatic S9.  The overall 
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performance of each method is summarized in Table IV.9 (MA) and Table IV.15 
(SSS), measured by the absolute average fold error (AAFE) and the average fold 
error (AFE), described by Equations II.16 and II.17, respectively, where an AAFE of 
≤ 3 was considered successful.  An AFE > 1 indicates an overall bias of the method 
towards over-prediction, while an AFE < 1 indicates bias towards under-prediction.  
Plots of the observed CLint for each compound versus the human CLint predicted by 
each method are displayed in Figures IV.2 and IV.3; these data are also tabulated in 
Tables IV.10-14, along with the allometric exponent and correlation coefficients 
observed for each MA method (i.e., each species combination).   
Multispecies allometry (MA) of CLint   
An AAFE of ≤ 2.0 was obtained from all of the 4-species combinations and 
from the rhesus/rat/mouse combination, with rhesus/rat/mouse yielding the 
lowest AAFE (1.7) and 80% of the five compounds predicted within 2-fold of the 
experimentally measured human S9 CLint (Table IV.10). Only two combinations, 
cynomolgus/rat/mouse and cynomolgus/guinea pig/mouse, resulted in an AAFE of 
> 3.0 (3.3-fold and 3.5-fold, respectively). SGX523 is the only compound of the five 
for which a fold-error of < 3 could not be obtained by at least one of the species 
combinations; however, the minipig/rhesus/guinea pig combination yielded a fold-
error of 3.0 (Figure IV.2, Table IV.14).  Interestingly, all but one of the species 
combinations (minipig/rat/mouse) had an AFE of ≥ 1.0, indicating that the 
predictions were biased towards over-prediction rather than under-prediction. This 
clearly was not the case in every instance, however, particularly for O6-
benzylguanine and zoniporide (Figure IV.2, Table IV.11-12).   
111 
Figure IV.2. Plots of observed human S9 CLint vs that predicted from multispecies allometry. 
Inner dotted line represents unity, solid line represents 2-fold-error, and outer dashed line 
represents 3-fold-error. CLint, intrinsic clearance; Cyno, cynomolgus monkey; Gpig, guinea 
pig; Mpig, minipig 
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Table IV.9. Absolute average fold-error (AAFE), average fold-error (AFE), and percentage 
of compounds predicted within 2 or 3 fold-error of observed CLint measured in human S9, as 
predicted by multispecies allometry (MA). Cyno = cynomolgus monkey; Rhesus = rhesus 
monkey; Gpig = guinea pig 
 
In addition to the CLint prediction and fold error values, Tables IV.10-14 report the 
correlation coefficient and the allometric exponent (b) obtained for each MA 
method.  These two values are commonly evaluated when considering the degree of 
confidence to be placed in predictions generated by MA.  Particularly, evaluation of 
the allometric exponent has been proposed as a tool to guide employment of 
correction factors, referred to as the “rule of exponents” or ROE (Mahmood and 
Balian, 1996).  Use of these correction factors results in a lower CL prediction, and 
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therefore serves only to improve an over-prediction (and consequently would 
worsen an under-prediction).  According to the ROE, when 0.55 ≤ b < 0.71, simple 
allometry with no correction should be employed, when b ≥ 1.0, a correction for 
brain weight should be applied, and when 0.71 ≤ b ≤1.0, a correction for maximum 
lifespan potential is recommended.  In addition, the ROE suggests that a useful 
prediction will not be obtained for compounds with b < 0.55 due to substantial 
under-prediction.  However, a comprehensive analysis evaluating the use of ROE 
indicated that employment of correction factors was not superior to universal 
application of simple allometry (Nagilla and Ward, 2004).   We did not apply the 
ROE in our analyses, and a general evaluation of the data reveals that application of 
ROE would be substrate- and species-dependent in improving the prediction.  For 
example, in several instances, the exponent was > 0.71, and while the CLint was 
indeed over-predicted in some cases, in others it was actually under-predicted, and 
in some the fold-error was near unity.  Likewise, while five instances of b < 0.55 
resulted in some degree of under-prediction, three out of the five cases resulted in < 
3-fold-error (fold error = 0.36 – 0.75).  
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Table IV.10. Human CLint (mL/min/kg) of zaleplon predicted by each multispecies 
allometry (MA) method, fold-error of the prediction by each MA method compared to the 
reference CLint observed in human S9, correlation coefficient of each MA method, and 
allometric exponent (b) of each MA method. CLint, intrinsic clearance; Cyno = cynomolgus 
monkey; Rhesus = rhesus monkey; Gpig = guinea pig 
 
Table IV.11. Human CLint (mL/min/kg) of O6-benzylguanine predicted by each multispecies 
allometry (MA) method, fold-error of the prediction by each MA method compared to the 
reference CLint observed in human S9, correlation coefficient of each MA method, and 
allometric exponent (b) of each MA method. CLint, intrinsic clearance; Cyno = cynomolgus 
monkey; Rhesus = rhesus monkey; Gpig = guinea pig 
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Table IV.12. Human CLint (mL/min/kg) of zoniporide predicted by each multispecies 
allometry (MA) method, fold-error of the prediction by each MA method compared to the 
reference CLint observed in human S9, correlation coefficient of each MA method, and 
allometric exponent (b) of each MA method. CLint, intrinsic clearance; Cyno = cynomolgus 
monkey; Rhesus = rhesus monkey; Gpig = guinea pig 
 
Table IV.13. Human CLint (mL/min/kg) of BIBX1382 predicted by each multispecies 
allometry (MA) method, fold-error of the prediction by each MA method compared to the 
reference CLint observed in human S9, correlation coefficient of each MA method, and 
allometric exponent (b) of each MA method. CLint, intrinsic clearance; Cyno = cynomolgus 
monkey; Rhesus = rhesus monkey; Gpig = guinea pig 
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Table IV.14. Human CLint (mL/min/kg) of SGX523 predicted by each multispecies allometry 
(MA) method, fold-error of the prediction by each MA method compared to the reference 
CLint observed in human S9, correlation coefficient of each MA method, and allometric 
exponent (b) of each MA method. CLint, intrinsic clearance; Cyno = cynomolgus monkey; 
Rhesus = rhesus monkey; Gpig = guinea pig 
 
Single-species scaling (SSS) of CLint  
Single-species scaling (SSS) has been demonstrated to be as accurate as or 
more accurate than MA in predicting human clearance (Hosea et al., 2009).  
Therefore, we chose to investigate this method in addition to MA for prediction of 
human S9 CLint (calculated using a fixed exponent of 0.75—see Equation II.14). Plots 
of the observed CLint for each compound versus the human CLint predicted by each 
SSS method (each species) are displayed in Figure IV.3; these data are also tabulated 
in Table IV.16. SSS predictions yielded AAFEs of ≤ 2.0 when scaling from 
cynomolgus, rhesus, guinea pig, and minipig S9 CLint, with 80% of compounds 
predicted within 3-fold-error for cynomolgus, guinea pig, and minipig, and 100% for 
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rhesus (Table IV.15). The compound falling outside of 3-fold-error differed for each 
species—SGX523 for cynomolgus, BIBX1382 for guinea pig, and O6-benzylguanine 
for minipig (Figure IV.3; Table IV.16). AAFEs for rat and mouse were 4.1 and 3.8, 
respectively, with only 40% and 60% of compounds predicted within 3-fold-error, 
respectively. A tendency towards under-prediction was exhibited in all species 
except monkey, which had AFEs of 1.6 (cynomolgus) and 1.2 (rhesus) (Table IV.15). 
By comparison of AAFE, MA was not superior to SSS with cynomolgus, rhesus, or 
guinea pig, but was generally more accurate than SSS with mouse or rat, while SSS 
with minipig was also more accurate than MA in most cases. 
 
 
Figure IV.3. Plots of observed human S9 CLint vs that predicted from single-species scaling.  
Inner dotted line represents unity, solid line represents 2-fold-error, and outer dashed line 
represents 3-fold-error. CLint, intrinsic clearance 
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Table IV.15.  Absolute average fold-error (AAFE), average fold-error (AFE), and percentage 
of compounds predicted within 2 or 3 fold-error of observed CLint measured in human S9, as 
predicted by single-species scaling (SSS). 
 
 
Table IV.16. Human CLint (ml/min/kg) predicted by each SSS method and fold-error of the 
prediction by each SSS method compared to the reference CLint observed in human S9. CLint, 
intrinsic clearance; SSS, single-species scaling 
 
Multispecies allometry (MA) of CLHEP 
In addition to evaluating the fold-error in CLint predictions, we evaluated the 
fold-error in these predictions after converting them from CLint estimates to hepatic 
clearance (CLHEP) estimates according to Equation II.2 (Tables IV.17-20, Figures 
IV.4-5), in anticipation that substantial over- or under-predictions due to species 
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differences in metabolic efficiency would be minimized by the hepatic blood flow 
limitation occurring in vivo (particularly when observed or predicted CLint is high). 
Plots of the observed CLHEP for each compound versus the human CLHEP predicted by 
each MA method are displayed in Figure IV.4; these data are also tabulated in Table 
IV.18. The AAFE  was improved to < 2.0 for all species combinations and eleven out 
of the fourteen species combinations predicted 100% of the five compounds within 
3-fold and 80% within 2-fold of the experimentally measured human S9 CLHEP 
(Table IV.17). These improvements were primarily a result of improved BIBX1382 
and SGX523 predictions, which exceeded human hepatic blood flow (~21 
mL/min/kg) prior to conversion to CLHEP.  
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Figure IV.4. Plots of observed human S9 CLHEP vs that predicted from multispecies 
allometry. Inner dotted line represents unity, solid line represents 2-fold-error, and outer 
dashed line represents 3-fold-error. CLHEP, predicted hepatic clearance; Cyno, cynomolgus 
monkey; Gpig, guinea pig; Mpig, minipig. 
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Table IV.17. Absolute average fold-error (AAFE), average fold-error (AFE), and percentage 
of compounds predicted within 2 or 3 fold-error of observed CLHEP measured in human S9, 
as predicted by multispecies allometry (MA). Cyno = cynomolgus monkey; Rhesus = rhesus 
monkey; Gpig = guinea pig 
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Table IV.18. Human CLHEP (mL/min/kg) predicted by each MA method and fold-error of the 
prediction by each MA method compared to the reference CLHEP observed in human S9. 
CLHEP, hepatic clearance; MA, multispecies allometry 
 
Single-species scaling (SSS) of CLHEP  
Plots of the observed CLint for each compound versus the human CLHEP 
predicted by each SSS method (each species) are displayed in Figure IV.5; these data 
are also tabulated in Table IV.20. Like the predictions by MA, the predictions by SSS 
were generally improved when comparing CLHEP in comparison to CLint, with AAFEs 
of < 3.0 for all species and < 2.0 for all but rat and mouse (Table IV.19). Cynomolgus, 
rhesus, and guinea pig predicted a human S9 CLHEP for 100% of the five compounds 
within 2-fold-error and minipig predicted 80% of the compounds within 2-fold (O6-
benzylguanine was under-predicted with a fold-error of 0.27; Figure IV.5, Table 
IV.20). 
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Figure IV.5. Plots of observed human S9 CLHEP vs that predicted from single-species scaling.  
Inner dotted line represents unity, solid line represents 2-fold-error, and outer dashed line 
represents 3-fold-error. CLHEP, predicted hepatic clearance 
 
 
Table IV.19.  Absolute average fold-error (AAFE), average fold-error (AFE), and percentage 
of compounds predicted within 2 or 3 fold-error of observed CLHEP measured in human S9, 
as predicted by single-species scaling (SSS). 
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Table IV.20. Human CLHEP predicted by each SSS method and fold-error of the prediction by 
each SSS method compared to the reference CLHEP observed in human S9. CLHEP, hepatic 
clearance; SSS, single-species scaling 
 
SSS Correlation with Fm or E 
Based on their studies examining allometric scaling of UGT substrates, 
Deguchi et al. reported that overall Fm,UGT values in monkey were more similar to 
human than other species evaluated, concluding that this likely contributed to a 
higher rate of prediction accuracy from monkey SSS relative to the other species 
investigated (mouse, rat, and dog) (Deguchi et al., 2011). Likewise, we observed 
similar Fm,AO values between monkey and human, as well as better overall success 
with predictions from monkey SSS.  However, a similar Fm,AO between animals and 
human did not always translate to a more accurate CLint prediction. For example, 
similar Fm,AO estimates were observed between cynomolgus (0.58-0.68)  and human 
(0.36-0.61) for SGX523, yet the human CLint prediction by cynomolgus SSS yielded 
the largest fold-error (3.1) versus all other species, including minipig (2.4-fold-
error) which displayed a Fm,AO of 0.12-0.18  (Table IV.8, Figure IV.3, Table IV.16).  
Likewise, rat and human exhibited similar Fm,AO estimates for zoniporide (rat = 0.72-
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0.74, human = 0.72-0.77) with a rat SSS CLint prediction 6.4-fold higher than the CLint 
observed in human S9 (Table IV.6, Figure IV.3, Table IV.16).   Furthermore, in 
Deguchi’s report it can also be observed when comparing individual Fm,UGT of each 
compound for each species with predicted CLp by SSS, that a species exhibiting a 
similar Fm,UGT to human did not always yield a more accurate prediction versus 
another species displaying a Fm,UGT substantially different from human (Deguchi et 
al., 2011).  In some cases, however, we observed a similar E between human and a 
given species (Table IV.2) despite a divergence in Fm,AO, suggesting that other 
metabolism pathways are contributing to compensate for the lacking AO pathway, 
resulting in a reasonable human CLint prediction. For example, the Fm,AO of zaleplon 
in minipig (≤ 0.17) was much lower than the human estimates (≥ 0.71), while the 
fold-error of human CLint predicted from minipig SSS was less than 2-fold (fold-error 
= 0.64; Figure IV.3, Table IV.16). Comparison of the E between the species however 
revealed a similar E, despite the Fm,AO discrepancy (minipig E = 0.16, human E = 
0.22).  This situation was also observed for zaleplon in mouse. To better understand 
the relationship between Fm,AO or E and the accuracy of prediction by SSS, the CLint 
prediction fold-error by SSS was plotted against the animal:human ratio of either 
Fm,AO or E (Figure IV.6) A very poor correlation was observed between the 
animal:human ratio of Fm,AO and the fold-error in the CLint predicted from SSS (r2 = 
0.0051). However, a positive correlation was observed between SSS CLint prediction 
fold-error and E (r2 = 0.6488).  
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Figure IV.6. Correlation of SSS fold-error and animal/human ratios of Fm, AO or E. (A) Fold-
error in CLint predicted by SSS vs animal/human ratio of Fm,AO (inset, axes magnified). (B) 
Fold-error in CLint predicted by SSS vs animal/human ratio of E. (inset, axes magnified). 
Data points represent measurements obtained for each substrate in mouse, rat, guinea pig, 
cynomolgus monkey, rhesus monkey, or minipig. CLint, intrinsic clearance; E, estimated 
hepatic extraction; Fm,AO; fraction metabolized by AO; SSS, single-species scaling. 
 
 
The same plots were also generated replacing CLint prediction fold-error by SSS with 
CLHEP prediction fold-error by SSS (Figure IV.7).  A poor correlation again was 
observed between SSS prediction fold-error and Fm,AO (r2 = 0.00017), but an even 
stronger correlation resulted between SSS prediction fold-error and E (r2 = 0.9184).  
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Figure IV.7. Correlation of SSS fold-error and animal/human ratios of Fm, AO or E. (A) Fold-
error in CLHEP predicted by SSS vs animal/human ratio of Fm,AO. (B) Fold-error in CLHEP 
predicted by SSS vs animal/human ratio of E. Data points represent measurements obtained 
for each substrate in mouse, rat, guinea pig, cynomolgus monkey, rhesus monkey, or 
minipig. CLHEP, predicted hepatic clearance; E, estimated hepatic extraction; Fm,AO; fraction 
metabolized by AO; SSS, single-species scaling. 
 
To determine if similar trends existed among the 12 UGT substrates evaluated by 
Deguchi et al, data was obtained from this report (Deguchi et al., 2011) to plot the 
CLp prediction fold-error by SSS against the animal:human ratio of Fm,UGT (Figure 
IV.8A) or against the animal:human ratio of CLp as a percentage of QH (Figure IV.8B). 
Because CLp as a percentage of QH will be equal to E when clearance is mediated 
exclusively by hepatic elimination, but greater than E when extra-hepatic clearance 
contributes, we excluded UGT substrates that are predominantly cleared renally.  
Once again, correlation with Fm,UGT was very poor (r2 = 0.00069), but was strong 
with CLp as a percentage of QH (r2 = 0.9581).  Overall, these data suggest that the 
fold-error in clearance prediction by SSS is more closely associated with the overall 
hepatic extraction efficiency than the Fm between human and a given species. 
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Figure IV.8. Correlation of SSS fold-error and animal/human ratios of Fm, UGT or CLp as a 
percentage of liver blood flow for in vivo data of UGT substrates reported by Deguchi et al. 
(A) Fold-error in CLp predicted by SSS vs animal/human ratio of Fm,UGT (inset, axes 
magnified). (B) Fold-error in CLp predicted by SSS vs animal/human ratio of CLp as a 
percentage of liver blood flow (inset, axes magnified). Data points represent measurements 
obtained for each UGT substrate in rat, mouse, monkey, or dog. CLp, plasma clearance, E, 
estimated hepatic extraction; Fm,UGT, fraction metabolized by UGT; UGT, uridine 
diphosphate-glucuronosyltransferase; SSS, single-species scaling. 
 
Sex Differences in Intrinsic Clearance 
 Species-specific sex differences exist in the expression and/or activity of 
some drug metabolizing enzymes (e.g., certain P450s) (Martignoni et al., 2006) 
(Mugford and Kedderis, 1998; Bogaards et al., 2000). For example, male rats 
generally exhibit higher P450 activity than female rats, particularly with regard to 
P450 3A-mediated metabolism (Bogaards et al., 2000), the predominant metabolic 
pathway for drugs on the market (Wienkers and Heath, 2005). Consequently, male 
rats are more representative of human P450 metabolism (Bogaards et al., 2000) and 
thus are typically employed rather than female rats in preclinical studies used to 
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predict human clearance of compounds cleared via P450s.  Sex differences in AO-
mediated metabolism have also been noted in the literature (Beedham, 1985; 
Klecker et al., 2006; Akabane et al., 2011; Dalvie et al., 2013). This observation, as 
previously described, has occurred in both a species- and substrate-dependent 
manner, and has primarily been investigated in mice, rats, and humans.  As sex 
selection could potentially influence human clearance predictions obtained from 
allometric scaling, we elected to evaluate the intrinsic clearance of the five AO 
substrates in female pooled hepatic S9.  Intrinsic clearance is reported in the 
presence or absence of NADPH, providing insight as to the enzymatic source (e.g., 
P450 vs. AO) responsible for any observed male-to-female differences in intrinsic 
clearance.  We did not evaluate CLint in male versus female human S9, although 
literature reports have consistently demonstrated no sex differences in AO activity 
in humans (Al-Salmy, 2001; Klecker et al., 2006; Dalvie et al., 2013).   
Male and female rat S9 CLint  
Total CLint (NADPH-dependent and –independent) in female rat S9 was 
generally low compared to that obtained from male rat S9 (Figure IV.9).  CLint of 
BIBX1382 was only measurable in female S9 when fortified with NADPH. In some 
cases (O6-benzylguanine and zaleplon), substrate turnover was too slow in female 
S9 to measure intrinsic clearance even in the presence of NADPH.  In the case of 
SGX523, NADPH-independent CLint was similar between male and female rat S9, 
while a greater disparity was observed in the presence of NADPH, with higher 
activity in male S9.  This observation indicates higher P450 activity in male S9, 
which is consistent with the current understanding that male rats exhibit higher 
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P450 activity than female rats. This may also explain the ability to measure O6-
benzylguanine and zaleplon CLint in male S9 fortified with NADPH (due to 
contribution of P450 metabolism), but not in female S9. Unlike the observation with 
SGX523, NADPH-independent CLint of zoniporide was substantially higher in male 
rat S9 versus female.  While a difference in AO activity may be responsible for this 
observation, it is also possible that another enzyme may be involved, as hydrolysis 
has also been demonstrated as a metabolic pathway of zoniporide in rats (though it 
was reported to be a minor pathway) (Dalvie et al., 2010).   
 
Figure IV.9. Intrinsic clearance in male and female rat hepatic S9 in the presence (A) or 
absence (B) of NADPH.  Data represent the mean ( SD) of triplicate determinations from 1-
3 experiments.  
 
Male and female mouse S9 CLint  
Total CLint in female mouse S9 was low compared to that obtained in male 
mouse S9, with the exception of O6-benzylguanine, which was higher in female 
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(Figure IV.10).  NADPH-independent substrate depletion was only measurable in 
male mouse S9 for SGX523 and zoniporide and only for zoniporide in female S9, 
which was lower than that observed in male S9.  The inability to measure substrate 
depletion in the absence of NADPH in most cases in mouse S9 prevents an 
assignment of any observed sex differences to AO versus NADPH-dependent 
enzymes.  
 
Figure IV.10. Intrinsic clearance in male and female mouse hepatic S9 in the presence (A) 
or absence (B) of NADPH.  Data represent the mean ( SD) of triplicate determinations from 
1-4 experiments. 
 
 
Male and female cynomolgus S9 CLint 
Female cynomolgus S9 demonstrated low substrate turnover of all 
compounds in the presence of NADPH compared to that obtained in male 
cynomolgus S9 (Figure IV.11).  In fact, CLint could only be calculated from female 
cynomolgus S9 incubations for BIBX1382 and SGX523.  Low turnover was also 
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observed in female cynomolgus S9 incubations absent NADPH, permitting an 
NADPH-independent CLint calculation only for BIBX1382 and SGX523, which were 
much lower than that observed in male S9. Our observation of decreased NADPH-
independent activity in female cynomolgus S9 relative to male is consistent with a 
previous report by Dalvie at al, who observed 4-fold higher CLint of zoniporide in 
male S9 versus female (Dalvie et al., 2013).  Dalvie’s studies did not evaluate 
NADPH-dependent activity. 
 
Figure IV.11. Intrinsic clearance in male and female cynomolgus monkey hepatic S9 in the 
presence (A) or absence (B) of NADPH. Data represent the mean ( SD) of triplicate 
determinations from 1-2 experiments. 
 
 
Male and female rhesus S9 CLint  
Male and female rhesus S9 exhibited similar activity towards all compounds 
in the presence of NADPH, with slightly higher CLint observed in female S9 in most 
cases (Figure IV.12).  Similar results were obtained from incubations absent NADPH, 
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where female exhibited slightly higher CLint in most cases. Interestingly, these 
results contrast the data obtained from cynomolgus S9 incubations, which 
demonstrated very little activity in female versus male S9. Dalvie reported a much 
higher CLint of zoniporide in female rhesus S9 versus male, whereas we saw a 
relatively moderate difference between the sexes (Dalvie et al., 2013).  It is unclear 
as to why we observed much higher activity in our studies with male rhesus S9 
(zoniporide CLint = 30.2 mL/min/kg versus 2.5 mL/min/kg in Dalvie’s report); 
however, we observed very similar activity in our female rhesus S9 experiments 
(zoniporide CLint = 39.8 mL/min/kg versus 31.5 mL/min/kg in Dalvie’s report).  
   
Figure IV.12. Intrinsic clearance in male and female rhesus monkey hepatic S9 in the 
presence (A) or absence (B) of NADPH. Data represent the mean ( SD) of triplicate 
determinations from 1-4 experiments. 
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Male and female guinea pig S9 CLint  
CLint measured in female guinea pig S9 was similar to or lower than that 
observed in male guinea pig S9 for all compounds in the presence of NADPH (Figure 
IV.13).  Turnover of zaleplon was too slow to calculate CLint in female guinea pig S9 
(with or without NADPH).  In the absence of NADPH, female activity again was 
similar to male or somewhat lower towards all compounds. While male and female 
guinea pig S9 demonstrated similar activity towards BIBX1382 and O6-
benzylguanine in the presence of NADPH, NADPH-independent CLint of these two 
substrates was decreased in female S9 relative to male.  Dalvie et al also reported 
NADPH-independent CLint of zoniporide in male and female guinea pig S9, observing 
mildly decreased activity in female S9 (Dalvie et al., 2013). 
 
 Figure IV.13. Intrinsic clearance in male and female guinea pig hepatic S9 in the presence 
(A) or absence (B) of NADPH. Data represent the mean ( SD) of triplicate determinations 
from 1-4 experiments. 
 
 
135 
Male and female minipig S9 CLint 
Unlike most cases in the previous species evaluated, CLint measured in female 
minipig S9 was higher than that observed in male minipig S9 for all compounds in 
the presence of NADPH (Figure IV.14).  Likewise, in the absence of NADPH, female 
minipig S9 also exhibited higher activity toward all compounds; however, turnover 
of zaleplon was too slow in both male and female S9 to calculate NADPH-
independent CLint for this compound.  It should be noted that because the 
elimination of BIBX1382 from female minipig S9 was so rapid, the CLint value 
obtained for BIBX1382 in female S9 was estimated using only 2 data points (0 and 7 
minutes), as the compound was below the limits of detection beyond these time 
points. These data again replicate male:female differences in zoniporide CLint 
observed in Dalvie’s report, where female minipig S9 exhibited 4-fold higher 
NADPH-independent activity (Dalvie et al., 2013). 
 
Figure IV.14. Intrinsic clearance in male and female minipig hepatic S9 in the presence (A) 
or absence (B) of NADPH. Data represent the mean ( SD) of triplicate determinations from 
1-4 experiments. 
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In almost all cases, any difference observed in the CLint between male and 
female S9 in the presence of NADPH was also observed in the absence of NADPH, 
and was often exaggerated in the absence of NADPH.  This observation is consistent 
with literature reports of sex differences in AO activity (Beedham, 1985; Klecker et 
al., 2006; Akabane et al., 2011; Dalvie et al., 2013).  In particular, our data are similar 
to that observed by Dalvie et al. with regard to sex differences observed among each 
species in the NADPH-independent metabolism of zoniporide, with the exception of 
rhesus monkey, in which case Dalvie observed much lower CLint in male versus 
female rhesus S9 (Dalvie et al., 2013).  In addition, these data indicate that while sex 
differences may or may not be present in the AO-mediated metabolism of a 
compound, the sex-dependency of its overall CLint may depend on metabolism via 
other pathways (e.g. P450) which may exhibit different sex-dependent patterns 
from AO.  
Single species scaling (SSS) of female CLint 
Together with prior published reports of sex differences in AO activity, our 
observations highlight the possibility that sex may influence human clearance 
predictions obtained from single- or multi-species scaling and may warrant 
consideration when selecting a preclinical model. Using Equation II.14, we 
estimated human S9 CLint by SSS of the CLint data obtained from incubations with 
female S9 (Table IV.21).  Because the CLint of BIBX1382 in female minpig S9 was 
estimated using only 2 data points, these data were therefore excluded from the 
analysis. 
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Table IV.21. Human CLint (ml/min/kg) predicted by SSS with female S9 and fold-error of 
the prediction by each SSS method compared to the reference CLint observed in human S9. 
CLint, intrinsic clearance; SSS, single-species scaling 
 
 
In accordance with the CLint data obtained from male versus female hepatic S9, 
human CLint predictions from SSS of female CLint were mostly higher than 
predictions obtained from SSS of male data in rhesus and minipig, with more 
pronounced increases in minipig.  Alternatively, predictions were mostly lower by 
SSS with female cynomolgus, rat, mouse, and guinea pig S9 CLint relative to SSS 
predictions obtained using male CLint. For comparison, Figure IV.15 displays the 
CLint predictions obtained from SSS with male or female data, with the observed 
human CLint value indicated by the dotted line.  
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Figure IV.15. Predicted human CLint of zaleplon (A), O6-benzylguanine (B), zoniporide (C), 
BIBX1382, or SGX523 (E) from SSS with male and female hepatic S9. Dotted line indicates 
the observed human S9 CLint. 
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Multispecies allometry (MA) with female minipig CLint substitution for male minipig 
CLint 
In addition, when female minipig data is substituted for male data in MA for 
zaleplon, O6-benzylguanine, zoniporide, and SGX523, human CLint predictions are 
increased in all cases relative to those obtained from MA of only male data (Table 
IV.22, Figure IV.16). While human CLint of zoniporide and O6-benzylguanine was 
mostly under-predicted by each MA method using all male data, the substitution of 
male for female minipig data resulted mostly in over-prediction by each MA method. 
Consequently, over-predictions obtained from MA of all male data for zaleplon and 
SGX523 were worsened by substation of female minipig data into the MA analysis. 
Overall, improvements in prediction fold-error using CLint obtained from female 
hepatic S9 versus male hepatic S9 were substrate-dependent, and therefore do not 
indicate that SSS or MA using one sex over the other is always preferable in any of 
the six species evaluated.    
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 Table IV.22. Human CLint (mL/min/kg) predicted by multispecies allometry (MA) using CLint data from female minipig and male data 
from all other species, fold-error of the prediction by each MA method compared to the reference CLint observed in human S9, correlation 
coefficient of each MA method, and allometric exponent (b) of each MA method. CLint, intrinsic clearance; Cyno = cynomolgus monkey; 
Rhesus = rhesus monkey; Gpig = guinea pig 
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Figure IV.16. Predicted human CLint of zaleplon (A), O6-benzylguanine (B), zoniporide (C), or SGX523 (D) from MA using all male data 
(black bars) or male data for all species except minipig (patterned bars). Dotted line indicates the observed human S9 CLint. 
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Multispecies Biotransformation 
 As described above, species differences were observed in Fm,AO and/or E of 
zaleplon, O6-benzylguanine, zoniporide, BIBX1382, and SGX523.  To further 
understand the species differences in metabolism-mediated clearance of the five 
compounds, biotransformation experiments were conducted in male hepatic S9 of 
human (mixed gender), mouse, rat, guinea pig, cynomolgus monkey, rhesus monkey, 
and minipig in the presence or absence of NADPH.  Structures of proposed 
metabolites were elucidated by LC-MS/MS using full scan MS and data dependent 
full scan MS/MS (selection of most intense ion or fixed mass) techniques, coupled 
with comparison to any metabolite/fragmentation data available in the literature 
for the compounds of interest.  As the primary goal of these experiments was to 
understand species differences in NADPH-dependent versus NADPH–independent 
metabolism rather than structural identification of metabolites, additional 
experiments or use of authentic metabolite standards were not conducted to 
confirm proposed metabolite structures.  The metabolism of each compound in 
human and structural identity of the associated AO metabolite have been 
thouroughly reviewed by others, as noted in the following sections.  Throughout this 
section, metabolites denoted as “M1,” refer to the AO-mediated metabolite, which 
was identified based on the NADPH-independent nature and MS/MS spectra, but 
was not confirmed in our studies to be solely mediated by AO with hydralazine (it is 
possible that XO could potentially contribute to M1 formation in some species), nor 
was its identity confirmed by comparison to an authentic standard.  
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Zaleplon  
The metabolism of zaleplon was previously reported in human, rat, and 
monkey in vitro and/or in vivo (Beer et al., 1997; Kawashima et al., 1999; Lake et al., 
2002b; Renwick et al., 2002).  The principal NADPH-dependent and –independent 
metabolism of zaleplon observed in hepatic S9 is summarized in Figure IV.17.  
HPLC-UV chromatograms depicting the principal metabolites formed in the 
presence or absence of NADPH in each species are shown in Figures IV.18-19, and 
the MS/MS spectra and proposed fragmentation of each metabolite are shown in 
Figures IV.21-24.  Fragmentation of a metabolite detected at 8.9 min ([M+H]+ at m/z 
322) was indicative of zaleplon oxidation to M1 (Figure IV.21) in all species in 
extracts from S9 incubations both in the absence (Figure IV.18) and presence 
(Figure IV.19) of NADPH.  Consistent with no quantifiable substrate depletion in 
mouse, rat, and minipig S9 CLint experiments without NADPH, turnover of zaleplon 
to M1 appeared to be decreased in these species relative to monkey, guinea pig, and 
human (Figure IV.18). The metabolite eluting at 9.1 min, M2 ([M+H]+ at m/z 278),   
produced fragments indicative of zaleplon N-deethylation, was detected  in all 
species in S9 containing NADPH, and was the predominant metabolite in minipig 
(Figure IV.19, Figure IV.22).  Trace amounts of M2 were also detected in minipig S9 
incubations without NADPH fortification, likely resulting from low levels of 
endogenous NADPH present in the minipig S9 fractions (Figure IV.18).  An N-
desethyl-monooxidative metabolite, designated as M3 ([M+H]+ at m/z 294, 5.8 min),  
was also detected in S9 extracts of all species when NADPH was present (Figure 
IV.19, Figure IV.23).  It is likely that M3 corresponds to the N-desethyl analog of M1, 
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which has been previously reported (Beer et al., 1997; Kawashima et al., 1999; Lake 
et al., 2002b; Renwick et al., 2002).  Trace amounts of another NADPH-dependent 
metabolite, M4 ([M+H]+ at m/z 236, 9.0 min), having a mass consistent with the 
deacetylated analog of M2 (Lake et al., 2002b), were detected in all species except 
human and guinea pig (Figure IV.19, Figure IV.24).  
Overall, with regard to metabolites produced as well as the relative amounts 
of each metabolite, guinea pig exhibited a metabolism profile most similar to human, 
though cynomolgus and rhesus were also quite similar with the exception of M4 
formation.  Minipig exhibited the most dissimilar profile to human with regard to 
relative amounts of metabolites generated (M1 and M2). Though the low substrate 
turnover created a challenge in estimating Fm,AO of zaleplon in all species, the 
metabolism data supports the higher Fm,AO in human, guinea pig, and monkey, and 
the low or immeasurable Fm,AO in mouse, rat, and minipig.  Interestingly, despite the 
apparently lower NADPH-independent turnover to M1 in mouse, rat, and minipig, 
the hepatic extraction in these species was similar to human, as described 
previously (Table IV.2), supporting the notion that the NADPH-dependent 
metabolism (e.g., to M2) may have compensated for the lesser NADPH-independent 
metabolism in these species to result in a similar hepatic extraction efficiency (E) to 
human, but a lower Fm,AO. Likewise, this observation appears to contribute to the 
successful SSS of human CLint by all species, including those with a decreased AO-
mediated metabolism. 
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Figure IV.17. Proposed multispecies metabolism of zaleplon in hepatic S9. H, human; M, 
mouse; R, rat; G, guinea pig; C, cynomolgus monkey; Rh, rhesus monkey; MP, minipig
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Figure IV.18. Representative LC-UV chromatograms depicting principal metabolite(s) from 
S9 extracts of human, mouse, rat, guinea pig, cynomolgus monkey, rhesus monkey, and 
minipig incubated with zaleplon in the absence of NADPH.    
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Figure IV.19. Representative LC-UV chromatograms depicting principal metabolites from 
S9 extracts of human, mouse, rat, guinea pig, cynomolgus monkey, rhesus monkey, and 
minipig incubated with zaleplon in the presence of NADPH.    
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Figure IV.20. LC/MS/MS spectra of zaleplon ([M+H]+ at m/z 306).   
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Figure IV.21. LC/MS/MS spectra of zaleplon metabolite M1 ([M+H]+ at m/z 322).  Fragment 
ions occurring at m/z 304, 294, 280, 276, and 252 correspond to a 16-Da increase over 
zaleplon fragment ions at m/z 288, 278, 264, 260, and 236, respectively. 
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Figure IV.22. LC/MS/MS spectra of zaleplon metabolite M2 ([M+H]+ at m/z 278). Fragment 
ions occurring at m/z 260 and 236 correspond to a 28-Da decrease relative to zaleplon 
fragment ions at m/z 288 and 264, respectively. 
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Figure IV.23. LC/MS/MS spectra of zaleplon metabolite M3 ([M+H]+ at m/z 294).  Fragment 
ions occurring at m/z 276 and 252 correspond to a 12-Da decrease (+16 -28) relative to 
zaleplon fragment ions at m/z 288 and 264, respectively. 
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Figure IV.24. LC/MS/MS spectra of zaleplon metabolite M4 ([M+H]+ at m/z 236). The 
fragment ion occurring at m/z 209 may correspond to fragmentation of the 
pyrazolopyrimidine or loss of the cyano moiety. 
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O6-benzylguanine  
In vitro and/or in vivo metabolism of O6-benzylguanine in rat, mouse, and 
human was previously investigated (Dolan et al., 1994; Roy et al., 1995a; Roy et al., 
1995b).  Only a single principal metabolite was detected in S9 incubations both in 
the presence and absence of NADPH, depicted in Figure IV.25.  O6-benzylguanine 
was metabolized to M1 (Figure IV.32) in S9 fractions absent NADPH in all species.  
Co-elution of a protonated molecular ion at m/z 258 with the parent compound 
([M+H]+ at m/z 242), resulted in a single peak in the UV chromatograms (Figures 
IV.26-27); however, extracted ion chromatograms (XIC, Figure IV.28) for m/z 242 
(parent) and m/z 258 (M1) reveal slightly different retention times for the two 
peaks (parent = 11.60 min, metabolite = 11.54 min).  Species comparison of MS/MS 
chromatograms for M1 (total ion current (TIC), m/z 258) indicate decreased 
NADPH-independent turnover to M1 in mouse, rat, and minipig, relative to the other 
species (Figure IV.29). This observation is consistent with the low turnover 
observed in rat, mouse, and minipig S9 intrinsic clearance experiments absent 
NADPH (Table IV.5). However, in mouse, rat, and minipig S9 incubations fortified 
with NADPH, higher levels of M1 were detected (Figure IV.30), indicating that 
NADPH-dependent enzyme(s) (e.g., P450) contributed to the generation of M1 in 
these species. By comparison of the M1 peak area in Figure IV.30 versus Figure 
IV.29, it appears that NADPH-dependent enzymes were largely responsible for M1 
formation in mouse S9 (M1 peak area ratio of 3.64) and rat S9 (M1 peak area ratio 
of 2.64); these ratios for human, guinea pig, cyno, rhesus, and minipig were 1.06, 
1.08, 1.49, 1.11, and 1.65, respectively, indicating a primary NADPH-independent 
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(e.g., AO) mechanism in these species (Table IV.23). These data are consistent with a 
prior report of in vitro metabolism of O6-benzylguanine in male SD rat, which 
demonstrated M1 formation was greater in microsomes relative to cytosol, was 
induced by the P450 inducer phenobarbital, and was inhibited by carbon monoxide 
bubbling (inactivates P450s) into microsomal incubations (Roy et al., 1995a), all of 
which indicate a role of P450.  
Overall, with regard to M1 formation, all species except rat and mouse 
exhibited similar NADPH-dependency to human, where the majority of M1 was 
formed in an NADPH-independent manner, indicating AO as the primary pathway.  
These data support the high Fm,AO estimated in all species except rat, mouse, and 
minipig, which could not be determined due to low substrate turnover. Accordingly, 
SSS with cynomolgus, rhesus, and guinea pig resulted in predictions within 2-fold of 
the observed human CLint, while scaling with rat, mouse, and minipig resulted in 
substantial under-prediction. Unlike the case for zaleplon, an alternate major 
metabolite was not identified in S9 extracts from mouse, rat, or minipig when O6-
benzylguanine was incubated with NADPH, which may explain why the estimated 
hepatic extraction in these species was lower than human, monkey, and guinea pig, 
and consequently resulted in the under-prediction.   
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Figure IV.25. Proposed multispecies metabolism of O6-benzylguanine in hepatic S9. Species 
highlighted in bold (rat and mouse) exhibited greater dependence on NADPH for formation 
of M1 versus other species, which exhibited predominantly NADPH-independent formation 
of M1. H, human; M, mouse; R, rat; G, guinea pig; C, cynomolgus monkey; Rh, rhesus 
monkey; MP, minipig 
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Figure IV.26. Representative LC-UV chromatograms depicting principal metabolite from S9 
extracts of human, mouse, rat, guinea pig, cynomolgus monkey, rhesus monkey, and minipig 
incubated with O6-benzylguanine in the absence of NADPH.     
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Figure IV.27. Representative LC-UV chromatograms depicting principal metabolite from S9 
extracts of human, mouse, rat, guinea pig, cynomolgus monkey, rhesus monkey, and minipig 
incubated with O6-benzylguanine in the presence of NADPH.     
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Figure IV.28. Extracted ion chromatograms of m/z 242 (top) and m/z 258 (bottom) 
revealing elution times of 11.54 min and 11.60 min, respectively, for the parent O6-
benzylguanine and the AO metabolite M1. The representative chromatogram was obtained 
from an extract of human S9 incubated with O6-benzylguanine in the absence of NADPH.  
XIC, extracted ion chromatogram    
 
 
 
 
159 
 
 
 
 
 
Figure IV.29. Chromatograms representing the total ion current of fragment ions produced 
by m/z 258 (M1) from S9 extracts of human, mouse, rat, guinea pig, cynomolgus monkey, 
rhesus monkey, and minipig incubated with O6-benzylguanine in the absence of NADPH.  
TIC, total ion current   
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 Figure IV.30. Chromatograms representing the total ion current of fragment ions produced 
by m/z 258 (M1) from S9 extracts of human, mouse, rat, guinea pig, cynomolgus monkey, 
rhesus monkey, and minipig incubated with O6-benzylguanine in the presence of NADPH.  
TIC, total ion current 
 
 
  
 Table IV.23. Peak area ratio of M1 (presence of NADPH/ absence of NADPH) detected in S9 
extracts of human, mouse, rat, guinea pig, cynomolgus monkey, rhesus monkey, and minipig 
incubated with O6-benzylguanine.  Ratios determined from peak areas of the XICs in Figure 
IV.30 versus Figure IV.29. 
 
161 
 
 
 
 
 
 
Figure IV.31. LC/MS/MS spectra of O6-benzylguanine ([M+H]+ at m/z 242). 
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Figure IV.32. LC/MS/MS spectra of O6-benzylguanine metabolite M1 ([M+H]+ at m/z 258). 
Fragment ions occurring at m/z 241 and 180 correspond to a 16-Da increase over O6-
benzylguanine fragment ions at m/z 225 and 164, respectively. 
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Zoniporide 
The in vivo metabolism of zoniporide was previously characterized in rat, 
dog, and human following IV administration of radiolabeled zoniporide (Dalvie et 
al., 2010). The principal NADPH-dependent and –independent metabolism of 
zoniporide observed in hepatic S9 is summarized in Figure IV.33.  HPLC-UV 
chromatograms depicting the principal metabolites formed in the presence or 
absence of NADPH in each species are shown in Figures IV.34-35, and the MS/MS 
spectra and proposed fragmentation of each metabolite are shown in Figures IV.37-
38. Fragmentation of the metabolite detected at 7.9 min ([M+H]+ at m/z 337) was 
indicative of zoniporide oxidation to M1 (Figure IV.37) in all species in extracts from 
S9 incubations both in the absence (Figure IV.34) and presence (Figure IV.35) of 
NADPH.  Extensive conversion of zoniporide to M1 in mouse and rat S9 was 
consistent with the rapid intrinsic clearance observed in mouse and rat S9 in both 
the presence and absence of NADPH. Unlike the low conversion of zaleplon and O6-
benzylguanine to their respective M1 metabolites (5-oxozaleplon and 8-oxo-O6-
benzylguanine) in minipig S9, conversion of zoniporide to M1 (2-oxozoniporide) in 
minipig S9 was similar to that in human S9 (Figures IV.28-29).  A minor oxidative 
metabolite, M2 (Figure IV.38), was observed at 5.3 min ([M+H]+ at m/z 337)  in S9 
extracts of all species in incubations containing NADPH (Figure IV.35).  
Fragmentation of M2, similar to that of M1, indicates likely oxidation of the 
quinoline or the pyrazole. Particularly, the loss of 17 Da (-OH) from the fragment ion 
at m/z 278 (resulting in a fragment ion at m/z 261), is indicative of an N-oxide 
(Figure IV.38). Dalvie noted minor formation of an N-oxide detected in rat urine, but 
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not in human (Dalvie et al., 2010).  Dalvie also identified a carboxylic acid derivative 
of zoniporide, as well as a carboxlic acid derivative of M1, in vivo in human plasma 
and feces, respectively (the former was also detected in rat plasma and urine) 
(Dalvie et al., 2010).  Though the carboxylic acid derivative of zoniporide 
represented as much as 6-9% of circulating radioactivity in human and rat, 
respectively, it was reportedly only detected at trace levels in incubations with 
human S9 (Dalvie et al., 2010).  The carboxylic acid derivative of M1 reportedly was 
not detected at all in S9 extracts, and because it was only detected in human feces, it 
was proposed that this metabolite may be formed via gut microflora (Dalvie et al., 
2010). In our S9 studies, neither of these two metabolites was detected. It is possible 
that the ionization efficiency of the carboxylic acid metabolites did not permit 
detection via positive electrospray ionization (ESI), as ESI negative mode was not 
explored; however, an unidentified prominent peak was not observed in the UV 
chromatogram, indicating that if this were the case, the metabolite(s) were present 
at very low levels. Alternatively, it is also possible that the carboxylic acid 
metabolite(s) were not retained on the C18 column, as the carboxyl group may have 
been detprotonated at the pH used (4.1) for the aqueous mobile phase (a pH of 3.0 
was utilized in Dalvie’s studies) or that the extraction of the metabolite from S9 was 
inefficient.   
Overall, all species exhibited similar metabolite profiles with regard to 
metabolites produced (M1 and M2), while minipig and rhesus exhibited the most 
similar profiles to human with regard to the efficiency of zoniporide turnover to M1. 
Unfortunately, these data are inconclusive as to the source of metabolism 
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accounting for the minor NADPH-independent clearance observed in human, rat, 
and guinea pig S9, as only one metabolite (M1) was observed in extracts of 
incubations absent NADPH.  It is possible that XO could play a minor role in M1 
formation in these cases; however, Dalvie reported that the XO inhibitor allopurinol 
had no effect on M1 formation (Dalvie et al., 2010). These data are, however, 
consistent with the high Fm,AO estimated in all species.  The substrate turnover to 
metabolites mirrored the estimated hepatic extraction (E) in each species, with 
mouse and rat demonstrating higher E relative to other species, and accordingly, 
SSS with mouse and rat resulted in the greatest degree of over-prediction of human 
S9 CLint. 
 
 
 
Figure IV.33. Proposed multispecies metabolism of zoniporide in hepatic S9. H, human; M, 
mouse; R, rat; G, guinea pig; C, cynomolgus monkey; Rh, rhesus monkey; MP, minipig 
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Figure IV.34. Representative LC-UV chromatograms depicting principal metabolite from S9 
extracts of human, mouse, rat, guinea pig, cynomolgus monkey, rhesus monkey, and minipig 
incubated with zoniporide in the absence of NADPH.     
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Figure IV.35. Representative LC-UV chromatograms depicting principal metabolites from 
S9 extracts of human, mouse, rat, guinea pig, cynomolgus monkey, rhesus monkey, and 
minipig incubated with zoniporide in the presence of NADPH.
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Figure IV.36. LC/MS/MS spectra of zoniporide ([M+H]+ at m/z 321). 
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Figure IV.37. LC/MS/MS spectra of zoniporide metabolite M1 ([M+H]+ at m/z 337). 
Fragment ions occurring at m/z 320, 295, 278, and 250 correspond to a 16-Da increase over 
zoniporide fragment ions at m/z 304, 279, 262, and 234, respectively. 
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Figure IV.38. LC/MS/MS spectra of zoniporide metabolite M2 ([M+H]+ at m/z 337). 
Fragment ions occurring at m/z 320, 295, and 278 correspond to a 16-Da increase over 
zoniporide fragment ions at m/z 304, 279, and 262, respectively.  Loss of 17(-OH) from the 
fragment ion at m/z 278 to form the fragment ion at m/z 261 is indicative of an N-oxide. 
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BIBX1382  
The metabolism of BIBX1382 was previously characterized in human and 
cynomolgus monkey hepatic cytosol, S9, and hepatocytes (Hutzler et al., 2014a).  
The principal NADPH-dependent and –independent metabolism of BIBX1382 
observed in hepatic S9 is summarized in Figure IV.39.  Extracted ion chromatograms 
(XIC) depicting the principal metabolites formed in the presence or absence of 
NADPH in each species are shown in Figures IV.40-41, and the MS/MS spectra and 
proposed fragmentation of each metabolite are shown in Figures IV.43-51. 
Fragmentation of a metabolite detected at 9.6 min ([M+H]+ at m/z 404) was 
indicative of BIBX1382 oxidation to M1 (Figure IV.43) in all species in extracts from 
S9 incubations both in the absence (Figure IV.40) and presence (Figure IV.41) of 
NADPH.  In addition, an NADPH-independent secondary oxidation to M2 ([M+H]+ at 
m/z 420, 9.3 min) was observed in all species and was a prominent metabolite in 
most species (Figure IV.40-41). Fragmentation of M1 (Figure IV.43) and M2 (Figure 
IV.44) is consistent with that reported for metabolites denoted as M1 and M2 by 
Hutzler et al (Hutzler et al., 2014a).  Low levels of an additional monooxidative 
metabolite, M3 ([M+H]+ at m/z 404, 11.3 min) were detected in rat, mouse, and 
guinea pig S9 both in the absence (Figure IV.40) and presence (Figure IV.41) of 
NADPH, producing a major fragment at m/z 373 (Figure IV.45), as well as other 
minor fragments also produced by M1. Given the NADPH-independent nature of M3, 
it is likely that M3 results from AO or XO-mediated oxidation of the pyrimido-
pyrimidine core and that M2 results from dioxidation of the pyrimido-pyrimidine 
core (e.g., M1M2 and/or M3M2), as both AO and XO typically oxidize carbon 
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atoms alpha to a nitrogen of aromatic heterocyles.  Overall, NADPH-independent 
metabolism appeared to be low in mouse and rat compared to other species and 
moderate in guinea pig, consistent with S9 intrinsic clearance experiments.  Prior 
studies reported that BIBX1382 is N-demethylated in rat and mouse (Dittrich et al., 
2002).  This metabolite, M4 ([M+H]+ at m/z 374, 12.0 min), was detected in mouse, 
rat, and guinea pig, but was below detection in the other species (Figure IV.41 and 
Figure IV.46).  Two additional oxidative metabolites, M5 (Figure IV.47) and M6 
(Figure IV.48), were also detected in S9 extracts of mouse, rat, and guinea pig at 12.9 
min ([M+H]+ at m/z 404) and 13.1 min ([M+H]+ at m/z 404), respectively, in 
incubations both absent and present NADPH.  Fragmentation of these metabolites; 
however, indicated possible oxidation of the N-methyl piperidine moiety (Figures 
IV.47-48), and when incubated in the presence of NADPH (Figure IV.41), peak areas 
of M5 and M6 were approximately 10-fold higher than in the absence of NADPH 
(Figure IV.40).  There are examples in the literature of AO-mediated oxidation of an 
aliphatic nitrogen-containing ring; however, these examples required P450-
mediated generation of an intermediate iminium ion prior to oxidation of the carbon 
located alpha to the nitrogen (Pryde et al., 2010). It is possible that low levels of 
NADPH were already present in the S9, resulting in minor NADPH-dependent 
metabolism even when S9 was not fortified with the cofactor.  M5 and M6 were also 
detected in S9 extracts of minipig in the presence of NADPH, as was M5 in rhesus, 
though M5 was a very minor metabolite in these species (Figure IV.41).  A 
prominent NADPH-dependent metabolite in minipig and guinea pig with a mass 
shift of +32 Da, M7 ([M+H]+ at m/z 420, Figure IV.49), was observed at 10.0 min, 
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followed by a minor +32 Da metabolite, M8 ([M+H]+ at m/z 420, Figure IV.50)  at 
10.4 min (Figure IV.41). Though less prominent than in minipig or guinea pig 
extracts, M7 was also detected in extracts of all other species, and M8 was detected 
in all species except mouse and rat.   Based on the fragmentation and retention 
times, it is possible that these metabolites result from sequential oxidation of M5 
and M6 (e.g., M5M7 and M6M8). The presence of a fragment ion at m/z 373 and 
absence of m/z 389 suggests that one of the oxidations occurs on the nitrogen or the 
methyl substituent of the N-methyl piperidine moiety (Figure IV.49-50).  Finally, a 
trace NADPH-dependent metabolite, M9 (Figure IV.51), with a mass shift of +16 Da 
([M+H]+ at m/z 404) was observed at 10.4 min in mouse and rat extracts, but was 
not detected in other species (Figure IV.41). Similar fragmentation to M1 and M3, 
for example, fragments at m/z 373, m/z 361, m/z 307, and m/z 292, indicate the 
likelihood that the oxidation occurs on the pyrimido-primidine core or possibly the 
phenyl ring.   
Overall, substantial species differences were observed in the metabolism of 
BIBX1382, particularly when comparing rodent species to human.  Rhesus exhibited 
a profile most similar to human with regard to the relative levels of each metabolite, 
though trace levels of an additional metabolite, M5, were detected in rhesus, but not 
human or cynomolgus.  Low turnover in S9 of mouse, rat, and guinea pig is 
consistent with substantial under-prediction of human S9 CLint by SSS with these 
species.  The presence of M2 in human extracts absent NADPH suggests the 
possibility that the minor NADPH-independent substrate depletion observed in the 
presence of hydralazine in CLint experiments resulted from XO-mediated formation 
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of an M2-precursor metabolite (e.g., M3, which may not have been detected in 
human extracts due to conversion to M2).  These data support the Fm,AO estimates 
obtained from CLint experiments, which were high (≥ 0.85) in human, rhesus, 
cynomolgus, and minipig, and lower or immeasurable in guinea pig, rat, and mouse. 
Unfortunately, from these experiments, a clear explanation could not be determined 
as to the discrepancy in Fm,AO calculated by methods A and B  in rat.  However, as 
previously mentioned, it is possible that the metabolism of BIBX1382 could have 
been shunted towards NADPH-dependent metabolism (e.g., to M4, M5, M6, and/or 
M9) when AO was inhibited by hydralazine, resulting in a compensatory effect in the 
CLint.   
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Figure IV.39. Proposed multispecies metabolism of BIBX1382 in hepatic S9. H, human; M, mouse; R, rat; G, guinea pig; C, cynomolgus 
monkey; Rh, rhesus monkey; MP, minipig 
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Figure IV.40. Representative extracted ion chromatograms (m/z 388, 374, 404, and 420) 
depicting principal metabolites from S9 extracts of human, mouse, rat, guinea pig, 
cynomolgus monkey, rhesus monkey, and minipig incubated with BIBX1382 in the absence 
of NADPH. 
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Figure IV.41. Representative extracted ion chromatograms (m/z 388, 374, 404, and 420) 
depicting principal metabolites from S9 extracts of human, mouse, rat, guinea pig, 
cynomolgus monkey, rhesus monkey, and minipig incubated with BIBX1382 in the presence 
of NADPH.   
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Figure IV.42. LC/MS/MS spectra of BIBX1382 ([M+H]+ at m/z 388). 
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Figure IV.43. LC/MS/MS spectra of BIBX1382 metabolite M1 ([M+H]+ at m/z 404). 
Fragment ions occurring at m/z 292, 307, 347, 361, and 373 correspond to a 16-Da increase 
over parent fragment ions at m/z 276, 291, 331, 345, and 357, respectively. 
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Figure IV.44. LC/MS/MS spectra of BIBX1382 metabolite M2 ([M+H]+ at m/z 420). 
Fragment ions occurring at m/z 308, 323, 377, and 389 correspond to a 32-Da increase over 
parent fragment ions at m/z 276, 291, 345, and 357, respectively. 
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Figure IV.45. LC/MS/MS spectra of BIBX1382 metabolite M3 ([M+H]+ at m/z 404). 
Fragment ions occurring at m/z 292, 307, 361, and 373 correspond to a 16-Da increase over 
parent fragment ions at m/z 276, 291, 345, and 357, respectively. 
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Figure IV.46. LC/MS/MS spectra of BIBX1382 metabolite M4 ([M+H]+ at m/z 374). The 
major fragment at m/z 291, along with other minor fragments at m/z 276, 345, 331, and 
particularly the fragment ion at m/z 357, which were also all produced by the parent 
BIBX1382, indicates that the mass shift of -14 Da from the parent [M+H]+ of m/z 388 is a 
result of N-demethylation of the N-methyl piperidine moiety. 
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Figure IV.47. LC/MS/MS spectra of BIBX1382 metabolite M5 ([M+H]+ at m/z 404). The 
fragment ion at m/z 357, along with m/z 291 and 331, which were all produced by the 
parent, BIBX1382, indicates that the mass shift of +16 Da from the parent [M+H]+ at m/z 
388 is a result of oxidation of the nitrogen or methyl substituent of the N-methyl piperidine 
moiety. 
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Figure IV.48. LC/MS/MS spectra of BIBX1382 metabolite M6 ([M+H]+ at m/z 404). The 
fragment ion at m/z 357, along with m/z 291 and 331, which were all produced by the 
parent, BIBX1382, indicates that the mass shift of +16 Da from the parent [M+H]+ at m/z 
388 is a result of oxidation of the nitrogen or methyl substituent of the N-methyl piperidine 
moiety. 
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Figure IV.49. LC/MS/MS spectra of BIBX1382 metabolite M7 ([M+H]+ at m/z 420). 
Fragment ions occurring at m/z 292, 307, 361, and 373 correspond to a 16-Da increase over 
parent fragment ions at m/z 276, 291, 345, and 357, respectively, indicating that one 
oxidation occurs to the left of the mass fragmentation producing the fragment ion at m/z 
373, while the fragment ion at m/z 292 suggests the other oxidation occurs to the right of 
this fragmentation. 
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Figure IV.50. LC/MS/MS spectra of BIBX1382 metabolite M8 ([M+H]+ at m/z 420). 
Fragment ions occurring at m/z 307 and 373 correspond to a 16-Da increase over parent 
fragment ions at m/z 291 and 357, respectively, indicating that one oxidation occurs to the 
left of the mass fragmentation producing the ion at m/z 373, while the fragment ion at m/z 
307 suggests the other oxidation occurs to the right of this fragmentation. 
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Figure IV.51. LC/MS/MS spectra of BIBX1382 metabolite M9 ([M+H]+ at m/z 404). 
Fragment ions occurring at m/z 292, 307, 361, and 373 correspond to a 16-Da increase over 
parent fragment ions at m/z 276, 291, 345, and 357, respectively.
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SGX523  
The metabolism of SGX523 was previously reported in human, cynomolgus 
monkey, dog, and rat S9 and in vivo in monkey (Diamond et al., 2010a). The 
principal NADPH-dependent and –independent metabolism of SGX523 observed in 
hepatic S9 is summarized in Figure IV.52.  HPLC-UV chromatograms depicting the 
principal metabolites formed in the presence or absence of NADPH in each species 
are shown in Figures IV.53-54, and the MS/MS spectra and proposed fragmentation 
of each metabolite are shown in Figures IV.67-68.  Several of the metabolites either 
co-elute or elute very closely together, which can be better viewed in Figure IV.55, 
depicting XICs of each metabolite from extracts of human S9 (+NADPH).  
Fragmentation of the metabolite detected at 10.3 min ([M+H]+ at m/z 376) was 
indicative of SGX523 oxidation to M1 (Figure IV.57) in all species in S9 fractions 
absent (Figure IV.53) and present (Figure IV.54) NADPH.  Two additional major 
NADPH-dependent oxidative metabolites, M2 and M3 (Figures IV.58-59), co-eluted 
at 9.7 min ([M+H]+ at m/z 376) and were generated by all species (Figure IV.54).  
The fragment occurring at m/z 176 for both M2 and M3 suggests the oxidation is 
likely located on the quinoline moiety or the sulfur atom. The major loss of 18 Da 
(m/z 358, indicates loss of water) from M2 is indicative of S-oxidation, while the loss 
of 18 Da as well as 17 Da (m/z 359, indicates possible loss of OH radical) from M3 is 
indicative of N-oxidation.  However, a fragment ion produced by SGX523 at m/z 343 
corresponds to a loss of 17 Da, in which case, it is unclear without further 
investigation whether the M3 fragment at m/z 359 resulted from loss of an OH 
radical. Several other minor NADPH-dependent metabolites were also detected in 
189 
all species (Figure IV.54), including an N-desmethyl metabolite, M4 (Figure IV.60), 
at 10.5 min ([M+H]+ at m/z 346), and two other metabolites, M5 and M6 (Figures 
IV.61-62), at 10.6 and 10.7 min, respectively, both with a mass shift of +16 Da 
([M+H]+ at m/z 376) over the parent. The presence of a fragment at m/z 176 in M5 
and M6 again suggests that the oxidation may be located on the quinoline moiety. 
NADPH-dependent metabolites with a mass shift of +32 over the parent ([M+H]+ at 
m/z 392), M7, M8, and M9 (Figures IV.63-65), eluting at 10.9, 8.0, and 8.5 min,  
respectively, were also detected in S9 extracts of all species (Figure IV.54).  
Fragments at m/z 192 (+32 Da over the parent fragment at m/z 160) and m/z 247 
(+16 over the parent fragment at m/z 231) suggested M8 and M9 were S-oxides 
with a secondary oxidation located on the quinoline moiety.  Fragmentation of M7 
(Figure IV.63), as well as the late retention time (10.9 min) indicates the likelihood 
that both oxidations are located on the sulfur atom, producing a sulfone metabolite.  
Finally, three NADPH-dependent metabolites, M10, M11, and M12, with a mass shift 
of +2 Da over the parent ([M+H]+ at m/z 362) and fragmentation suggestive of N-
demethylation and monooxidation (Figures IV.66-68), were detected in a species-
specific manner (Figure IV.54).  M10 was detected in extracts of all species except 
mouse, M11 in all but mouse and rat, and M12 in all but mouse, rat, and minipig.  
Overlapping retention times of M10 and M11 (9.0 min) as well as similarities in 
fragmentation, including the major loss of 18 Da from M10 (Figure IV.66) and the 
major loss of both 17 and 18 Da from M11 (Figure IV.67) suggest the likelihood that 
these two metabolites are the N-desmethyl analogs of M2 and M3, respectively.  
M12, which eluted at 9.6 min, also produced fragments indicative of N-
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demethylation and oxidation, with fragment ion intensities at m/z 145, 176, and 217 
mirroring those of fragment ions produced by M1 at m/z 159, 176, and 231 (each + 
14 Da over M12 fragments), indicating the possibility that M12 is the N-desmethyl 
analog of M1.  
Overall, metabolism of SGX523 was relatively similar across all species, with 
cynomolgus, rhesus, and guinea pig demonstrating the most similar profile with 
regard to detection of all 12 metabolites.  Despite the lack of detection of M10, M11, 
and/or M12 in rat or mouse, the rodents (including guinea pig) demonstrated the 
most similarities in overall turnover of the substrate.  Accordingly, SSS with mouse, 
rat, and guinea pig resulted in the most accurate predictions of human S9 CLint. 
These data also support the low Fm,AO observed in minipig and the low-moderate 
Fm,AO in the remaining species.  The detection of only a single metabolite (M1) in S9 
extracts absent NADPH suggests that the portion of NADPH-independent clearance 
not inhibited by hydralazine in mouse, guinea pig, and rhesus monkey S9 could be 
attributed to the contribution of XO to the formation of M1.  Diamond et al 
previously reported little-to-no inhibition of  M1 formation in incubations of human 
and cynomolgus S9 in the presence of allopurinol or oxypurinol (XO inhibitors) 
(Diamond et al., 2010a).  
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Figure IV.52. Proposed multispecies metabolism of SGX523 in hepatic S9. H, human; M, mouse; R, rat; G, guinea pig; C, cynomolgus 
monkey; Rh, rhesus monkey; MP, minipig 
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Figure IV.53. Representative LC-UV chromatograms depicting principal metabolite(s) from 
S9 extracts of human, mouse, rat, guinea pig, cynomolgus monkey, rhesus monkey, and 
minipig incubated with SGX523 in the absence of NADPH.  
 
 
 
 
 
 
193 
 
 
 
 
Figure IV.54. Representative LC-UV chromatograms depicting principal metabolites from 
S9 extracts of human, mouse, rat, guinea pig, cynomolgus monkey, rhesus monkey, and 
minipig incubated with SGX523 in the presence of NADPH.  
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Figure IV.55. Representative extracted ion chromatograms (XIC, m/z 376, 392, 346, and 
362) depicting principal metabolites from S9 extracts of human incubated with SGX523 in 
the presence of NADPH. 
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Figure IV.56. LC/MS/MS spectra of SGX523 ([M+H]+ at m/z 360).   
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Figure IV.57. LC/MS/MS spectra of SGX523 metabolite M1 ([M+H]+ at m/z 376).  Fragment 
ions occurring at m/z 308 and 176 correspond to a 16-Da increase over parent fragment 
ions at m/z 292 and 160, respectively, while fragment ions to the left of the quinoline 
moiety at m/z 231 and 159 remained the same. 
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Figure IV.58. LC/MS/MS spectra of SGX523 metabolite M2 ([M+H]+ at m/z 376).  The 
fragment ion occurring at m/z 176 corresponds to a 16-Da increase over parent fragment 
ion at m/z 160, while the fragment ion at m/z 159 remained the same.  The major fragment 
at m/z 358 represents loss of water, with an intensity of 100% suggesting the likelihood 
that the oxidation is located on the sulfur atom. 
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Figure IV.59. LC/MS/MS spectra of SGX523 metabolite M3 ([M+H]+ at m/z 376).  The 
fragment ion occurring at m/z 176 corresponds to a 16-Da increase over parent fragment 
ion at m/z 160, while the fragment ion at m/z 231 remained the same.  The major fragment 
at m/z 358 representing loss of water, along with the fragment ion at m/z 359 (possible loss 
of OH radical), suggests the possibility that the oxidation is located on the nitrogen of the 
quinoline moiety. 
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Figure IV.60. LC/MS/MS spectra of SGX523 metabolite M4 ([M+H]+ at m/z 346).  Fragment 
ions occurring at m/z 217 and 145 correspond to a 14-Da decrease from parent fragment 
ions at m/z 231 and 159, respectively, while the fragment ion at m/z 160 remained the 
same. 
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Figure IV.61. LC/MS/MS spectra of SGX523 metabolite M5 ([M+H]+ at m/z 376).  The 
fragment ion occurring at m/z 176 corresponds to a 16-Da increase over parent fragment 
ion at m/z 160, while the fragment ion at m/z 159 remained the same.   
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Figure IV.62. LC/MS/MS spectra of SGX523 metabolite M6 ([M+H]+ at m/z 376).  The 
fragment ions occurring at m/z 308 and 176 correspond to a 16-Da increase over parent 
fragment ions at m/z 292 and 160, respectively, while the fragment ion at m/z 159 
remained the same.   
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Figure IV.63. LC/MS/MS spectra of SGX523 metabolite M7 ([M+H]+ at m/z 392).  The 
fragment ions occurring at m/z 263 and 192 correspond to a 32-Da increase over parent 
fragment ions at m/z 231 and 160, respectively, while the fragment ion at m/z 159 
remained the same.   
 
 
 
 
 
203 
 
 
 
Figure IV.64. LC/MS/MS spectra of SGX523 metabolite M8 ([M+H]+ at m/z 392).  The 
fragment ions occurring at m/z 247 and 192 correspond to a 32-Da and 16-Da increase, 
respectively, over parent fragment ions at m/z 231 and 160, respectively, likely placing one 
of the oxidations on the sulfur atom and the other on the quinoline moiety. 
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Figure IV.65. LC/MS/MS spectra of SGX523 metabolite M9 ([M+H]+ at m/z 392).  The 
fragment ions occurring at m/z 247 and 192 correspond to a 32-Da and 16-Da increase, 
respectively, over parent fragment ions at m/z 231 and 160, respectively, likely placing one 
of the oxidations on the sulfur atom and the other on the quinoline moiety. 
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Figure IV.66. LC/MS/MS spectra of SGX523 metabolite M10 ([M+H]+ at m/z 362).  The 
fragment ions occurring at m/z 176 and 145 correspond to a 16-Da increase and 14-Da 
decrease, respectively, from parent fragment ions at m/z 160 and 159, respectively. The 
major fragment at m/z 344 represents loss of water, with an intensity of 100% suggesting 
the likelihood that the oxidation is located on the sulfur atom. 
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Figure IV.67. LC/MS/MS spectra of SGX523 metabolite M11 ([M+H]+ at m/z 362).  The 
fragment ions occurring at m/z 176 corresponds to a 16-Da increase over the parent 
fragment ion at m/z 160 and fragment ions at m/z 217 and 145 correspond to a 14-Da 
decrease from parent fragment ions at 231 and 159, respectively. The major fragment at 
m/z 344 representing loss of water, along with the fragment ion at m/z 345 (possible loss of 
OH radical), suggests the possibility that the oxidation is located on the nitrogen of the 
quinoline moiety. 
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Figure IV.68. LC/MS/MS spectra of SGX523 metabolite M12 ([M+H]+ at m/z 376).  The 
fragment ion occurring at m/z 176 correspond to a 16-Da increase over the parent fragment 
ion at m/z 160, while fragment ions at 217 and 145 correspond to a 14-Da decrease from 
parent fragment ions at m/z 231 and 159, respectively. Intensities of fragment ions at m/z 
217 (100%), 176 (~100%), and 145 (~25%) are similar to the corresponding fragments of 
M1 (m/z 231, 176, and 145, respectively), suggesting the possibility that M12 is the N-
desmethyl analog of M1. 
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 In general, major differences were not observed in the qualitative 
assessment of interspecies metabolism of the five compounds.  In some cases, 
metabolites were detected in a species-specific manner, though in general, these 
metabolites were only present at trace levels.  Instead, the primary differences 
observed between species concerned the relative amounts of each metabolite 
detected.   In agreement with the intrinsic clearance data, similarities in metabolite 
profile between human and any one species was substrate-dependent.  Likewise, 
mouse and rat generally exhibited metabolite profiles least similar to human, 
particularly with regard to efficiency of substrate turnover to M1 versus NADPH-
dependent metabolites.  Interestingly, the difference in turnover efficiency to M1 in 
mouse and rat was not always decreased relative to human, but in the case of 
zoniporide was increased.  Minipig generally exhibited greater NADPH-dependent 
metabolism versus human, with similar or decreased NADPH-independent 
metabolism. Guinea pig metabolite profiles in some instances were very similar to 
human, while in others (zoniporide and BIBX1382) it better resembled the rat and 
mouse profiles.  Overall, the greatest similarities were observed between human 
and the two monkey species. 
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DISCUSSION 
  The general assumption in the utility of allometric scaling to predict human 
clearance is that it requires conserved drug elimination mechanisms across species. 
Accordingly, where AO-mediated clearance exists, confidence in this approach is 
lacking due to differences in expression and activity between human and preclinical 
species traditionally employed with this method (e.g., mouse, rat, dog), resulting in 
limited studies examining allometry to predict human clearance of AO substrates. 
Given the successful allometric scaling of human clearance of UGT substrates 
despite species differences in glucuronidation (Deguchi et al., 2011), we sought to 
evaluate the ability to scale clearance (specifically, hepatic clearance) of compounds 
exhibiting an AO elimination pathway by MA and SSS.  This was accomplished by 
scaling in vitro CLint of five structurally and therapeutically diverse AO substrates, 
determined in hepatic S9 of several species known to express AO in the liver. In the 
present investigation, human in vitro hepatic clearance of the five AO substrates was 
successfully predicted by either MA or SSS.  By comparison of AAFE, MA was not 
superior to SSS with cynomolgus, rhesus, or guinea pig, but was generally more 
accurate than SSS with mouse or rat (summarized in Tables IV.24-25).  It was 
anticipated that these species would out-perform mouse and rat since, like human, 
they express only the AOX1 isoform in the liver, unlike rat and mouse which express 
both AOX1 and AOX3 (Garattini and Terao, 2012). When comparing AFEs, with the 
exception of monkey, SSS tended more toward under-prediction versus most MA 
approaches. 
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Table IV.24. Summary of absolute average fold-error (AAFE), average fold-error (AFE), and 
percentage of compounds predicted within 2 or 3 fold-error of observed intrinsic clearance 
(CLint) measured in human S9, as predicted by multispecies allometry (MA) or single-
species scaling (SSS). Cyno = cynomolgus monkey; Rhesus = rhesus monkey; Gpig = guinea 
pig 
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Table IV.25. Summary of absolute average fold-error (AAFE), average fold-error (AFE), and 
percentage of compounds predicted within 2 or 3 fold-error of observed hepatic clearance 
(CLHEP) measured in human S9, as predicted by multispecies allometry (MA) or single-
species scaling (SSS). Cyno = cynomolgus monkey; Rhesus = rhesus monkey; Gpig = guinea 
pig 
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The use of minipigs in drug discovery and development is gaining popularity 
due to similarities in anatomy and physiology to humans, as well as advantages 
related to regulatory acceptability and animal welfare (Bode et al., 2010; van der 
Laan et al., 2010). With regard to drug metabolism, minipigs hold an advantage over 
dogs when AO is involved, as dogs are essentially devoid of AO activity in the liver 
(Dalgaard, 2015; Terao et al., 2016).  In addition, a recent report found minipig to be 
useful in allometric scaling of drugs mostly cleared by P450 or glucuronidation 
(Yoshimatsu et al., 2016). Consequently, for our studies we chose to replace dog, 
which is commonly used for allometric scaling, with minipig, a species of similar 
body weight.  We also evaluated the utility of guinea pig in addition to rat and 
mouse, since, as previously stated, guinea pig expresses only the AOX1 isoform in 
the liver, resembling human. Indeed, the use of minipig for MA enabled human S9 
CLint predictions within 3-fold of measured values, and SSS with both minipig and 
guinea pig predicted CLint within 2-fold for four out of the five substrates (all five 
with guinea pig for CLHEP). Despite successful SSS with minipig, monkey, and guinea 
pig, three-species allometry with minipig, monkey, and guinea pig was not always 
superior to the other species combinations. O6-benzylguanine, for example, was 
under-predicted (0.17-0.18 fold error) by MA with minipig, monkey, and guinea pig; 
however, the prediction resulting from MA is heavily influenced by the smallest and 
the largest species included in the analysis (see Figure II.2). In the case of O6-
benzylguanine, minipig demonstrated very low CLint, and thus the curve fit to these 
data results in a lower CLint value when extrapolated to human versus MA analyses 
where monkey (which exhibited higher CLint than minipig) is the largest animal 
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included in the analysis. When minipig, monkey, and guinea pig each produced good 
predictions by SSS for a particular compound, this species combination also resulted 
in good predictions by MA (e.g., zaleplon and zoniporide).   
While these data support the notion that allometry could be useful to predict 
human clearance of AO substrates, they only represent clearance mediated by 
hepatic metabolism. Substrates with minimal renal clearance were selected to avoid 
this source of inconsistency between in vitro and in vivo elimination. However, 
extra-hepatic expression of AO has been demonstrated in human as well as 
nonclinical species (Kurosaki et al., 1999; Moriwaki et al., 2001; Nishimura and 
Naito, 2006; Terao et al., 2016). Furthermore, differences in the AOX1 mRNA levels 
observed in various tissues between humans and mice (Terao et al., 2016) indicate 
tissue-specific expression patterns may not parallel across species. Any extra-
hepatic metabolism, therefore, could preclude in vivo translation of these data. For 
example, Hutzler et al. demonstrated elimination of BIBX1382 in lung and kidney S9 
fractions of human and cynomolgus monkey (Hutzler et al., 2014a). Furthermore, 
species differences were noted in the relative elimination of BIBX1382 from these 
two tissues. Indeed, human CLp for four of the five substrates we evaluated are 
reported in the literature and were each under-represented by our CLHEP estimates 
from human S9 incubations, including BIBX1382 (see Table V.2). This is not an 
uncommon observation, which may be attributed to extra-hepatic metabolism, 
among other possibilities, such as SNPs or other sources of donor variability, ex vivo 
protein instability, or procedural differences in tissue procurement (Hartmann et al., 
2012; Hutzler et al., 2012; Fu et al., 2013; Hutzler et al., 2014b). Therefore, while our 
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in vitro data indicate allometric scaling could be a potentially useful method to 
predict human hepatic clearance of AO substrates, its utility in predicting total body 
clearance will remain a significant challenge until extra-hepatic expression and 
activity of AO across species is better resolved. However, despite observed 
differences in elimination from extra-hepatic S9 fractions of cynomolgus and 
human, cynomolgus plasma clearance of BIBX1382 was still representative of the 
rapid clearance observed in clinical pharmacokinetic studies in terms of percentage 
of liver blood flow (Hutzler et al., 2014a), suggesting preclinical species such as 
monkey may still be useful for predicting total body clearance.  
Comparison of prediction fold-errors by SSS (CLint or CLHEP) with the 
animal:human ratio of either Fm,AO or E revealed little correlation with Fm,AO, but a 
positive correlation with E (Figures IV. 6-7). Likewise, the same trends were 
observed for UGT substrates when plotting SSS prediction fold-error of CLp versus 
the animal:human ratio in Fm,UGT or versus CLp as a percentage of QH (Figure IV.8). 
We observed some examples where a discrepancy in Fm,AO between human and 
animal did not preclude a similar E, indicating a non-AO metabolism pathway may 
compensate for the lacking AO pathway to result in an overall similar hepatic 
extraction efficiency. For example, the Fm,AO obtained for zaleplon was substantially 
higher in human (≥ 0.71) versus minipig (≤ 0.17), while the E between the two 
species was similar (human = 0.22, minipig = 0.16). Accordingly, biotransformation 
experiments revealed decreased NADPH-independent oxidation of zaleplon to M1 in 
minipig S9 relative to human S9, while instead NADPH-dependent N-deethylation to 
M2 appeared to be the major metabolite in minipig S9. Consequently, these data 
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may indicate that compounds containing a mixed AO/P450 metabolism phenotype, 
or possessing P450 favorable sites in addition to the AO metabolism site, could help 
to enable allometric scaling approaches since alternate metabolism pathway(s) in 
certain species may compensate for reduced AO-mediated clearance. Nonetheless, 
these observations suggest that there is not a strong relationship between Fm and 
the prediction fold-error by SSS or that methods to obtain Fm are not sufficiently 
accurate to observe this relationship. With regard to the present study, it should be 
noted that our Fm,AO calculations assume that 50 M hydralazine is adequate to 
selectively and completely inhibit AO metabolism, whereas the potency and 
selectivity of hydralazine is not known for all species studied. In addition, our Fm,AO 
calculations are dependent on the ability to measure substrate depletion when 
turnover may be low, which presents an additional challenge in obtaining an 
accurate Fm,AO estimate. Finally, four of the five compounds exhibited an Fm,AO in 
human of ≥ 0.70. A larger data set consisting of compounds exhibiting a broader 
range of Fm,AO would help to better understand the importance of this value to 
obtaining an accurate human hepatic clearance prediction by SSS.  
Because we cannot assume that human clearance predictions derived from 
allometrically scaled in vitro data are representative of total body clearance, we do 
not propose that this method should be used for predicting human total body 
clearance.  Instead, it may be useful in selecting the best species for conducting in 
vivo pharmacokinetic (PK) studies and subsequent allometric scaling of in vivo data 
to predict human total body clearance. Recently, Choughule et al., reported that 
relative hepatic CLint mediated by AO in human, rhesus and guinea pig cytosol was 
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substrate-dependent, suggesting that no single species could be reliably employed 
to consistently predict human clearance (Choughule et al., 2013b). We too observed 
substrate-dependent variability in all species evaluated, with a particular species (or 
species combination) resulting in over-prediction for some substrates and under-
prediction for others. These studies may therefore serve as a useful tool to guide 
species selection for in vivo assessments. Particularly, evaluation of Fm,AO and E in 
combination with the in vitro SSS and biotransformation analyses may be useful  to 
support decisions in selecting the most appropriate species, with the suggestion that 
confidence not be placed in Fm,AO alone to indicate which species is expected to 
provide a more accurate human hepatic clearance prediction by SSS, but rather Fm,AO 
should be considered secondary to E in guiding this decision. For example, based on 
our SSS analysis, cynomolgus might be selected for in vivo studies of BIBX1382, 
when all in vitro data is taken into consideration.  Cynomolgus monkey exhibited a 
similar E to human (cynomolgus = 0.80, human = 0.79) as well as Fm,AO ( cynomolgus 
= 1.0, human = 0.92), and the fold-error in prediction of CLint by SSS was 1.1, while 
the fold-error in CLHEP prediction by SSS was 1.0. Furthermore, biotransformation of 
BIBX1382 by human and monkey was similar, with the exception of secondary 
metabolism of M1M2 (appears greater in cynomolgus), which does not directly 
contribute to elimination of the parent drug.   Based on Hutzler’s report of in vivo 
clearance in cynomolgus, this species would indeed be an appropriate selection for 
in vivo studies and subsequent human in vivo clearance prediction. Rat and mouse, 
on the other hand, would not be expected to accurately scale human clearance based 
on our analysis. Both mouse and rat exhibited low E relative to human (mouse = 
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0.27, rat = 0.30), while Fm,AO estimates were unclear. In addition, fold-errors in SSS 
CLint prediction by mouse and rat were 0.05 and 0.09, respectively, with some 
improvement when predicting CLHEP at 0.22 and 0.33-fold under-prediction, 
respectively. Likewise, metabolite profiles of mouse and rat were dissimilar to 
human, particularly with regard to NADPH-dependent versus –independent 
metabolism and the major metabolite(s) produced. Accordingly, preclinical studies 
in rat and mouse PK did not predict the rapid clearance of BIBX1382 observed in 
clinical trials (Dittrich et al., 2002), and thus were an ineffective species selection. In 
addition to evaluating in vitro data for selection of species, it may also be important 
to evaluate sex differences for selection of male versus female animals.  Sex 
evaluation may be particularly important for compounds exhibiting other 
metabolism pathways in addition to AO, as in some cases, the sex differences may 
oppose one another depending on which enzymes are involved (e.g., females may 
exhibit higher AO activity, while males may exhibit higher P450 3A4 activity, etc.).   
It is also important to note that while we did observe substrate-dependence 
in the accuracy of the prediction with regard to which species were included in the 
analysis, this result is not contrary to findings in other evaluations of allometry 
approaches for compounds cleared by non-AO mechanisms such as cytochrome 
P450 metabolism. In a report by Hosea et al., for example, half-life of only ~60-80% 
of 50 proprietary compounds exhibiting P450, nonP450, and renal clearance 
mechanisms were predicted within 3-fold of clinically observed measurements 
using multiple different allometric scaling approaches, and of those cleared by P450, 
the oral clearance of only ~30-50% were predicted within 2-fold by SSS with rat, 
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dog, or monkey (Hosea et al., 2009). Therefore, according to our in vitro results, it 
may be possible to predict human hepatic clearance of AO substrates with allometry 
at a rate similar to that obtained for compounds cleared via other mechanisms.  The 
larger issue may rather lie in the potential differences in extra-hepatic expression of 
AO, and thus, total body clearance prediction.      
In conclusion, we have demonstrated that human in vitro hepatic CLint may 
be successfully scaled by MA and SSS using the species presented, albeit in a 
substrate-dependent manner with regard to species. We have offered a potentially 
useful approach, not to predict human in vivo clearance of AO substrates, but to aid 
in selection of preclinical species that, when evaluated in vivo, may provide the best 
estimates of human in vivo clearance, particularly when in vivo clearance is 
predominantly mediated by hepatic metabolism. In vivo studies will be required to 
fully understand the utility of this approach (Chapter V) as will further work to 
understand species differences in extra-hepatic metabolism with regard to total 
body clearance. 
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CHAPTER V 
ALLOMETRIC SCALING OF IN VIVO HEPATIC CLEARANCE OF DRUGS 
POSSESSING AN ALDEHYDE OXIDASE PATHWAY IN HUMAN 
 
INTRODUCTION 
In vitro clearance measurements in hepatocytes or subcellular liver fractions 
(e.g., microsomes) are considered to be a reliable tool for estimating in vivo human 
clearance of compounds metabolized by cytochrome P450s (Obach et al., 1997; 
Hosea et al., 2009; Di et al., 2013). In order to build confidence in in vivo human 
clearance predictions extrapolated from in vitro human clearance measurements, 
cross-species in vitro: in vivo correlation (IVIVC) of clearance is commonly evaluated 
(Di et al., 2013). However, while in vitro-based clearance prediction methods are 
well-established for P450-mediated metabolism, those for metabolism mediated by 
non-P450 enzymes such as aldehyde oxidase (AO) remain to be improved. Poor 
IVIVC in the clearance of several AO substrates has been reported for in vitro 
clearance estimates derived from incubations with S9, cytosol, or hepatocytes, with 
under-prediction of in vivo clearance observed in each case (Zientek et al., 2010) 
(Akabane et al., 2012; Hutzler et al., 2012). These observations were proposed to be 
potentially attributable to extra-hepatic metabolism or possibly ex vivo enzyme 
instability. Others have studied the donor composition of in vitro systems (e.g., 
hepatocytes) and observed interindividual variability (Hutzler et al., 2014b), which 
may also play a role in the in vitro under-prediction of in vivo clearance of AO 
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substrates. Altogether, these drawbacks have resulted in skepticism toward 
traditional in vitro methods for prediction of in vivo clearance mediated by AO. In 
the absence of reliable in vitro techniques, the identification of dependable animal 
model(s) to estimate human AO clearance would be a highly valuable contribution 
to the drug discovery community.  
Our in vitro studies described in Chapter IV indicated reasonable prediction 
of human hepatic clearance by multispecies simple allometry (MA) or single-species 
scaling (SSS) may be achievable, despite the observation of species differences in 
AO-mediated metabolism. However, the potential issues with in vitro systems 
described above could prevent the translation of these results in vivo.  Thus, our 
next step in seeking to understand the utility of allometric scaling approaches in 
predicting the human clearance of AO substrates was to investigate the ability to 
predict human total body clearance in vivo.  To conduct this investigation, we 
administered the five AO substrates previously studied in vitro (zaleplon, O6-
benzlguanine, zoniporide, BIBX1382, and SGX523) to mice, rats, guinea pigs, and 
minipigs as a single IV bolus cassette dose and collected blood samples to determine 
their plasma concentration-time profiles for pharmacokinetic (PK) analysis. Plasma 
clearances (CLp) obtained from noncompartmental PK analysis were compared to 
hepatic clearances (CLHEP) estimated in vitro (Chapter IV) to determine the IVIVC for 
each compound in each species. Subsequently, the CLp obtained from mouse, rat, 
guinea pig, and minipig were subjected to MA and SSS for the prediction of human 
CLp. When available, CLp values in cynomolgus monkey (as well as mouse and rat in 
some instances) were obtained from the literature and included in these studies.  
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Finally, in vitro data described in Chapter IV were compared to the in vivo data 
reported here for the purpose of evaluating the use of MA and SSS of in vitro CLint as 
a tool to guide selection of a suitable species for in vivo PK analysis and subsequent 
allometric scaling to predict human CLp. 
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RESULTS 
Pharmacokinetic Parameters in Preclinical Species 
Pharmacokinetic (PK) parameters of SGX523, zoniporide, O6-benzylguanine, 
and zaleplon obtained from an IV cassette dose in minipig, guinea pig, rat, and 
mouse are summarized in Table V.1, and plasma concentration-time curves are 
displayed in Figures V.1-4. Low plasma concentrations of BIBX1382 did not permit 
quantitation in any species evaluated, and thus, PK parameters could not be 
obtained for this compound. Likewise, quantitation limits prevented PK analysis of 
zoniporide in all species except minipig. Plasma clearance (CLp) of zaleplon was 
highest in mouse (83.9 mL/min/kg) and guinea pig (49.2 mL/min/kg) and 
moderate in rat and minipig (33.7 and 15.4 mL/min/kg, respectively), with 
moderate volumes of distribution (Vss) ranging from 1.24 – 1.77 L/kg.  O6-
benzylguanine CLp exceeded hepatic blood flow in all species (454, 203, and 206 
mL/min/kg in mouse, rat, and guinea pig, respectively) except minipig (24.1 
mL/min/kg), which was near hepatic blood flow. Vss of O6-benzylguanine was 
moderately high in all species, ranging from 2.32 and 3.01 L/kg, respectively, in 
guinea pig and minipig to 4.0 and 4.55 L/kg, respectively, in rat and mouse. 
Clearance of zoniporide from minipig plasma was rapid, exceeding hepatic blood 
flow (193 mL/min/kg), and Vss was also very high at 42.7 L/kg. Though a PK 
analysis of zoniporide could not be conducted due to low plasma concentrations in 
mouse, rat, and guinea pig, zoniporide CLp has been reported in the literature for rat 
and mouse, which also exceeded hepatic blood flow (237 and 298 mL/min/kg, 
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respectively); however, the Vss was reported to be much lower at 7.2 and 2.2 L/kg, 
respectively (Tracey et al., 2003). SGX523 CLp varied across species, with rapid 
clearance in mouse (82.9 mL/min/kg), moderate clearance in minipig and guinea 
pig (19.1 and 34.5 mL/min/kg, respectively), and low clearance in rat (8.4 
mL/min/kg). Vss was also lowest in rat (0.761 L/kg), while higher in mouse (2.34 
L/kg), guinea pig (1.75 L/kg), and minipig (4.79 L/kg). The reported CLp of SGX523 
was low in cynomolgus monkey at 3.7 mL/min/kg (Diamond et al., 2010b). Area 
under the plasma concentration-time curve (AUC), which represents the total drug 
exposure, as well as mean residence time (MRT) and terminal half-life (t1/2), which 
reflect the amount of time the drug is present in the body, are also listed in Table 
V.1.   
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Figure V.1. Plasma concentration-time curves obtained from mouse plasma following an IV 
cassette dose (0.2 mg/kg) of (A) zaleplon, (B) SGX523, (C) O6-benzylguanine, zoniporide 
(not shown), and BIBX1382 (not shown).  Plasma concentrations of zoniporide and 
BIBX1382 were below the quantitation limit (5 ng/mL). Data represent mean of n = 3 ( 
SD). 
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Figure V.2. Plasma concentration-time curves obtained from rat plasma following an IV 
cassette dose (0.2 mg/kg) of (A) zaleplon, (B) SGX523, (C) O6-benzylguanine, zoniporide 
(not shown), and BIBX1382 (not shown).  Plasma concentrations of zoniporide and 
BIBX1382 were below the quantitation limit (5 ng/mL). Data represent mean of n = 3 ( SD) 
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Figure V.3. Plasma concentration-time curves obtained from guinea pig plasma following 
an IV cassette dose (0.2 mg/kg) of (A) zaleplon, (B) SGX523, (C) O6-benzylguanine, 
zoniporide (not shown), and BIBX1382 (not shown).  Plasma concentrations of zoniporide 
and BIBX1382 were below the quantitation limit (5 ng/mL). Data represent mean of n = 3 
( SD). 
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Figure V.4. Plasma concentration-time curves obtained from minipig plasma following an 
IV cassette dose (0.2 mg/kg) of (A) zaleplon, (B) SGX523, (C) O6-benzylguanine, (D) 
zoniporide, and BIBX1382 (not shown).  Plasma concentrations of BIBX1382 were below 
the quantitation limit (5 ng/mL). Data represent mean of n = 2 ( SEM). 
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Table V.I. Pharmacokinetic parameters of zaleplon, O6-benzylguanine, zoniporide, and SGX523 obtained from a cassette IV bolus 
dose (0.2 mg/kg per compound) to mouse, rat, guinea pig and minipig. Data represents mean of n = 3 (rat, mouse, and guinea pig) 
or n = 2 (minipig). MP, minipig; GP, guinea pig; R, rat; M, mouse 
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In Vitro-in Vivo Correlation (IVIVC) 
In vitro hepatic clearance (CLHEP) for zaleplon, O6-benzylguanine, zoniporide, 
SGX523, and BIBX1382 was previously estimated in S9 of human, mouse, rat, guinea 
pig, cynomolgus, rhesus, and minipig (Chapter IV). Comparisons of these CLHEP 
values with CLp obtained for each species are displayed in Table V.2.  In instances 
where CLp data were available in the literature on species or compounds for which 
we did not obtain PK parameters, these data were included in the analysis where 
indicated. In all species evaluated, in vitro estimates of zaleplon CLHEP under-
estimated in vivo CLp.  However, the fold-difference between in vitro and in vivo CL 
of zaleplon was fairly consistent across all species (range 0.23 - 0.38). O6-
benzylguanine CLp was under-estimated by in vitro assessments as well in each 
species. The fold-difference was similar between guinea pig and minipig (0.15 and 
0.16, respectively) and between rat and mouse (0.04 in rat and mouse).   The under-
estimation was less severe in human (fold-difference = 0.66). Zoniporide under-
estimations were worst in minipig (fold-difference = 0.07), similar between mouse 
and rat (0.24 and 0.26, respectively), and were more reasonable in cynomolgus and 
human (0.83 and 0.46, respectively).  Human CLp of BIBX1382 reported in the 
literature ranged from 25 – 55 mL/min/kg (Dittrich et al., 2002), resulting in an in 
vitro underestimation of 0.66 – 0.30 fold (Hutzler et al., 2014a).  Cynomolgus 
monkey CLp BIBX1382 likewise was under-estimated by in vitro CLHEP, with a 
reported CLp of 118 mL/min/kg and a fold-difference of 0.30 (Hutzler et al., 2014a). 
BIBX1382 CLp of 55 mL/min/kg was reported in rat and mouse, with an in vitro 
underestimation of 0.39 and 0.44, respectively (Dittrich et al., 2002). Fold-
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differences in estimation of SGX523 were again similar between guinea pig and 
minipig (0.72 and 0.70, respectively), but were very different between mouse, which 
under-estimated CLp (fold-difference = 0.33) and rat, which over-estimated CLp 
(fold-difference = 2.65). Cynomolgus monkey overestimated the SGX523 CLp 
reported in the literature by 6-fold (Diamond et al., 2010b).  Human CLp was not 
available in the literature for SGX523 and therefore could not be evaluated. 
 Overall variability was observed in the IVIVC both across species and across 
compounds, with most cases resulting in underestimation of in vivo CLp by the CLHEP 
measured in vitro. However, for both zaleplon and BIBX1382, the in vitro – in vivo 
fold-difference was fairly consistent across all species examined (~ 0.3 on average), 
which was also observed in mouse, rat, and human for zoniporide and in mouse for 
SGX523. 
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Table V.2. In vitro-in vivo correlation (IVIVC) of S9 hepatic clearance (CLHEP, mL/min/kg) and plasma clearance (CLp, mL/min/kg) in 
preclinical species for zaleplon, O6-benzylguanine, zoniporide, BIBX1382, and SGX523. CLp, plasma clearance 
a Hutzler, et al. (2014a). Drug Metab Dispos 42:1751-1760. 
b Diamond, et al. (2010). Drug Metab Dispos 38:1277-1285. 
c Zientek, et al. (2010). Drug Metab Dispos 38:1322-1327. 
d Dittrich, et al. (2002). Euro J Canc. 38:1072-1080. 
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Single-Species Scaling (SSS) of Plasma Clearance 
Human clearance predicted by SSS is displayed in Table V.3.  All species 
evaluated produced reasonable and similar human CLp predictions for zaleplon 
ranging from 8.8 – 13.6 mL/min/kg, with fold-errors ranging from 0.55 – 0.85. O6-
benzylguanine CLp was over-predicted by mouse, rat, and guinea pig 4.1, 3.7, and 
3.9-fold, respectively (predicted human CLp = 59.8, 53.8, and 57.2 mL/min/kg, 
respectively), while minipig predicted a human CLp of 13.8 mL/min/kg (0.95-fold-
error). For zoniporide, however, minipig over-predicted 5.3 fold (predicted human 
CLp = 110.6 mL/min/kg).  Mouse and rat data taken from the literature scaled to 
over-predict human zoniporide CLp to a lesser extent than minipig, with predictions 
of 39.2 and 62.7 mL/min/kg, respectively, resulting in fold-errors of 1.9 and 3.0, 
respectively. Cynomolgus monkey CLp (from literature) more closely predicted 
human CLp of zoniporide at 15.3 mL/min/kg, with a fold error of 0.72. Using 
cynomolgus monkey data reported in the literature, BIBX1382 was predicted within 
2.2-fold error at 56.0 mL/min/kg. Literature data for rat and mouse resulted in a 
human CLp under-predictions of 14.6 and 7.2 mL/min/kg, respectively, for a fold-
error of 0.58 – 0.26 for rat and 0.29 – 0.13 for mouse. 
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Table V.3.  Human CLp (mL/min/kg) predicted by single-species scaling (SSS) of CLp obtained from IV administration (Table V.1 or from 
literature data) and fold-error of the prediction for zaleplon, O6-benzylguanine, zoniporide, and BIBX1382.  
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As previously mentioned, human CLp data are not available in the literature for 
SGX523, so a fold-error in the prediction could not be calculated.  Minipig, guinea 
pig, and mouse all predicted similar SGX523 CLp values (11.0, 9.6, and 10.9 
mL/min/kg, respectively), while rat and cynomolgus monkey (from literature CLp) 
predicted lower, yet similar values of 2.2 and 1.9 mL/min/kg, respectively. 
 
 
Table V.4.  Human SGX523 CLp (mL/min/kg) predicted by single-species scaling (SSS) of 
CLp obtained from IV administration (Table V.1 or from literature data). No human CLp data 
are available for SGX523 to perform a fold error analysis. 
 
Prediction accuracy by SSS was substrate-dependent, with each species 
evaluated demonstrating under-prediction of some substrates and over-prediction 
of others.  With the exception of cynomolgus monkey, no species accurately 
predicted human CLp (i.e., ≤ 3-fold error) for all compounds evaluated. However, 
while cynomolgus monkey SSS provided reasonable predictions for both zoniporide 
and BIBX1382, data were not available to assess the other three compounds.   
235 
 
Multispecies Simple Allometry (MA) of Plasma Clearance 
Human clearance predicted by MA with three or four species is displayed in 
Table V.5 for zaleplon, O6-benzylguanine, zoniporide, and BIBX1382. Three-species 
MA with minipig/guinea pig/mouse or minipig/rat/mouse produced reasonable 
predictions for zaleplon with fold-errors of 0.56 and 0.49, respectively.  Likewise, 
predictions with the same three-species combinations resulted in fold-errors of 0.69 
and 0.65, respectively, for O6-benzylguanine.  The minipig/rat/mouse combination, 
however, resulted in a 7.7-fold over-prediction for zoniporide.  Inclusion of 
cynomolgus monkey data produced predictions of < 3-fold error by three- or four-
species MA for zoniporide, with a 0.56 and 2.0-fold error by cynomolgus/rat/mouse 
and minipig/cynomolgus/rat, respectively and a 2.3-fold error by 
minipig/cynomolgus/rat/mouse.  Three species MA with cyno/rat/mouse predicted 
BIBX1382 CLp with a fold error of 2.9 – 6.4.  
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Table V.5.  Human CLp (mL/min/kg) predicted by multispecies simple allometry (MA) of CLp obtained from IV administration (Table V.1 
or from literature data), fold-error of the prediction, correlation coefficient of each method, and allometric exponent (b) for each method 
for  zoniporide, O6-benzylguanine, zaleplon and BIBX1382. Cyno, cynomolgus monkey; Gpig, guinea pig 
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SGX523 human CLp predictions obtained from MA are listed in Table V.6.  
Predictions were mostly low, with minipig/cyno/rat and minipig/rat/mouse 
generating moderately higher predictions. 
 
 
Table V.6.  Human CLp (mL/min/kg) predicted by multispecies simple allometry (MA) of 
CLp obtained from IV administration (Table V.1 or from literature data), correlation 
coefficient of each method, and allometric exponent (b) for each method for SGX523. No 
human CLp data are available for SGX523 to perform a fold error analysis. Cyno, cynomolgus 
monkey; Gpig, guinea pig 
 
In Vitro Allometry to Guide Species Selection for In Vivo PK Anyalsis 
Due to substrate-dependent species differences in AO-mediated metabolism, 
no single species is considered to be a reliable resource for estimating human 
clearance of all AO substrates.  However, in Chapter IV we proposed that, taken 
together, the in vitro data (allometry, Fm,AO, E, and biotransformation) may be a 
useful guide for selecting an appropriate species for in vivo PK studies and 
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subsequent allometric scaling to predict human CLp. Comparing our in vitro data to 
the available in vivo CLp data, we evaluated the potential utility of this “in vitro 
guide” toward selecting a species for in vivo allometry.  
Zaleplon 
Evaluation of in vitro zaleplon data reveals that SSS of zaleplon CLint in all 
species (excluding monkey since no in vivo CLp is available), resulted in similar fold 
errors of around 0.60, as well as similar E of around 0.20 (Figure V.5).  While this 
may indicate that any of the four species might be suitable for predicting zaleplon 
PK, guinea pig may be the most reasonable selection when also taking Fm,AO and 
biotransformation data into account, as guinea pig exhibited a more similar Fm,AO to 
human versus other species (also reflected in biotransformation experiments, 
where the AO metabolite was more prominent in guinea pig and human S9 extracts 
versus other species). Indeed, while SSS with mouse, rat, and minipig resulted in 
reasonable predictions (8.8-11.0 mL/min/kg, fold error = 0.55- 0.69) of the 
observed human CLp (16 mL/min/kg), guinea pig provided the most accurate 
prediction (13.6 mL/min/kg), with a fold-error of 0.85.  
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Figure V.5. Evaluation of in vitro data to select a preclinical species for in vivo PK of 
zaleplon and subsequent SSS to predict human CLp. Top: In vitro zaleplon biotransformation 
experiments reveal similar metabolism between human and guinea pig, while greater 
differences were observed between human and mouse, rat, or minipig. Middle: In vitro 
zaleplon CLint experiments reveal similar E across all species, as well as a reasonable 
prediction of human CLint by SSS; however, guinea pig exhibited a higher Fm,AO versus other 
species, which was more similar to human. Bottom: In vivo zaleplon PK studies reveal CLp 
as a % of liver blood flow most similar between human and guinea pig, which yielded the 
most accurate human CLp prediction by SSS.  Although guinea pig provided the most 
accurate CLp prediction, SSS with all species generated similar predictions. 
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In addition, according to our in vitro MA studies, either species combination of 
minipig/guinea pig/mouse or minipig/rat/mouse may be selected based on the 
favorable fold error of 0.68 by both methods (Table V.7). However, as guinea pig 
was selected for SSS based on biotransformation and Fm,AO data, guinea pig may also 
be a more appropriate selection than rat to include in 3-species allometry along 
with minipig and mouse. Indeed, in vitro and in vivo MA with minipig/guinea 
pig/mouse and with minipig/rat/mouse both resulted in human predictions within 
2-fold of observed CL values, with the inclusion of guinea pig resulting in a slightly 
improved in vivo prediction (9.03 mL/min/kg) versus inclusion of rat (7.82 
mL/min/kg).  
 
 
Table V.7. In vitro-to-in vivo comparison of zaleplon human CL (CLint or CLp) predictions by 
multispecies allometry (MA) using minipig, guinea pig, and mouse or using minipig, rat, and 
mouse. 
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O6-benzylguanine 
All in vitro data obtained for O6-benzylguanine indicates guinea pig may be 
the most appropriate species selection to predict human CLp (Figure V.6). 
Biotransformation experiments (Figure V.6 shows relative formation of M1, which 
was the only metabolite observed in S9 extracts) revealed low turnover of O6-
benzylguanine to M1 in mouse, rat, and minipig, while guinea pig demonstrated 
similar M1 formation to human.  Likewise, guinea pig demonstrated a similar E and 
Fm,AO to human while the other three species exhibited lower E, and their Fm,AO could 
not be estimated. In vivo, however, the rodent species all exhibited very high O6-
benzylguanine CLp, which exceeded hepatic blood flow (i.e., CLp as % Liver Blood 
Flow > 100%), while minipig CLp was high, but below hepatic blood flow. As a result, 
SSS with the rodent species generated 3-4 fold over-predictions (53.8-59.8 
mL/min/kg) of the observed human CLp (14.5 mL/min/kg), whereas minipig SSS 
predicted a human CLp of 13.8 mL/min/kg, with a fold error of 0.95.  
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Figure V.6. Evaluation of in vitro data to select a preclinical species for in vivo PK of O6-
benzlguanine and subsequent SSS to predict human CLp. Top: In vitro O6-benzylguanine 
biotransformation experiments reveal low formation of M1 in mouse, rat, and minipig, 
while guinea pig demonstrated similar M1 formation to human. Middle: In vitro O6-
benzylguanine CLint experiments reveal similar Fm,AO and E between human and guinea pig, 
with low E in mouse, rat, and minipig and low CLint preventing estimation of Fm,AO in these 
species. Likewise, guinea pig SSS accurately predicted human CLint, while predictions from 
the other three species were low. Bottom: In vivo O6-benzylguanine PK studies reveal CLp as 
a % of liver blood flow most similar between human and minipig, which also yielded the 
most accurate human CLp prediction by SSS, while mouse, rat and guinea pig over-predicted 
human CLp ~3-4 fold.   
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MA with minipig/guinea pig/mouse or minipig/rat/mouse yielded reasonable 
human O6-benzylguanine CLp predictions (10.1 and 9.48 mL/min/kg, respectively) 
with fold errors of 0.69 and 0.65, respectively (Table V.8).  Due to low in vitro CLint in 
mouse, rat, and especially minipig, human in vitro CLint predictions by these MA 
methods were low, as was the case with in vitro SSS predictions using these species. 
 
Table V.8. In vitro-to-in vivo comparison of O6-benzylguanine human CL (CLint or CLp) 
predictions by multispecies allometry (MA) using minipig, guinea pig, and mouse, or 
minipig, rat, and mouse. 
 
Zoniporide 
When comparing zoniporide in vitro data of mouse, rat, cynomolgus monkey, 
and minipig, the species exhibiting the most similarity to human across all data 
(with the exception of Fm,AO) is minipig, though cynomolgus monkey also produced 
similar in vitro data to human with a SSS CLint prediction fold error of 1.7 (Figure 
V.7). Rat and mouse in vitro data indicated that these species may be likely to over-
predict human CLp, and, as anticipated, rat and mouse did over-predict human CLp 
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(21 mL/min/kg), though both over-predictions were within 3-fold (62.7 and 39.2 
mL/min/kg, respectively). In addition, cynomolgus monkey did generate a more 
accurate prediction (15.2 mL/min/kg) than mouse and rat, with a fold error of 0.72.  
SSS with minipig, however, produced a 5-fold over prediction (111 mL/min/kg) of 
human CLp. The CLp data employed in the SSS analysis for mouse, rat, and 
cynomolgus were obtained from the literature, as plasma concentrations obtained 
from our cassette dosing studies in rat and mouse were below our quantitation 
limits, therefore preventing PK analysis. Observed concentrations in minipig plasma 
were also very low (peak concentrations < 10 ng/mL), which may have limited the 
ability to obtain an accurate PK assessment.   
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 Figure V.7. Evaluation of in vitro data to select a preclinical species for in vivo PK of 
zoniporide and subsequent SSS to predict human CLp. Top: In vitro zoniporide 
biotransformation experiments reveal similar metabolism between all species, with rat and 
mouse exhibiting much higher turnover of zoniporide relative to human and minipig and 
somewhat higher relative to cynomolgus monkey. Middle: In vitro zoniporide CLint 
experiments reveal similar Fm,AO across all species, with rat exhibiting a Fm,AO most similar to 
human. However, minipig and cynomolgus monkey exhibit an E most similar to human, as 
well as more accurate predictions of human CLint by SSS. Bottom: In vivo zoniporide PK 
studies reveal CLp as a % of liver blood flow most similar between human and cynomolgus 
monkey, which also yielded the most accurate human CLp prediction by SSS.   
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In addition, both in vitro and in vivo 3- or 4-species MA with minipig, cynomolgus, 
rat, and/or mouse resulted in zoniporide human CLint or CLp predictions within 2-
fold of observed human values, with the exception of the minipig/rat/mouse 
combination, which resulted in a > 7-fold over-prediction of human CLp (Table V.9).   
 
 
Table V.9. In vitro-to-in vivo comparison of zoniporide human CL (CLint or CLp) predictions 
by multispecies allometry (MA) using 3- or 4-species combinations of minipig, cynomolgus 
monkey, rat, and/or mouse. 
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BIBX1382 
Based on our in vitro analyses of BIBX1382, cynomolgus monkey appears to 
be a more appropriate species selection than mouse and rat (Figure V.8).  In this 
case, all in vitro data pointed toward cynomolgus monkey over the rodent species, 
as cynomolgus exhibited similar biotransformation, E, Fm,AO, and most accurately 
predicted human CLint by SSS, whereas mouse and rat exhibited dissimilar 
biotransformation of BIBX1382, lower E values, lower or unobtainable Fm,AO 
estimates, and substantially under-predicted human CLint by SSS. In vivo SSS 
resulted in human CLp predictions of 56 mL/min/kg with cynomolgus monkey, 7.2 
mL/min/kg with mouse, and 13.4 mL/min/kg with rat, revealing that cynomolgus 
monkey indeed was the more appropriate species to predict the observed human 
CLp of BIBX1382 (25-55 mL/min/kg). In addition, literature reports note that oral 
bioavailability of BIBX1382 in monkey (6%) mirrored that of human (5%) (Hutzler 
et al., 2014a), unlike rat and mouse which exhibited 50-100% oral bioavailability 
(Dittrich et al., 2002). Hutzler et al. likewise concluded in their report that 
cynomolgus monkey accurately represented the rapid clearance of BIBX1382 in 
human and that cynomolgus may therefore serve as a suitable animal model for 
estimating human AO metabolism and clearance (Hutzler et al., 2014a). 
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 Figure V.8. Evaluation of in vitro data to select a preclinical species for in vivo PK of 
BIBX1382 and subsequent SSS to predict human CLp. Top: In vitro BIBX1382 
biotransformation experiments reveal similar metabolism between human and cynomolgus, 
while greater differences were observed between human and rodents. Middle: In vitro 
BIBX1382 CLint experiments reveal similar E and Fm,AO between human and cynomolgus, as 
well as a reasonable prediction of human CLint by SSS with cynomolgus, while rodents 
exhibited lower E, Fm,AO, and predicted human CLint by SSS. Bottom: In vivo BIBX1382 PK 
studies reveal similar CLp as a % of liver blood flow and oral bioavailability between human 
and cynomolgus, as well as a reasonable human CLp prediction by SSS with cynomolgus, 
while rodents under-represented clearance. 
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In addition, allometric scaling of in vitro CLint with cynomolgus/rat/mouse resulted 
in a similar fold-error to that obtained from allometric scaling of in vivo CLp using 
these species (Table V.10).  As was the case in vitro, SSS from cynomolgus monkey 
CLp provides the best prediction of human CLp over SSS with mouse and rat or over 
MA with the three species. 
 
 
Table V.10. In vitro-to-in vivo comparison of BIBX1382 human CL (CLint or CLp) predictions 
by multispecies allometry (MA) using cynomolgus monkey, rat, and mouse. 
 
SGX523 
In vivo allometry could not be evaluated for accuracy of prediction of human 
SGX523 CLp, as human CLp data for this compound is not available in the literature. 
Evaluation of the in vitro data indicates that mouse, rat, and perhaps guinea pig may 
each serve as more suitable species for in vivo SSS to predict human CLp than 
cynomolgus monkey or minipig when considering E and SSS CLint predictions 
(Figure V.9). Fm,AO estimations were somewhat variable by the two calculation 
methods (see Chapter IV), and, therefore, may not serve as a useful parameter for 
species selection in this case.  In vitro biotransformation of SGX523 was relatively 
similar across all species, with some trace metabolites detected in human that were 
not detected in mouse and rat, while minipig produced lower levels of M1 relative to 
250 
 
other species.  SSS of in vivo CLp with mouse, guinea pig, and minipig resulted in 
similar human CLp predictions ranging from 9.6-11.0, whereas SSS with rat and 
cynomolgus monkey produced lower predictions of 2.2 and 1.9, respectively. CLp as 
a percentage of liver blood flow in guinea pig and minipig (57% and 68%, 
respectively) were a bit higher (but fairly similar) to the E estimated in vitro (0.41 
and 0.48, respectively), while rat CLp as a percentage of liver blood flow was lower 
(12%) than E estimated in vitro (0.33).  CLp as a percentage of liver blood flow was 
substantially higher than E in mouse (92% and 0.30, respectively); the opposite was 
true for cynomolgus monkey, where E was much higher in vitro (0.50) than CLp as a 
percentage of liver blood flow in vivo (8%). 
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Figure V.9. Evaluation of in vitro data to select a preclinical species for in vivo PK of SGX523 
and subsequent SSS to predict human CLp. Top: In vitro SGX523 biotransformation 
experiments reveal similar metabolism across all species, with greater turnover of SGX523 
by guinea pig and minipig, and some trace metabolites detected in human which were not 
detected in mouse and rat. Middle: In vitro SGX523 CLint experiments reveal mouse and rat 
E most similar to human and ambiguous Fm,AO values in the low-moderate range for all 
species. Prediction of human CLint by SSS were lower using rat and mouse, higher using 
cynomolgus and minipig, and in the middle using guinea pig. Bottom: In vivo SGX523 PK 
studies reveal similar low human CLp prediction by SSS with cynomolgus and mouse, and 
higher predictions by SSS with the other three species. 
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MA of SGX CLp resulted in similar human predictions as those obtained from SSS, 
ranging from 0.6-10.5 mL/min/kg (Table V.11). As was observed with SSS, the rank 
order (according to predicted CLint) of MA methods in vitro did not mirror the in vivo 
rank order—for example, the cyno/rat/mouse combination predicted the highest 
human CLint in vitro, but this method predicted the lowest human CLp in vivo. 
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Table V.11. In vitro-to-in vivo comparison of SGX523 human CL (CLint or CLp) predictions by 
multispecies allometry (MA) using minipig, cynomolgus monkey, guinea pig, rat, and/or 
mouse. 
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As previously noted, the in vivo-in vitro ratios for zaleplon were relatively 
consistent across all species, and the same was true of the in vivo-in vitro ratios for 
BIBX1382. The in vivo-in vitro ratios for zoniporide, O6-benzylguanine, and SGX523, 
alternatively, were more varied across species.  This is important to note with 
regard to MA, as substantial species differences in IVIVC would be expected to 
impact the translation of in vitro MA to in vivo MA with regard to maintaining a 
similar fold-error of prediction between in vitro MA and in vivo MA.  For example, 
MA of zaleplon clearance resulted in similar prediction fold errors both in vitro and 
in vivo (average fold error in vitro = 0.68, average fold error in vivo = 0.53, Table 
V.7).  MA of BIBX1382 clearance likewise resulted in similar fold errors both in vitro 
and in vivo (Table V.10). In vivo fold errors obtained for O6-benzylguanine and 
zoniporide, however, deviated (sometimes substantially) from in vitro fold errors 
(Tables V.8-9).  In addition, in cases where the fold errors by MA were similar in 
vitro and in vivo (i.e., zaleplon and BIBX1382), the allometric exponent (b) was also 
similar in vitro and in vivo (Table V.12).  This observation may suggest that a MA 
prediction fold error observed in vitro may be expected to translate to a similar fold 
error in vivo, when the allometric exponent obtained from in vitro MA is similar to 
the allometric exponent obtained from in vivo MA.  As noted previously, however, 
this will likely be dependent on human exhibiting a similar IVIVC (i.e., in vivo-in vitro 
CL ratio) to the species used for MA predictions, which was the case for zaleplon and 
BIBX1382. 
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Table V.12 In vitro-to-in vivo comparison of allometric exponents (b) obtained from 
multispecies allometry (MA) using minipig, cynomolgus monkey, guinea pig, rat, and/or 
mouse. Cyno, cynomolgus monkey; Gpig, guinea pig 
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DISCUSSION 
In Chapter IV, we evaluated species differences in the metabolism and 
clearance of five AO substrates in vitro, as well as the ability to scale in vitro hepatic 
CLint of these substrates by MA and SSS to predict human in vitro hepatic CLint.  
Successful prediction of human in vitro hepatic CLint was achieved by one or more of 
these methods, albeit in a substrate-dependent manner with regard to the species 
employed in the scaling analysis.  As traditional in vitro techniques have repeatedly 
resulted in under-prediction of in vivo CLp for compounds metabolized by AO 
(proposed to potentially be associated with extra-hepatic AO metabolism, instability 
of AO in vitro, or interindividual AO variability) (Zientek et al., 2010; Akabane et al., 
2012; Hutzler et al., 2012), we presently sought to evaluate the multispecies IVIVC 
(in vitro-in vivo correlation ) of clearance for these five AO substrates.  Furthermore, 
we evaluated the ability to predict human in vivo CLp of these compounds by MA and 
SSS, employing CLp obtained from multiple species. Finally, we assessed the utility of 
comparing in vitro metabolism and clearance data from multiple species for the 
purpose of selecting suitable species for in vivo PK analysis and subsequent human 
CLp prediction by MA or SSS. 
Of the compounds/species for which in vivo data was available to evaluate, a 
prediction within 3-fold of observed human CLp was successfully obtained by at 
least one MA or SSS method for all compounds. In instances where IVIVC was 
similar across species (i.e., demonstrated a similar in vivo-in vitro clearance ratio) 
employed in MA or SSS analyses , human prediction fold errors obtained from both 
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in vitro and in vivo allometric scaling with these species were also similar. 
Consequently, for compounds exhibiting similar IVIVC across all species (e.g., 
zaleplon and BIBX1382) in vitro data successfully indicated which species would be 
suitable for employing in vivo CLp in MA or SSS analyses to predict human CLp. 
Furthermore, these two cases resulted in similar in vitro and in vivo allometric 
exponents obtained from MA, indicating that the interspecies relationship between 
in vitro CLint and body weight reflected the interspecies relationship between in vivo 
CLp and body weight (i.e., the rate of change in CL with change in body weight was 
similar in vitro and in vivo). However, in cases where IVIVC was inconsistent across 
species, in vitro data was not always predictive of the most appropriate species for 
in vivo allometry. This may indicate that species-specific extra-hepatic mechanisms 
may contribute to the clearance of these compounds in vivo, since the in vitro 
clearance estimated in our studies is limited to hepatic mechanisms (CLint obtained 
using hepatic S9 fractions). 
In addition, the IVIVC analyses may offer some possible insight into which of 
the previously proposed mechanisms (e.g., extra-hepatic elimination, AO instability 
in vitro, interindividual variability, etc.) may be contributing the observed IVIVC 
disconnects frequently encountered with AO substrates.  For example, for any one 
species in our cassette dosing studies, the fold difference between in vitro and in 
vivo CL was not always consistent across each compound (e.g., rat demonstrated an 
in vivo-in vitro fold-difference of 0.38, 0.04, and 2.6 for zaleplon, O6-benzylguanine, 
and SGX523, respectively).  Because the same lot of hepatic S9 was used to obtain in 
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vitro CLint estimates for each of the three compounds, the substrate-dependent 
variability in IVIVC for a single species cannot be attributed to variable AO activity 
in the S9 used to measure the CLint for each compound (e.g., manufacturer 
differences in preparation of S9 fractions or lot-to-lot donor variability).  Likewise, 
because the same animals were used to obtain in vivo CLp of zaleplon, O6-
benzylguanine, and SGX523 (all three compounds dosed together as a cassette to the 
same animals), the variability in IVIVC across the three compounds cannot be 
attributed to variable AO activity (i.e., interindividual variability) in the animals 
receiving each compound. Rather, the differences may likely be ascribed to 
substrate-dependent parameters such as red blood cell distribution and/or extra-
hepatic metabolism (tissue or plasma), since the S9 CLHEP data only represents 
hepatic clearance.  This proposal is also supported by CLp values, either observed in 
our studies or reported by others, which exceeded hepatic blood flow (e.g. O6-
bezylguanine, zoniporide, and BIBX1382). Interestingly, the fold-difference was very 
similar across all species in the in vitro-in vivo comparison of zaleplon. This might 
indicate that the under-estimation is a result of an extra-hepatic mechanism that is 
conserved across species. Previous studies in rats receiving a 5 mg/kg oral dose of 
[14C]-zaleplon found that highest concentrations of the drug were distributed into 
the liver, kidney, gastrointestinal tract, and adrenal glands (Beer et al., 1997). 
Human AOX1 mRNA is present in each of these tissues, with the adrenal glands 
reported as one of the richest sources of the protein in addition to the liver (Terao et 
al., 2016). However, reported tissue expression patterns of AOX1 and other AO 
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isoforms between mouse and human are divergent, and the adrenal gland, for 
example, has not been shown to represent a rich source of mRNA for any AO isoform 
in mouse (Terao et al., 2016). Unfortunately, until multispecies expression and activity 
of extra-hepatic AO are better understood, the mechanism(s) responsible for IVIVC 
disconnects will remain unclear. 
While the variability in IVIVC for SGX523, O6-benzylguanine, and zaleplon for 
any given species could not have resulted from differences in preparation of S9 
fractions used to measure CLint for each compound or interindividual AO variability 
in the animals used to measure CLp for each compound, this does not preclude in 
vitro instability/decreased activity or interindividual variability between the S9 
donors and the subjects receiving the test article in vivo from speculation as a 
potential contributor to in vitro under-estimation of CLp.  Interestingly, however, 
SGX523 CLp was over-estimated by rat S9, while zaleplon and O6-benzylguanine 
were under-estimated. If in vitro AO instability or interindividual AO variability 
between the S9 donor rats and the rats administered substrate in vivo were 
responsible for the IVIVC disconnect, the disconnect would be expected to be in the 
same direction for all compounds (i.e., all under-estimated or all over-estimated), 
Notably, however, we previously reported an Fm,AO (fraction of metabolism mediated 
by AO) for SGX523 of 0.28-0.42 in rat S9.  This presence of non-AO metabolism 
pathways in the clearance of these substrates adds an additional complication to the 
interpretation of IVIVC disconnects for AO substrates. For example, in our in vitro 
CLint studies, we did not observe measurable substrate turnover of O6-benzylguaine 
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in rat, mouse, and minipig S9 in the absence of NADPH, whereas substrate depletion 
was observed in the presence of NADPH, indicating the contribution of a non-AO 
pathway. A prior report of O6-benzylguanine metabolism in rat and mouse in vivo 
revealed an N-acetyl metabolite in rats and a debenzylated metabolite in both rats 
and mice (Dolan et al., 1994). It was proposed that the acetylation may occur in the 
kidney since it was only detected in urine and not in the plasma (Dolan et al., 1994). 
Neither of these metabolites was detected in our biotransformation experiments in 
S9 incubations (Chapter IV), suggesting the possibility that these clearance 
pathways were present in vivo, but not in vitro, and contributed to the apparent 
extra-hepatic metabolism and IVIVC disconnect observed with O6-benzylguanine. 
However, even in the absence of extra-hepatic metabolism, differences in Fm,AO for 
each compound could result in variable IVIVC across substrates. Likewise, other 
non-AO substrate dependent parameters, such as red blood cell distribution, could 
also contribute to inconsistencies between in vitro estimated hepatic clearance 
(CLHEP) and CLp, as CLp reflects substrate clearance from plasma as opposed to 
whole blood. As additional research is needed to better understand extra-hepatic 
AO metabolism, additional research to clarify mechanisms of in vitro AO instability 
and interindividual variability (single nucleotide polymorphisms, influence of 
disease state, etc.) will be necessary to fully elucidate contributing factors to IVIVC 
discrepancies. 
Unfortunately, our studies of BIBX1382 were limited due to plasma 
concentrations below the limit of quantitation preventing pharmacokinetic 
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parameters from being obtained for this compound.  This perhaps is not altogether 
surprising, given the exposure in cynomolgus monkeys receiving an IV dose of 1 
mg/kg BIBX1382, where peak plasma concentrations only reached approximately 
70 nM (~180 ng/mL) (Hutzler et al., 2014a), and animals in our studies only 
received one fifth of this dose (0.2 mg/kg). It was determined that BIBX1382 
partitioned into red blood cells in cynomolgus monkey with a blood-to-plasma ratio 
of 2.1 (Hutzler et al., 2014a). Thus, it is possible that red blood cell partitioning 
could account for the low plasma concentrations we observed.  In addition, 
evaluation of human and cynomolgus plasma stability indicated BIBX1382 was 
stable in plasma (for at least 2 hours); however, it is still possible that plasma 
instability could contribute to low concentrations in mouse, rat, guinea pig and/or 
minipig. In particular, plasma instability of BIBX1382 could result from plasma 
xanthine oxidase (XO) mediated oxidation, as Sharma et al. previously demonstrated 
that a pyrazine-containing compound was oxidized by XO in plasma of  mouse, rat, 
and guinea pig plasma but was stable in human, monkey, and dog plasma (Sharma 
et al., 2011).  In addition, Hutzler et al. noted high AO activity towards BIBX1382 in 
cynomolgus monkey lung S9 fractions, suggesting the possibility that pulmonary 
first pass metabolism could contribute to the low peak plasma concentrations 
observed in our studies (Hutzler et al., 2014a).  These mechanisms could have 
potentially contributed to low zoniporide plasma concentrations observed in our 
studies as well.  Zoniporide was reported to partition 1:1 into plasma and red blood 
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cells in rat and human (Tracey et al., 2003), but has not been reported for the other 
species in our studies. 
In conclusion, we have demonstrated that allometric scaling may be useful to 
predict human CLp of AO substrates when the appropriate species are employed, as 
predictions within 2-3 fold of observed human CLp values were obtained for 
zaleplon, O6-benzylguanine, zoniporide, and BIBX1382 by one or more MA and/or 
SSS methods.  In addition, MA and SSS resulted in similar prediction fold errors in 
vitro and in vivo when IVIVC was consistent across species, suggesting that in vitro 
allometry may be useful to guide species selection to conduct in vivo allometric 
scaling for human CLp prediction.  While additional studies to elucidate mechanisms 
behind discrepancies in IVIVC, as well as allometry studies with a larger sample of 
AO substrates, would help to better understand the potential to broadly utilize this 
approach toward species selection and prediction of human CLp for drug candidates 
metabolized by AO, these studies offer direction towards a novel approach to 
estimate human clearance of AO substrates, which is of great necessity for the 
successful discovery and development of future therapeutics. 
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CHAPTER VI 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
Unacceptable pharmacokinetics (PK) once represented a leading cause of 
attrition of drug candidates during clinical trials (Kola and Landis, 2004). Today, 
with major advances in the understanding of cytochrome P450 function, expression, 
and regulation in human and nonclinical species, standardized methods to predict 
human PK of drugs metabolized by P450 enzymes are now available, resulting in a 
reduction in drug attrition rates associated with unexpectedly poor PK (Kola and 
Landis, 2004; Di et al., 2013). Unfortunately, application of these methodologies to 
human PK prediction of compounds exhibiting AO-mediated clearance has proven 
insufficient and consequently resulted in clinical failures of several promising drug 
candidates over the past several years (Kaye et al., 1985; Dittrich et al., 2002; 
Diamond et al., 2010a; Akabane et al., 2011; Zhang et al., 2011; Lolkema et al., 2015).  
Even so, reliable and standardized methodology to predict the human 
pharmacokinetics and drug interaction liability of compounds metabolized by AO 
has yet to be firmly established. The research described herein provides a 
foundation towards a solution to this challenging problem, offering several 
contributions to advance the field surrounding AO drug metabolism and human PK 
prediction, which are summarized below along with suggested future directions to 
continue improving and developing these methodologies. 
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Drug Interaction Liability Associated with AO-Mediated Drug Clearance 
Summary and conclusions 
Studies relating to the drug interaction potential associated with inhibition of 
AO have been conducted, and several drugs have been identified which exhibit 
inhibitory activity towards AO in vitro (Obach, 2004; Barr and Jones, 2011). 
However, given the numerous drugs which inhibit P450 enzymes currently on the 
market, studies to evaluate the impact of P450 inhibition on compounds 
metabolized by both P450 and AO may be of equal importance from a perspective of 
clinical significance. Interestingly, we found that administration of the mixed 
AO/P450 substrate VU0409106 along with the P450 inhibitor ABT to rats resulted 
in a drug interaction, where exposure to not only VU0409106 was elevated, but 
exposure to the AO metabolite M1 was also elevated.  Notably, while a drug 
interaction-mediated elevation in metabolite exposure is typically associated with 
induction of a drug metabolizing enzyme (DME), our studies demonstrated an 
elevation in metabolite exposure facilitated by DME inhibition. Reports of AO 
metabolite-related toxicity associated with methotrexate and the failed clinical drug 
candidates SGX523 and JNJ-38877605 highlight an additional concern regarding the 
potential clinical significance of this type of drug interaction (Diamond et al., 2010a; 
Lolkema et al., 2015). Taken together, these data reveal that mixed AO/P450-
metabolized drugs are susceptible to potentially clinically relevant interactions with 
P450-inhibiting drugs, and attention to this liability by the pharmaceutical industry is 
warranted.  
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Future directions  
The clinical relevance of a pharmacokinetic drug interaction is typically 
dependent on the magnitude of change in exposure to the pharmacologically (or 
toxicologically) active compound in question, in this case, the AO metabolite. 
Therefore, investigations into understanding how to predict the change in AO 
metabolite exposure and anticipate the conditions under which this exposure 
change is likely to occur will be an important next step in characterizing this type of 
drug interaction.  Our studies involved the administration of a pan-P450 inhibitor 
(ABT), a non-clinical tool which non-selectively inactivates P450 enzymes, resulting 
in the likelihood that metabolism of VU0409106 was primarily shunted toward a 
single enzyme (AO), thus maximizing the potential for increased exposure to the AO 
metabolite. In a clinical setting, the co-administration of a P450-inhibiting drug (or 
even multiple drugs) would be unlikely to result in inhibition of all P450 enzymes, 
and consequently, shunting may occur toward other uninhibited P450s in addition 
to AO, potentially limiting an increase in AO metabolite exposure. For this reason, 
future investigations with mixed AO/P450 substrates should focus on modeling 
interactions which are likely to occur in a clinical setting. In addition, determination 
of the influence of Fm,P450 vs Fm,AO on the magnitude of change in AO metabolite 
exposure resulting from P450 inhibition will be an important next step toward 
establishing methods to predict drug interactions involving mixed AO/P450-
metabolized drugs.  The influence of fraction metabolized via a single P450 
isoenzyme (e.g., Fm, 3A4) on drug interaction liability has been established, such that 
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the increase in parent drug exposure under conditions of P450 inhibition can be 
predicted when the Fm of that P450 isoenzyme is known (Di et al., 2013). In this 
case, a larger Fm, P450 is associated with a greater increase in parent drug exposure 
when that P450 isoenzyme is inhibited (Di et al., 2013). Accordingly, a greater 
increase in AO metabolite exposure might be expected under conditions of P450 
inhibition when the Fm,P450 is large; however, studies to demonstrate this 
relationship have yet to be conducted. Furthermore, as the extra-hepatic expression 
and activity of AO is poorly understood (Terao et al., 2016), studies examining the 
potential influence of intestinal AO-mediated metabolism will be important to 
determine the impact of route of administration (e.g., oral versus intravenous) on 
the likelihood of a clinically relevant interaction. Many questions remain to be 
answered concerning the role of intestinal (as well as other extra-hepatic) AO 
expression to drug metabolism and total body clearance of AO-metabolized drugs, 
such as endogenous and exogenous factors regulating expression in various tissues 
(e.g., influence of the gut microbiome on intestinal expression). Likewise, 
investigations into identifying sources of the interindividual variability (hepatic or 
extra-hepatic) that has been observed in AO-mediated metabolism (Fu et al., 2013; 
Hutzler et al., 2014b) will be of great importance to understand the likelihood of 
experiencing a drug interaction. Many possible factors may contribute to variability, 
such as disease state, diet, and single-nucleotide polymorphisms (SNPs), and while 
efforts have been made to identify these associations, none have been firmly 
established (Hartmann et al., 2012; Hutzler et al., 2012; Fu et al., 2013; Hutzler et al., 
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2014b). In addition, though SNPs of AO are currently poorly understood, SNPs of 
P450 enzymes are well-established (Zhou et al., 2009) and also have the potential to 
influence the drug interaction liability of a mixed AO/P450 substrate, thus 
warranting additional evaluation.  These future works will all be essential in 
establishing guidelines on metabolite safety testing and drug interaction studies 
involving mixed AO/P450 drug substrates, which are likely to increase in number 
given the emergence of AO-metabolized drug candidates reaching clinical trials. 
 
Multispecies Allometry to Predict Human Clearance of Drugs Metabolized 
by Aldehyde Oxidase 
Summary and conclusions 
In addition to gaps in our understanding of how to predict drug interactions 
associated with AO metabolism, perhaps a more significant challenge remains in 
identifying reliable methods to predict the human clearance associated with AO 
metabolism. Likely due to the assumption that species differences in clearance 
mechanisms precludes the ability to scale clearance by allometry, studies evaluating 
allometric scaling in the prediction of human clearance of AO-metabolized drugs are 
sparse. While methotrexate, an AO substrate, ironically represents one of the oldest 
examples of allometric scaling of clearance, AO-mediated metabolism is a minor 
contributor to the clearance of this drug, with renal elimination serving as the major 
clearance mechanism (Boxenbaum, 1982). The work described herein not only 
provides an evaluation of allometric scaling to predict human plasma clearance 
268 
 
 
(CLp) of AO substrates, but also includes assessments using minipig (as opposed to 
dog, which is typically used in allometric scaling), which has been sparsely studied 
with regard to AO metabolism and human clearance prediction. Importantly, our 
evaluations indicate that multispecies allometry (MA) may be useful in predicting 
human CLp of AO substrates, as most human CLp predictions were within 3-fold of 
observed values (Table V.5).  It is also encouraging to note that in the two instances 
where MA did not predict human CLp within 3-fold, these were over-predictions 
rather than under-predictions (over-prediction was also more prevalent than 
under-prediction in our MA studies using in vitro CLint).  While a substantial over-
prediction of human CLp may result in the oversight of a compound that actually 
possesses acceptable human PK, a substantial under-prediction could result in the 
costly failure of a drug candidate that was inappropriately advanced to clinical 
trials. Traditional in vitro methods used to predict human in vivo clearance typically 
result in under-prediction for AO substrates (Zientek et al., 2010; Akabane et al., 
2012), and likewise, in vivo PK assessments in traditional preclinical species (mouse, 
rat, and dog) also commonly under-represent clearance in human (Kaye et al., 1985; 
Dittrich et al., 2002; Akabane et al., 2011; Zhang et al., 2011). Multispecies allometry 
utilizing the species evaluated herein may therefore represent a method which can 
reduce the risk of encountering unexpectedly rapid human CLp when advancing an AO-
metabolized compound to clinical trials. 
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Future directions  
While our data indicate potential utility of MA for human CLp prediction of AO 
substrates, understanding the full value of this method will benefit from additional 
investigations extended to a larger collection of substrates with reported clinical PK 
data (CLp). In general, the ability to study human clearance prediction of AO 
substrates is limited by the small number of available compounds for which human 
(in vivo) PK have been reported.  In addition, most known AO substrates with 
reported human PK data are rapidly cleared (Zientek et al., 2010; Akabane et al., 
2011; Zhang et al., 2011), limiting the evaluation of prediction methodologies 
primarily to “high clearance” compounds. Importantly, clearance of “high clearance” 
compounds are more likely to scale according to an allometric relationship, as the 
plasma clearance of these compounds is limited by hepatic blood flow (Wilkinson 
and Shand, 1975; Pang and Rowland, 1977), which scales according to an allometric 
relationship (Boxenbaum, 1980).  Therefore, extension of studies evaluating in vivo 
allometric scaling to predict human in vivo CLp to a larger set of compounds, 
particularly those exhibiting a wider sampling of low, moderate, and high clearance 
AO substrates, would provide a better understanding of the broad applicability of 
these methods.  
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Application of In Vitro Intrinsic Clearance to Allometric Scaling 
Summary and conclusions  
In addition to providing a traditional examination of allometric scaling to 
predict human in vivo CLp of AO-metabolized compounds, we also evaluated a novel 
approach to allometric scaling with the application of in vitro CLint to these analyses.  
Others have proposed that species expressing only the AOX1 isoenzyme in the liver 
(e.g., guinea pig, monkey, and pig) may serve as better species to estimate human 
AO-mediated metabolism versus species expressing both the AOX1 and AOX3 
isoenzymes (e.g., rat and mouse) (Garattini and Terao, 2012). Consistent with this 
proposal, our in vitro data indicate that the hepatic CLint of AO substrates may be 
scaled from preclinical species to human by SSS with monkey, guinea pig, and 
minipig with reasonable accuracy and precision, while this relationship does not 
appear to be consistent (highly substrate-dependent) when directly scaling from rat 
or mouse. However, similar to our observations in vivo, use of rat and mouse in 
combination with guinea pig, monkey, and/or minipig generally enabled allometric 
scaling to a reasonable human hepatic CLint prediction. In particular, these in vitro 
allometry assessements indicate that 4-species allometry utilizing the species 
evaluated herein may provide the greatest utility with regard to minimizing 
substrate-dependence in the ability to reasonably predict human clearance. In 
addition, comparison of in vitro allometry data to in vivo allometry data suggest that 
a fold-error analysis of in vitro allometry predictions could be useful to help 
determine which species would be more likely to permit allometric scaling of in vivo 
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CLp (MA or SSS) to predict human CLp. While this approach proved useful for 
demonstrating appropriate species to predict human CLp of zaleplon and BIBX1382, 
overall the translation of in vitro-to-in vivo allometry (regarding prediction fold-
error) was substrate-dependent, with only those compounds which exhibited a 
consistent IVIVC across species (zaleplon and BIBX1382) resulting in successful 
species selection.  Overall, these data indicate a potential utility of in vitro allometry 
in the determination of appropriate species to predict human clearance of AO-
metabolized drugs, while elucidation of discrepancies in interspecies IVIVC will be 
important to better understand the full potential of this approach.  
Future directions  
A factor limiting the interpretation of our current approach to in vitro allometry 
is the inconsistent in vitro: in vivo correlation (IVIVC), illustrating the substrate-
dependency of AO mediated metabolism.  The assumption that in vitro hepatic CLint 
represents in vivo hepatic CLint is hindered by speculation of ex vivo AO instability, 
single-nucleotide polymorphisms, and other sources of possible interindividual 
variability (e.g., disease state, etc.) (Hartmann et al., 2012; Hutzler et al., 2012; Fu et 
al., 2013; Hutzler et al., 2014b). Furthermore, pharmacokinetic properties such as 
plasma stability and red blood cell distribution were not determined in each species, 
and because these properties could influence in vivo CLp (and consequently the 
IVIVC since these components are not present in vitro) the IVIVC across species 
could vary if these properties are species-specific. Finally, an additional unknown 
factor complicating IVIVC interpretation, is the extra-hepatic expression and activity 
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of AO (Kurosaki et al., 1999; Moriwaki et al., 2001; Nishimura and Naito, 2006; 
Terao et al., 2016), which is poorly understood at present, particularly concerning 
its contribution to total body clearance of AO substrates. Prior studies indicate that 
extra-hepatic AO expression is species-specific (Terao et al., 2016), which could also 
influence consistency of IVIVC across species if extra-hepatic metabolism 
contributes to CLp. Consequently, each of these factors could have impacted the 
interspecies IVIVC obtained in our studies. As mentioned previously, while others 
have already initiated research aimed at addressing these questions, a thorough 
investigation to build upon their findings will be necessary to elucidate the 
mechanisms behind variable AO activity and will be essential to improve current in 
vitro techniques to estimate AO-mediated clearance. Likewise, future research to 
establish species-specific tissue expression patters, mechanisms regulating AO 
expression, and importantly, to develop standardized in vitro scaling factors that can 
be used to estimate total organ clearance from in vitro CLint in extra-hepatic tissues 
will all be critical steps towards understanding the potential contribution of extra-
hepatic metabolism and establishing confidence in in vitro-to-in vivo extrapolation 
where AO metabolism is concerned. In addition, as 4-species allometric scaling of in 
vitro CLint appears to exhibit minimal substrate-dependence with regard to 
obtaining a reasonable human CLint prediction, evaluation of these species 
combinations in vivo will help to validate the proposed use of this method.  
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Influence of Fraction Metabolized by AO (Fm,AO) and Hepatic Extraction (E) 
on SSS Prediction Accuracy 
Summary and conclusions  
Along with our in vitro allometry studies, we estimated interspecies fraction 
metabolized by AO (Fm,AO) and hepatic extraction (E) for each of our probe AO 
substrates in order to evaluate how these parameters might influence the ability to 
predict human hepatic CLint by SSS. Our findings revealed a poor relationship 
between the animal:human ratio of Fm,AO and prediction accuracy by SSS, while 
further investigation instead revealed a relationship between animal:human ratio of 
E and prediction accuracy by SSS. Importantly, these relationships were 
recapitulated when the analyses were conducted using in vivo CLp and Fm,UGT data 
reported by Deguchi et al. for several UGT substrates (Deguchi et al., 2011), 
indicating this is not an isolated observation. In addition, biotransformation 
experiments revealed that human and preclinical species may exhibit a similar E 
despite divergent Fm,AO values due to compensation via greater NADPH-dependent 
metabolism in the preclinical species (e.g., minipig vs. human metabolism of 
zaleplon). Consequently, these findings suggest that Fm,AO may be more important to 
consider from a metabolite exposure (i.e., toxicology) perspective than a clearance 
perspective concerning extrapolation of animal PK to human, whereas consideration 
of E should be given priority to Fm,AO when selecting species for human clearance 
estimation. 
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Future directions  
As four of the five compounds studied herein exhibited human Fm,AO values 
≥.0.70., evaluation of additional compounds exhibiting a wider distribution of Fm,AO 
values in human would improve our understanding of how important this 
parameter may be to accurately predicting human clearance with allometry. In 
addition, our understanding of how to appropriately utilize preclinical species for 
toxicology studies/metabolite safety testing with regard to AO substrates will 
benefit from future investigations focusing on the influence of interspecies Fm, AO. In 
addition, while our findings implicated interspecies E as an important factor 
associated with SSS prediction accuracy, extension of these analyses to prediction of 
oral bioavailability would be a valuable next step to understand the utility of 
preclinical species in predicting human PK of AO-metabolized compounds (again 
emphasizing the importance of evaluating the role of interspecies 
expression/regulation of intestinal AO to oral bioavailability). 
 
Interspecies Evaluation of Metabolism, Clearance, and SSS to Predict 
Human Clearance of AO Substrates 
Summary and conclusions  
Within our in vivo SSS analyses, an apparent substrate-dependency was 
observed with regard to successful SSS using a particular species (Table V.3).  In 
addition, our data (along with prior clinical failures where rat and/or mouse were 
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used for preclinical PK assessments) appear to indicate that MA may be more useful 
than SSS with rat or mouse to predict human CLp (even when rat and/or mouse are 
included in the MA assessment), which, as previously discussed, was reiterated by 
our in vitro SSS assessments.  SSS with cynomolgus monkey, on the other hand, 
successfully predicted both zoniporide and BIBX1382 CLp in human, and though CLp 
data in cynomolgus for zaleplon and O6-benzylguanine was not available for 
evaluation, AO-mediated zaleplon metabolite formation in vivo in cynomolgus has 
been reported to be similar to human (Kawashima et al., 1999). In addition, while 
human CLp of SGX523 was not available for analysis of prediction fold-error by 
cynomolgus SSS, Diamond et al. reported that cynomolgus monkey would have 
served as a more relevant species for nonclinical toxicological evaluation of SGX523 
than rat, which produced low levels of the offending AO metabolite in vivo (Diamond 
et al., 2010b).  Likewise, comparison of monkey and human in vitro data obtained 
from our studies (SSS of CLint, estimated E and Fm,AO, and biotransformation) for each 
of the five AO substrates also supports monkey as a suitable species to estimate 
human clearance and extent of AO-metabolite formation.  Furthermore, a recent 
report where unexpectedly rapid AO metabolism resulted in clinical failure of Lu 
AF09535 indicated that monkey would have been a suitable species to predict the 
poor oral exposure observed in humans (Jensen et al., 2016).  However, even 
monkey may exhibit some substrate-dependence with regard to predicting human 
PK of AO substrates, as Zhang et al. reported that formation of the AO metabolite of 
the p38 kinase inhibitor RO1 identified in human was negligible in monkey (Zhang 
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et al., 2011). Overall, monkey appears likely to be an appropriate species for 
estimating AO-mediated metabolism and clearance in human and should be 
considered more reliable than rat or mouse, particularly when AO-mediated 
metabolism is low in rodent and higher in monkey.  
Though some substrate dependence was observed, our in vitro data also support 
prior speculation that guinea pig could serve as a suitable species for estimation of 
human AO-mediated metabolism (Garattini and Terao, 2012). SSS with guinea pig 
CLint predicted four of the five compounds within 2-fold of human CLint, and Fm,AO, E, 
and biotransformation for these four compounds were similar between human and 
guinea pig. However, guinea pig metabolism and clearance of BIBX1382 
demonstrated a closer resemblance to the other rodent species than to human, and 
consequently, SSS with guinea pig CLint under-predicted human CLint, of BIBX1382 
similar to SSS of CLint with rat and mouse.  Likewise, though guinea pig SSS 
accurately predicted human CLint of O6-benzylguaine in vitro, SSS with guinea pig in 
vivo over-predicted human CLp 3.9-fold, similar to over-predictions obtained using 
rat and mouse.  These data indicate that perhaps guinea pig may be used as an initial 
screening tool for metabolic stability, with the recommendation that potential drug 
candidates be evaluated in monkey prior to advancing to clinical trials. Notably, when 
guinea pig exhibits similar metabolism/clearance to rat and mouse in vitro and/or in 
vivo (especially if different from human in vitro), it may be particularly important to 
evaluate additional species such as monkey. 
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While minipig successfully predicted human in vivo CLp of zaleplon and O6-
benzylguanine within 2-fold, human zoniporide CLp was over-predicted ~5-fold. In 
addition, substrate-dependence of AO metabolism in vitro further indicates that 
caution should be advised with regard to broad use of this species to estimate AO-
mediated metabolism in human. Though minipig SSS of in vitro CLint predicted 
human CLint within 3-fold for four of the five compounds evaluated, Fm,AO and 
biotransformation experiments revealed AO-mediated metabolism was not always 
similar between minipig and human (decreased AO-mediated metabolism of 
zaleplon and O6-benzylguanine in minipig S9 relative to human). Interestingly, 
NADPH-dependent metabolism of zaleplon in minipig S9 apparently compensated 
for the decreased AO metabolism, resulting in a similar E between minipig and 
human.  While this apparent compensation effectively permited prediction of 
zaleplon human CLint by minipig SSS, this NADPH-dependent compensatory effect 
was not observed for O6-benzylguanine. Furthermore, while an NADPH-dependent 
mechanism may compensate for low AO metabolism in a hepatic in vitro system, this 
compensatory effect would not be expected in extra-hepatic tissues where AO 
metabolism might also occur in vivo. Interestingly, there was essentially no 
difference in the IVIVC of zaleplon between human and minipig, though it is not 
known if zaleplon is subject to extra-hepatic metabolism in vivo.  While minipig is 
increasing in popularity as a model species for preclinical toxicology evaluations 
(Bode et al., 2010; van der Laan et al., 2010), this apparent substrate-dependence in 
AO vs. P450-mediated metabolite formation poses another cause for concern in the 
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utility of this species for toxicology when AO metabolism predominates in human. 
However, MA with the inclusion of minipig was generally successful, particularly 
with regard to methods employing four species in in vitro allometry assessments 
(CLp data was not available for a comprehensive assessment of 4-species allometry 
in vivo). Overall, the present data indicate that broad application of a minipig model 
for human PK of AO substrates is not advisable, though it still may be useful in 
combination with other preclinical species for multispecies allometry.   
Future directions   
As our in vitro examination of minipig S9 revealed substrate-dependency in 
AO-mediated metabolism relative to that in human S9, investigations to study in 
vitro versus in vivo metabolism of AO substrates in minipig would shed light on the 
potential to use in vitro metabolism data to determine if minipig would be an 
appropriate species for toxicology assessments. While we evaluated interspecies in 
vivo PK in the present investigations, we did not examine metabolite formation in 
vivo. In addition, as was previously reported by Dalvie et al with regard to 
metabolism of zoniporide (Dalvie et al., 2013), we observed higher CLint of all five 
compounds in hepatic S9 of female minipigs relative to male minipig S9. This 
observation leaves open the question as to whether female minipig may serve as a 
more useful human PK model than male minipig. Biotransformation experiments 
and in vivo PK assmessments in female minipigs will be required to better 
understand this possibility. Extension of the proposed future investigations 
concerning minipig to investigations in guinea pig and monkey, of course, would 
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also serve well to better inform the drug metabolism and disposition community as 
to the general utility of preclinical species in human PK prediction.  
 
Commentary 
A comprehensive assessment of all data presented, including in vitro 
biotransformation, in vitro estimation of Fm,AO and E, and SSS with both in vitro CLint 
and in vivo CLp support prior postulations that guinea pig and monkey would likely 
serve as better models of AO-mediated drug clearance in human versus commonly 
employed nonclinical models such as rat or mouse (Garattini and Terao, 2012; 
Hutzler et al., 2013; Hutzler et al., 2014a); importantly, no single species should be 
expected to reflect human clearance of all AO substrates (Choughule et al., 2013b; 
Hutzler et al., 2013).  Moreover, the minipig represents a species to consider when 
investigating AO metabolism, particularly when employed in multispecies allometry. 
Collectively, our data support the need for a multiple species assessment when gauging 
the intrinsic lability of new chemical entities (NCEs) towards AO metabolism and the 
projection of that metabolism-mediated drug clearance in human. With regards to 
human pharmacokinetic predictions, our data support a confidence-inspiring 
approach towards the  scaling of human clearance when nonclinical species 
metabolism, single-species scaling, and the corresponding IVIVC assessments are all 
similar between the species employed during preclinical investigations (e.g., rat, 
guinea pig, and monkey); when these confidence inspriring tenets are not observed, 
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the present data would support use of nonhuman primate for the in vitro and in vivo 
investigations of NCEs. Applications of the methodology presented herein, either as a 
stand alone or in combination with previously published strategies (Zientek et al., 
2010) would likely reduce the risks associated with AO-mediated clearance in 
clinical trials.  While mechanisms behind variable AO activity (in vitro and/or in 
vivo) and contributions of extra-hepatic metabolism remain important unanswered 
questions towards the implementation of standardized methods pertaining to AO-
mediated drug disposition, the work provided here offers new insight to aid in the 
appropriate application of preclinical species, thus helping to prevent future clinical 
failures resulting from unexpected human AO metabolism.  Furthermore, the 
present body of research may in fact be applied to other emerging drug 
metabolizing enzyme classes by which standardized methodologies (i.e., for P450-
mediated drug clearance) also falls short of predicting hepatic metabolism and drug 
clearance.  
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